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ABSTRACT 
Polymeric carner molecules have been shown to improve the pharmacokinetics and 
pharmacological profile of small·molecule anticancer drugs. The variolins are a group of marine 
natural product-derived cytotoxins whose clinical efficacy may be improved through conjugation 
with a polymer backbone. 
This thesis first describes the optimisation of a synthesis of the non-natural analogue 
deoxyvariolin B, a synthesis that was devised by Anderson and Morris immediately prior to the 
commencement of this project. The synthesis, comprised of six linear steps, was refined to give 
an overall yield of25%. 
As part of a much larger structure-activity relationship investigation being carried out by Pharma 
Mar, SA (a Spanish pharmaceutical company specialising in marine natural products), a small 
libraty of deoxyvariolin analogues, numbering approximately fifteen, was also synthesised and 
tested in vitro against the P388 murine leukaemia cell line. All analogues synthesised showed an 
appreciable loss of bioactivity (typically around an order of magnitutude) compared to that of 
deoxyvariolin B, 
Attempts at acylating deoxyvariolin B with the tetrapeptide biolinker were hampered by DVB's 
awkward reactivity and the low stability of some of the products. A more suitable deoxyvariolin 
analogue, in terms of its bioactivity as well as chemical reactivity, was therefore chosen for 
development into a polymer therapeutic. This analogue was successfully conjugated with a 
tetrapeptide biolinker to give a compararably bioactive conjugate that was to be reacted with an 
activated polymer backbone. 
The final part of this thesis, however, describes work that was carried out with the polymeric 
starting material, in which it was revealed that two unforeseen side reactions were taking place. 
These side reactions ultimately precluded the synthesis of the target construots. 
.. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cancer 
A report published in 2003 by the World Health Organisation! stated that over 10 million people 
are diagnosed with cancer and over 6 million die from the disease annually (at the time of 
writing, the web pages of Cancer Research UK? report the figures as 10.9 million and 6.7 
million, respectively). Globally, there are marked regional differences in the occurrence and 
type of cancers. Western societies bear the greatest cancer burden, with tumours associated with 
smoking and Western lifestyles (specifically, cancers of the lung, colorectum, breast and 
prostate) being the most common. In Western Europe and the US, cancer is the leading disease 
cause of death in women between the age of 40 and 60 and is second only to heart attack as a 
cause of death in males over 30? In developing countries, up to 25% of tumours are associated 
with chronic infections, such as hepatitis B virus (liver cancer), human papillomaviruses 
(cervical cancer) and Helicobacter pylori (stomach cancer). 
The global incidence of and mortality from cancer increased by just under 20% in the decade 
from 1990 to 2000. 1 Furthermore, cancer is closely related to the ageing process, and so is set to 
become more common worldwide as more people live to an older age.3 
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1.1.1 Cancer biology 
The tenn cancer represents a group of diseases, all characterised by uncontrolled cell growth. 
The key cellular events in the progress of cancer include the loss of proliferative control, the 
failure to undergo apoptosis (programmed cell death), neoangiogenisis (the growth of new blood 
vessels), tissue remodelling, invasion of tumour cells into surrounding tissue and, finally, 
metastatic dissemination of tumour cells into distant organs.4 The process of malignant 
transformation is a multi-step one, requiring the sequential acquisition of genetic alterations. 
The transition from normal to malignant growth can sometimes take over 20 years.l 
In a typical tumour, the cancer cells often occupy less than half of the tumour volume, blood 
vessels 1-10%, and the remaining volume - termed the interstitium - being comprised of a 
collagen-rich matrix bathed in interstitial fluid. It is through this fluid that oxygen, metabolites 
and bioactive compounds must travel in order to reach and be absorbed by cancer cells. 5 
1.1.2 Cancer treatment 
Surgical removal or irradiation of tumours remalO the first choices of treatment, with 
chemotherapy being relied upon if a tumour has metastasized, or if parts of the primary tumour 
cannot be removed. 5 Non-selective classical anticancer drugs usually display a broad toxicity 
towards all dividing cells, with cancer cells generally dividing more rapidly than normal, healthy 
cells. This non-specific mechanism of toxicity therefore causes the death of healthy, as well as 
cancerous, tissue, leading to side effects which typically include mucositis (inflammation of a 
mucous membrane), hair loss, myelosuppression (suppression of the production of blood cells 
and platelets by the bone marrow) and various types of organ damage,6 
Small cytostatic drugs will distribute readily throughout most body tissues, with a rapid diffusion 
across plasma membranes. Better specificity, achieved through the use of drug delivery systems, 
may therefore help to circumvent the indiscriminate toxicity of existing drugs, and would 
represent a significant improvement on existing treatment regimes, 
1.1. 2.1 Barriers to drug delivery 
Chemotherapeutic agents are usually administered intravenously. However, the abnormal 
physiological architecture and properties of tumours lead to some serious limitations regarding 
the delivery of drugs via the blood supply.s Some of these limitations are particularly relevant 
for the type of construct that is the target of the work described in this thesis (see Section 
1.2.2.6), and so will be briefly discussed here in more detail. 
There are several important limiting factors in the diffusion of drugs to tumours, first and 
foremost of which is the heterogeneous, slower and intermittent blood flow that is typically 
observed within tumour tissue.7,s This, of course, leads to non-homogenous distribution within 
the tumour of intravenously-administered drugs. 
A second barrier to drug delivery is the higher hydrostatic pressures present within tumours.9,10 
In normal, healthy tissuethe hydrostatic pressure within the interstitium is significantly less than 
that within the vasculature. This pressure gradient ensures a flux of fluid (carrying dissolved 
solutes) out of the blood and through the interstitium, with the lymphatic drainage maintaining 
the pressure gradient. In tumour tissue, however, where numerous vascular and lymphatic 
anomalies occur,9,11-13 the interstitial pressure is elevated, uniform throughout the tumour (falling 
away sharply at the tumour periphery), and roughly equal to the microvascular pressure.S,lO This 
lack of a pressure gradient results in greatly reduced fluid flow: which in turn all but eliminates 
drug transport across capillary walls by the convective mechanism. Drugs must therefore be 
transported into the interstitium by simple diffusion, which is a much slower process than 
convection-based transport, particularly with respect to larger molecules. 5,9 
Poor lymphatic drainage within tumours, leading to accumulation of molecules in the 
interstitium, also reduces the osmotic gradient that is present in healthy tissues.9 This will further 
impede extravasation of macromolecules by diffusion in tumours. However, Jain notes that, 
despite these limitations, the "large microvascular permeability and interstitial diffusion 
coefficients of macromolecules in tumours compared to those in normal tissues provide a 
powerful rationale for the use of large molecular weight agents instead of conventional small 
molecular weight agents in cancer detection and treatment".9 
• There is still a small fluid flux through the tumour, as is evidenced by the obselVation that ~ 10% of the blood fluid 
leaving a solid tumour 'seeps' out from its periphery rather than draining via a vein.s 
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1.2 Polymer Therapeutics 
1.2.1 Brief overview of field 
The tenn polymer therapeutics is an umbrella tenn referring to several classes of compounds, 
including rationally-designed macromolecular drugs and prodrugs, polypi exes for DNA delivery, 
polymer-drug conjugates, polymer-protein conjugates and polymeric micelles containing 
covalently bound drug. 14 Polymer therapeutics will alter the biodistribution and/or 
phannacokinetics of a drug, and so can be used to target a range of diseases. This potential to 
alter the phannacological profile of a drug is particularly important in the treatment of solid 
tumours, reflected in the fact that 20 out of 32 drug delivery systems currently in use or in 
clinical trials target cancer. IS 
Though contemporary polymer synthetic .chemistry is yielding more structurally complex 
polymers that hold promise as carrier molecules, all polymer therapeutics that have been 
transferred to the clinic to date have been based around linear, random coil polymer structures. 
These polymers include synthetic polymers [poly( ethylene glycol) (PEG), N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymers, poly(vinylpyrrolidone), poly(ethyleneimine), linear 
polyamidoamines and pyran copolymers], natural polymers (dextran, dextrin, hyaluronic acid 
and chitosans) and pseudosynthetic polymers [man-made poly(amino acids)].14 Figure 1.1 gives 
the structures of some representative examples of these polymers. 
~H 
Y 
OH b) c) d) 
Figure 1.1: Examples of polymers used as carrier molecules for drugs; a) PEG, b) pHPMA, 
c) poly(glutamic acid), and d) N-acetyl-a-I,4-polygalactosamine. 
This thesis describes work towards the synthesis of linear polymeric constructs based around 
pHPMA and carrying anticancer cytotoxins. 
1.2.2 Polymer-drug conjugates 
In the 1970s De Duve recognised the potential for Iysosomotropic drug delivery by 
macromolecules and site-specific intralysosomal drug liberation. 16 Ringsdorf extended this idea 
in the same decade to propose an idealised structure for polymer-drug conjugates. 17 A viable 
mechanism to allow tumour-targeting of these proposed macromolecular prodrugs was not 
known at the time, other than the observed increased rates of endocytosis of cancer cells 
compared with normal cells. I8 It would not be till several years later, with the important 
discovery of the enhanced permeability and retention effect (EPR effect, see below), that a 
promising mechanism of drug targeting would be revealed. 
1.2.2.1 The EPR effect 
The EPR effect (Figure 1.2) leads to the accumulation of macromolecules in tumour tissue!9 
The phenomenon was first described by Matsumura and Maeda,20 following investigations 
involving SMANCS (a polymer-protein conjugate incorporating the antitumour protein 
neocarzinostatin) carried out by Maeda and colleagues,21 and is thought to be due to two 
synergistic features of tumour tissue. The first is the hyperpermeability of tumour blood vessels 
which, unlike healthy vasculature, leads to extravasation of macromolecules into the tumour 
interstitium.9 The second is the very poorly developed lymphatic system typically seen within 
tumours, which leads to accumulation ofthe macromolecules within the tumour. 12,13,21 
Tumour vasculature is 
'leaky', and so polymers 
will diffuse from the 
bloodstream into the 
tumour interstitium. 
Figure 1.2: The EPR effect. 
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1.2.2.2 Site .. specific drug liberation 
As was highlighted by de Duve and Ringsdorf 30 years ago,16,17 a crucially important feature of a 
polymer-drug construct is the moiety used to conjugate the drug onto the polymer backbone. 
This group needs to be stable in the blood plasma (and urine) yet cleaved at the site of action. It 
is important to optimise this reactivity, as a linker that is not cleaved at the site of action will 
permanently mask the therapeutic cytotoxicity of the bound drug, while one that allows 
premature drug liberation will lead to indiscriminate toxicity.22 
Following uptake by cancer cells through pinocytosis, polymer-drug constructs will be enclosed 
within lysosomes - intracellular vesicles possessing an acidic pH of 4-5 (typically around 4.8, 
though values as low as 4.0 have been measured),z3,24 Also present in lysosomes are a group of 
cysteine protease enzymes named the cathepsins. Either the drop in pH (from a blood plasma 
value of ~7.4) or the presence of this group of proteases can facilitate liberation of the active 
drug from the polymer backbone. 
The first of these mechanisms - acid-catalysed drug liberation - can be utilised through the use of 
acid-sensitive linker groups to conjugate the drug onto the polymer. Examples include cis-
aconityl, acetal and hydrazone linkages (Figure 1.3).14 The latter of these has been used in the 
construction of a pHPMA-doxorubicin conjugate, which shows superior activity over PK 1 (see 
Section 1.2.2.6 for a description of this prototypical polymer-drug conjugate) against lymphoma 
in ViVO,z5 
R",,'l.-;.N'N,R' 
c) ;"'l; H 
Figure 1.3: Examples of acid-sensitive linker groups, with the site of cleavage shown; 
a) the acetal, b) the cis-aconityl, and c) the hydrazone groups (the imine bond 
in the latter is replaced by an aldehyde group in the cleavage product). 
A variation on this theme employs a polyacetal backbone, so that acid-catalysed acetal 
hydrolysis gives an acylated bioactive analogue of the drug (carrying the non-biodegradable 
linker).26 
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As mentioned above, an alternative to the acid-catalysed route to drug liberation is the cathepsin-
mediated cleavage of peptide bonds. By analogy with the polyacetal backbone example, this can 
be capitalised on by using biodegradable cathepsin-cleavable polymers. An example of one such 
construct is the prodrug CT-2103,27 a promising paclitaxel-carrying polymer-drug conjugate 
currently in development that is based around poly(glutamic acid) - a polymer that is cleaved by 
cathepsin B to liberate a drug-glutamic acid conjugate from which the free drug is then liberated 
by non~enzymatic ester hydrolysis. 28 
Another well-established technology employs a non-biodegradable polymer carrying the 
tetrapeptide biolinker glycyl-L-phenylalanyl-L-Ieucyl-glycine (GFLG, Figure 1.4), a motif that is 
stable in circulation29 but cleaved intralysosomally by cathepsins B, Hand L.30 
Figure 1.4: The biodegradable tetrapeptide motif, GFLG. 
Antitumour drugs bound to a polymeric carrier via this biolinker will therefore be liberated 
intracellularly at their site of action, given that the EPR effect ensures accumulation of such 
polymeric prodrugs in the tumour interstitium and that macromolecules are inherently 
lysosomotropic.16 It is this mechanism of drug targeting and site-specific liberation that was 
chosen in the work described in this thesis. 
Finally, a related strategy in the early stages of development, termed polymer-directed enzyme 
prodrug therapy (pDEPT), involves the administration of two separate polymeric constructs- the 
first one bearing drug bound via a biodegradable linker, and the second, administered a short 
time later, carrying an enzyme which will cleave the biodegradable linker. Proof of concept was 
achieved in vivo, firstly with an HPMA-GFLG-doxorubicin copolymer combined with an 
HPMA-cathepsin B copolymer,31 and secondly with an HPMA copolymer bearing doxorubicin 
and cephalosporin, both bound via a glycylglycine dipeptide linker, combined with an HPMA 
copolymer-~-lactamase conjugate.32 With the drug being liberated in the tumour interstitium, 
diffusion rates will be higher5 and some types of drug resistance of tumour cells (specifically, 
that based on reduced rates of pinocytosis) may be overcome. 
1.2.2.3 Further discussion on plwrnulCokinetics (Imi ph(lrm(lcology 
The most obvious additional advantage of conjugating drugs onto polymers is that the toxicity of 
the drug is masked while in conjugate form. Assuming, then, that the biolinker is stable in both 
blood plasma and urine, this will lead to much lower levels of haemolysis and bladder toxicity, 
respectively. And to reiterate what has already been mentioned (1.2.2.1), indiscriminate toxicity 
towards other tissues and organs is avoided due to the vascular-localisation afforded by the size 
of the polymer constructs. 
Further advantages include the potential to increase the water solubility of drugs. Taken together 
with the above advantages, this will give superior pharmacokinetics of polymer-drug constructs 
over the free drugs. Specifically, higher plasma concentrations of a drug can be achieved 
(without the associated toxicity that would otherwise be observed with the free drug), with 
longer plasma residence times due to slower renal excretion?3 If effective targeting through the 
EPR effect can be achieved, the low toxicity of a polymeric prod rug will give a superior 
pharmacological profile compared with free drug, 
1.2.2.4 T(l1'geting lig(lnds 
In addition to the passive targeting afforded by the EPR effect, the potential also exists for 
receptor-mediated targeting through the attachment of tumour-targeting ligands on the polymer 
backbone. 17 However, due to the biochemical similarity between malignant and healthy cells, 
few ligand/receptor combinations have been identified. A further complication is the genetic 
instability seen in rapidly growing tumours, commonly leading to the appearance of 'antigen loss 
variants' ,I These resistant variants will be selected for through the use of chemotherapeutic 
strategies employing active targeting mechanisms. It is for these reasons that no polymer 
therapeutics bearing tumour-targeting ligands have thus far progressed into clinical 
development, 14 
The potential does exist, however, for more general active targeting mechanisms to be employed. 
One such example is PK2, the first polymer-drug conjugate bearing a targeting ligand to be 
clinically tested. 34 It is a galactosamine-bearing analogue ofPKl (see Section 1.2.2.6), designed 
to target the asialoglycoprotein (ASGP) receptors of hepatocellular carcinomas (though healthy 
ASGP receptor-bearing hepatocytes are also targeted).35 Clinical trials involving human patients 
and gamma camera imaging confirmed 15-20% dose targeting of PK2 to the liver after 24 h?6,37 
1.2.2.5 pHPMA 
Most anticancer polymer-drug constructs tested clinically have been based around pHPMA (see 
Figure 1. Ib), 14 a polymer originally developed by Kopecek and colleagues as a plasma 
expander.38,39 This is a highly water soluble and biocompatible polymer possessing very low, 
non-clinically relevant immunogenicity.40 
A 2003 review points out that most of the pHPMA copolymer constructs reported thus far have 
incorporated traditional small-molecule anticancer drugs.6 It goes on to summarise that 
experimental studies on pHPMA constructs carrying the anticancer drugs daunomycin, 
doxorubicin, farmorubicin, methotrexate and 5-fluorouracil showed a combination of markedly 
improved anti tumour activity, increased maximum tolerated dose (relative to free drug), activity 
towards multi drug resistant cells, reduced myelotoxicity, hepatotoxicity, cardiotoxicity, 
, 
nephrotoxicity and toxicity to thymus, prolonged circulation in the bloodstream and enhanced 
accumulation in solid tumours. 
1.2.2.6 The target construct 
This thesis describes work towards the synthesis of polymer therapeutics of type 1.1, based 
around pHPMA and carrying anticancer drugs bound via the tetrapeptide motif GFLG (Figure 
1.5). No attempts were made to include targeting moieties. 
There are many published accounts of the synthesis and biological activity of constructs of type 
1.1. The most well-documented is the prototypical PK 1, a doxorubicin-carrying polymer-drug 
conjugate of ~28 kDa.41 Doxorubicin is an anticancer drug widely used in the treatment of both 
solid tumours and leukaemia, though the clinical use of this chemotherapeutic is limited by its 
indiscriminate toxicity.42 PKI displays a more favourable pharmacological profile compared 
with that of free doxorubicin, and is currently in phase II clinical triais. 43 
1.1 
Figure 1.5: A generalised polymer-drug conjugate of type 1.1. 
PK1 has been extensively studied, with a large amount of published data regarding its in vivo 
biological properties in both mouse models and human patients. It was the first polymer-drug 
conjugate to enter phase I clinical trials as an anticancer agent, during which time it was found 
that it gave a four- to five-fold increase in the maximum tolerated dose of bound doxorubicin, a 
prolonged plasma half-life, an absence of liver accumulation and effective renal elimination. As 
part of the same study radionuclide imaging results were able to confirm uptake at known 
tumour sites by 6 out of 21 patients, with two 'partial responses' and two 'minor responses' 
being observed. Dose-limiting toxicities were typical of anthracyclines and no cardiotoxicity (a 
well documented side effect of doxorubicin chemotherapy) was observed.44 Results from a 
phase II clinical trial involving 63 patients showed that side effects were manageable and the 
treatment was 'tolerable', though only 6 of the patients showed a positive response.43 No 
polymer-related toxicity was detected. 
Examples of other conjugates of type 1.1 include the doxorubicin-carrying conjugate PK2 (see 
Section 1.2.2.4); a construct incorporating cisplatin, which when tested in vivo in mouse models 
showed a more favourable pharmacological profile than the free drug alone;45 a conjugate 
carrying the ellipticine derivative 6-(3-aminopropyl)-ellipticine (APE), which when tested in 
mouse models gave comparable results to free APE;46 a pac1itaxel-bearing conjugate which 
showed low toxicity in humans (however, the clinical trial was halted due to the severe 
neurotoxicity observed in parallel studies involving mouse models, possibly indicating premature 
drug liberation);47 a construct incorporating the anticancer fungal metabolite wortmannin, which 
has demonstrable activity in vitro and in vivo and is in the early stages of deve!opment;48 a 
construct carrying the antiangiogenesis fumigillol TNP-470, which gave an enhanced and 
prolonged effect of this broad-spectrum anticancer agent whose use is normally limited by 
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neurotoxicity at higher doses (the construct did not cross the blood-brain barrier);49 and finally, a 
polymer-bound cathepsin K inhibitor, which is in the early stages of development and is to be 
used in the treatment of osteoporosis and rheumatoid arthritis.so 
1.2.2.7 Polymer size and pharmacokinetics 
Polymer size is crucially important in determining the pharmacokinetics of macromolecular 
prodrugs. The polymers must be large enough to ensure vascular localisation in healthy 
vasculature and to prevent rapid renal excretion, but must also be small enough to allow slow 
renal excretion over a few days. 
It is possible to circumvent the upper limit imposed by the renal threshold for glomerular 
filtration through the use of biodegradable polymers, for example polyacetals and poly(amino 
acids) (see Section 1.2.2.2 for the mechanisms of biodegradation)?6,28 Upper size limits may 
still exist, however, as is highlighted by the' observation that pHPMA molecules larger than 80 
kDa accumulate in the skin,sl which is clearly an undesirable property for a cytotoxic prodrug. 
A further pharmacokinetic consideration when assessing optimal polymer size, and one that 
receives little attention in the existing polymer therapeutic literature, relates to the rates of 
prodrug transport within the tumour interstitium. Specifically, larger molecules will take much 
longer, once they have reached the tumour, to diffuse through the interstitium (which is 
significantly more extensive in tumour tissue than in healthy tissue) to the target cancer cells (see 
Section 1.1.2.1 for a more detailed discussion of this phenomenon). Calculations (based on 
experimental observations) made by Jain provide an illustrative example. He calculated that a 
150 kDa monoclonal antibody (corresponding in size to pHPMA sample of approximately 
40 kDa) supplied constantly to a tumour one centimetre in diameter with no blood supply to its 
core would take several months to reach a uniform concentration within the interstitial fluid. 5 
This highlights the significance of the distinction between tumour localisation (which is what is 
generally measured)5l and cellular uptake of macromolecules. 
Thus, two opposing effects will dictate the optimum size for polymeric prodrugs. Namely, 
accumulation of macromolecules in tumour tissue will improve with increasing prodrug size, 
while rates of diffusion through the tumour interstitium to the target cells will be decreased. It is 
therefore necessary to carefully tailor the size of non-biodegradable polymeric carrier molecules 
to optimise their pharmacokinetic properties. 
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It should be noted here that hydrodynamic radii, and therefore pharmacokinetic properties, may 
vary considerably between different molecules of the same size. The random-coil linear polymer 
PEG, for example, has a hydrodynamic radius some 5-10 times larger than that of a globular 
protein of equivalent molecular weight. 14 Similarly, pHPMA, also a flexible linear polymer, 
behaves on GPe as proteins sized 3-6 times as large. 52 Rates of renal excretion may also vary 
between macromolecules of the same size, depending on the degree of flexibility of the 
polymer. 52 
As pHPMA is the polymeric carrier molecule that was employed in the work described in this 
thesis (see Section 1.2.2.4), literature regarding the pharmacokinetics of this polymer is the most 
relevant here. Looking specifically at pHPMA, then, lower and upper limits for molecular 
weight have been determined by in vivo experiments. 51 ,52 Polymers less than ~20 kDa are 
excreted too rapidly, while those above ~70 kDa are excreted too slowly,52 Tumour 
accumulation is seen to increase linearly with size up to about 75 kDa,51 Based on these results,· 
and considering that polymer samples will always possess some degree of polydispersity 
(defined in Section 4,1.1), it can be concluded that pHPMA sizes of around 60 kDa would be 
optimal (although one experiment conducted in vivo with mouse models even showed a 
pHPMA-based polymer conjugate of 115 kDa as having a superior pharmacological profile over 
similar constructs of around 30 kDa),25 It is therefore unclear as to why 30 kDa is generally 
quoted as being the optimal size for pHPMA-based anticancer polymer-drug conjugates,14 nor 
why this molecular weight was chosen for the numerous clinical trials involving pHPMA-based 
polymer-drug conjugates carried out to date,34,43,49 As would be expected for a prodrug of this 
size, within 60-90 minutes of intravenous administration of PK2 (Mn = 27 kDa, PD ;::::: 1.4; see 
Section 1.2.2.4), half of it had been cleared from the blood plasma as the intact polymer-drug 
conjugate through renal excretion,37 
Of course, human physiology is complicated and, in the case of tumours, often varied, and so the 
idea that a single molecular weight for a polymeric delivery molecule will be ideal for all 
treatments is an oversimplification, Results obtained from investigations carried out in vivo, 
especially those involving human patients, are ultimately the most informative on the efficacy of 
It should be noted that the results obtained for the size.dependence of tumour accumulation of pHPMA differ 
considerably from those obtained with other macromolecules, 19,53 
therapeutics, In the development of new therapeutics, established parameters and methodologies 
should be employed wherever possible, to allow a more accurate comparison with existing 
technologies. For this reason, a pHPMA molecular size of 30 kDa, which, as has already been 
mentioned, is approximately that of PK 1 and PK2 (see Sections 1.2.2.4 and 1.2.2.6), was 
considered desirable for the polymeric constructs that were the target of the work being 
described in this thesis, 
1.2.3 Synthetic protocols 
Polymer synthesis presents specific challenges for pharmaceutical development. While a 
synthetic drug or prodrug should be homogenous and composed of a single, defined species, 
polymers are usually heterogeneous and can be difficult to characterise. Specifically, a polymer 
sample will contain individual molecules of ' different molecular weight. The distribution of this 
molar mass, referred to as the polydispersity (PD, defined in Section 4.1.1), will affect the 
biodistribution, and therefore the biological activity, of the pharmaceutical agent. 
Polymer samples of low PD can be obtained either by size exclusion chromatography (SEC) on 
polymers synthesised by conventional free radical protocols, or through the use of controlled 
polymerization protocols. The former is the conventional (though seldom used) method of size 
control in polymer therapeutic research, while the second is relatively new methodology that was 
explored in the work described in this thesis (see chapter 4). Both are discussed in more detail 
below. 
1.2.3.1 Conventional syntlletic protocols 
The synthetic route to polymer-drug conjugates that was developed by Kopecek in 197753 
dominates all published synthetic accounts to date. 25,37,40,43,46,49,54-57 In these protocols, free 
radical polymerisation gives an HPMA-based copolymer precursor of relatively high PD, 1.2 
(Figure 1.6), or an equivalent precursor, which can then be reacted with a nucleophilic drug to 
give a construct of type 1.1. Laborious size fractionation using SEC can be used to give a 
polymer of PD ~ 1.2,52 though this has not been employed in any of the reported polymer-drug 
conjugate syntheses to date. PDs of the synthesised polymers are often not given,22,25,4O,54,58 but 
those that are range from 1.446,59 to 1.7,49,5S Polymer sizes range from 19 kDa to 31 kDa, with 
the only notable exception being a construct of 115 kDa,25 
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Figure 1.6: Conventional synthetic route to polymer-drug conjugates of type 1.1. 
A related mechanism involves the copolymerisation of HPMA with the methacryloyl-
tetrapeptide-drug unit to give the polymer-drug conjugate in one step.48 Of course, the drug must 
be stable under the polymerisation reaction conditions, 
1.2.3.2 pMAOS as a precursor 
An alternative synthetic route to pHPMA-based polymer-drug conjugates involves the use of an 
'activated' homopolymer backbone, which is functionalised using appropriate nucleophiles. The 
polymeric activated ester poly(methacryloxysuccinimide) (pMAOS, Figure 1.7) is a relatively 
hydrolytically stable polymer that was first considered as a possible precursor in the synthesis of 
polymer therapeutics by Ringsdorf in his seminal 1975 paper.17 The interest in this polymer as a 
precursor in the synthesis of polymer-drug conjugates was greatly increased with a 2001 
publication by Godwin et al.,60 which reported on the synthesis of pMAOS samples of PD <1.2 
using controlled radical polymerisation protocols. Furthermore, the pMAOS was then reacted 
with glycyl-glycyl-p-naphthylamide, followed by 1-amino-2-propanol (lA2P) to reportedly give 
the naphthyl amide-bearing polymer-drug conjugate analogue 1.3 (Figure 1.7, see Section 4.3.2.8 
for a further discussion and investigation of this reaction). The reaction was followed by FTIR 
spectroscopy, with an observed quantifiable loss of the activated ester carbonyl signal at 
1735 cm"I. 
pMAOS 
Glyglynaphthylamide hydrochloride (0.1 eq) 
----------------lIIo-.. pMAOS Copolymer 
TEA (0.2 eq), DMSO, 50 °C, 2.5 h 
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Figure 1.7: The reported synthesis ofHPMA copolymer 1.3 from pMAOS. 
This synthetic route has two important advantages over the former. Firstly, the activated 
polymeric precursor, pMAOS, can be synthesised with a low PD, and, secondly, a single 
polymeric precursor can in theory be used to synthesise any number of polymer therapeutics 
incorporating different drugs, biolinkers and (if desired) targeting residues, and all with variable 
levels of loading. In short, a range of polymeric constructs can be synthesised from only the one 
precursor, which can be easily made in high quality. 
While to date there have been no further reported syntheses of polymer-drug conjugates utilising 
this type of chemistry, the methodology was employed by the same group in the synthesis of a 
range ofpoly(methacrylamide) copolymers.61 Furthermore, a 2004 Monge and Haddleton paper 
reported an optimised synthesis of pMAOS using controlled radical polymerisation protocols, as 
well as the subsequent aminolysis of the product with benzyl amine to give the benzylamide 
homopolymer product.62 
This pMAOS~based methodology was further investigated in the work described in this thesis 
(see chapter 4), with an aim to synthesise conjugates of type 1.1 bearing anticancer drugs. 
Specifically, variolins, discussed below, were employed as the cytotoxic compounds. 
1.3 The Variolins 
1.3.1 Discovery 
Two related papers published in 1994 by Perry et al. 63 and Trimurtulu et al. 64 reported on the 
discovery of a new class of marine alkaloids, the variolins, from the Antarctic sponge 
Kirkpatrickia varialosa (Figure 1.8). These compounds all share a novel tricyclic 
pyridopyrrolopyrimidine aromatic system otherwise unseen in natural products. 
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Figure 1.8: The four variolin structures reported in 1994, a) variolin A, b) vanolin B, 
c) N(3')-methyl tetrahydrovariolin B, and d) variolin D (a suspected artefact). 
Of the three natural products and single suspected artefact (variolin D) that were discovered, one 
in particular, variolin B (Figure 1 ,8b), showed pronounced anticancer cytotoxicity in vitro 
against the murine P388 leukaemia cell line, with an ICso of 210 ng/mL, or 0.72 jiM, An X-ray 
crystal structure showed the pendant pyrimidine ring of variolin B to be tilted out of the plane by 
24°, with the IH NMR spectrum confirming that the hydroxyl proton was strongly hydrogen 
bonded.63 
1.3.2 Mode of action of va rio lin B 
Variolin B exerts its cytotoxicity towards cancer cells through the rapid induction of apoptosis, 
specifically, via the intrinsic, or mitochondrial, pathway.65 Variolin B was initially suspected to 
be an intercalator due to structural similarities to other known intercalators. 66 However, it is now 
known to be a cyclin-dependent kinase (CDK) inhibitor.65 The ICso value of variolin B towards 
the human CDKI and CDK5 enzymes in vitro was shown to be 60 nM and 90 nM, 
respectively.67 Dysfunction (specifically, overexpression) of the CDK pathway, a crucially 
important pathway in the regulation of the cell cycle, is seen in most, if not all, human tumours.68 
Apoptosis-inducing CDK inhibitors have therefore been the focus of extensive interest in cancer 
therapy, with several such inhibitors currently in clinical trials.68.7o While structurally diverse, 
all other known CDK inhibitors are flat, hydrophobic heterocyclic compounds of molecular 
weight less than 600 gmor1, which all compete with ATP for binding in the kinase ATP-binding 
site.69 
Furthermore, variolin B is cytotoxic towards multiple-drug resistant (MDR) cells, and its 
cytotoxicity appears to be independent of the p53 status of the ceUs.65 The protein p53 is a 
transcription factor of central importance in the regulation of cell proliferation, differentiation, 
DNA repair and apoptosis. 71 Virtually all cancer cells possess a defective p53 system, and it is 
proposed that the observed chemoresistance of many tumours is due to this defective system 
(especially with respect to cytostatic and apoptosis-inducing drugs).72 
The p53-independence of the mode of action of variolin B, along with the observation that CDK 
inhibitors will produce synergistic effects when administered in conjunction with conventional 
anti-tumour agents,70 makes variolin B (and deoxyvariolin B, discussed in Section 1.3.3.1, which 
has a very similar biological activity profile) a very exciting lead compound in the treatment of 
cancer. 
1.3.3 Synthesis 
Given the inaccessibility and world heritage status of Antarctica, there was significant interest in 
the development of a synthesis of variolin B to provide material (including non-natural 
analogues) for further investigations. 
The synthetic protocols employed in the work described in this thesis are those developed by 
Anderson and Morris (see Sections 2.2 and 1.3.3.1). Before outlining these protocols, however, 
a brief overview of the other reported syntheses from three separate groups will be given. 
Fresneda, Molina and coworkers were the first to report a synthesis of the 
pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine variolin core, 1.4 (Figure 1.9).73 The synthesis was 
extended to give variolin B (shown retrosynthetically in Figure 1.9) in 13 steps with 6.5% overall 
yield. 74,75 
Varialin B 
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Figure 1.9: A retrosynthetic analysis of Fresneda and Molina's route to variolin B. 
Vaquero and colleagues also developed a synthesis of the variolin core, 1.5 (Figure 1.10, 
R;::;= C02Me)?6,77 Having altered their synthetic approach from an earlier proposed route,78 the 
researchers were served by serendipity in the development of a two step procedure with 49% 
overall yield. Their synthesis is shown retrosynthetically in Figure 1.10. 
1;, OMe 
Br~~ \_~~,.J O~"l. N 
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HN~,.J N 
Figure 1.10; Retrosynthetic analysis of the route developed by Vaquero et al. 
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The analogous deoxy core (deoxy 1.5, R = C02Me) was then synthesised by a similar route in 
two steps with 53% overall yield. This species was arylated at the C(S) position with the 
appropriate 2-thiomethyl pyrimidine stannane in a cross coupling reaction in 63% yield. The 
methyl ester was also removed from deoxy 1.5 by ester hydrolysis under basic conditions 
followed by decarboxylation in diphenyl ether at 250 DC to give deoxy 1.5 (R = H) with 30% 
yield over two steps. 
Finally, Alvarez, Fernandez and Joule worked on the following retrosynthetic pathway (Figure 
1.11). In 1999 they reported on the synthesis of fragments of the variolin core structure,79,80 
proving the validity of the proposed synthetic pathway. In 2001 they reported the synthesis of 
the non-natural analogue deoxyvariolin B (DVB, Figure 1.13) via the proposed pathway.8! In 
2002 they reported a synthesis of a further key variolin fragment,82 then in 2003, along with 
other researchers based in Spain, they reported the total synthesis of variolin B in ten steps and 
1.4% overall yield,83,84 DVB was also synth~sised using a similar strategy in ten steps and 4.1 % 
overall yield. 84 
Varlolln B 
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Figure 1.11: The Alvarez, Fernandez and Joule retrosynthetic pathway to variolin B. 
1.3.3.1 The AndenwnIMorris variolin Band deoxyvariolin B syntheses 
In 2001 Dr Regan Anderson, a doctorate student at the time supervised by Dr Jonathan Morris, 
completed the first total syntheses of both variolin B and the non-natural analogue DVB. 85.88 
The synthetic strategy was based on the insight that variolin B possesses a hidden element of 
symmetry, The initial synthetic route that was devised (shown retrosynthetically in Figure 1.13, 
and discussed below with respect to the deoxy series) gave favourable results when applied to 
the deoxy series, but unsatisfactory results when applied to the methoxy senes. The key 
shortcoming was an inefficient synthesis of the triaryl methanol species. For this reason, the 
retrosynthetic pathway shown in Figure 1.12 was developed. 
Variolin B > 
+ > + 
Figure 1.12: A retrosynthetic analysis of the AndersonlMorris synthesis of va rio lin B. 
This synthetic route involves the synthesis of a symmetrical ketone from the reaction of diethyl 
carbonate with the lithio species formed in situ from 4-iodo-2-thiomethylpyrimidine. This 
ketone is then arylated by the lithio species formed in situ from 2-chloro-4-methoxypyridine to 
give the triaryl methanol. Attempted deoxygenation of this compound using triethyl silane and 
TFA led to concomitant ring-closing to give the bis-thiomethyl core structure. This key reaction 
step was subsequently optimised by decreasing the amount of TF A used, and was also found to 
proceed more efficiently from the triaryl acetate. Introduction of the amino groups onto the 
pyrimidine rings of the core structure gave a triprotected compound that could be deprotected to 
give variolin Bin 8 steps and 15% overall yield. 
As was mentioned above, though not useful for the synthesis of the triaryl methanol required for 
the synthesis of variolin B, the synthetic route that was first pursued (Figure 1.13) gave good 
results in the deoxy series (which is discussed in more detail in Section 2.2). The synthesis 
involves the biarylation of 2-chloro-nicotinoyl chloride with the 4-lithio-2-thiomethylpyrimidine 
nucleophile (formed in situ from the iodide) to give a triaryl methanol species. The tri ary 1 
methanol was taken through to give the variolin core structure in one step (unlike in the methoxy 
series, the triaryJ acetate was not investigated in the deoxy series). As for the methoxy series, 
introduction of the amino groups onto the pyrimidine rings was achieved by an 
m-chloroperbenzoic acid oxidation of the thiomethyls to give the bis sulfone intermediate, 
followed by displacement of both sulfone moieties by p~methoxybenzylamine, The 
p-methoxybenzylamine groups of the resulting intermediate were removed by stirring with neat 
trimc acid to give DVB. DVB was therefore synthesised in six steps with 5.2% overall yield. 
Each of these synthetic steps is dealt with in more detail in Sections 2.2.1,2.4.1 and 2.5.1. 
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Figure 1.13: A retrosynthetic analysis of the Anderson/Morris synthesis of DVB. 
DVB is slightly more bioactive than variolin B, with an ICso of 0.47 ~ against the murine 
leukaemia P388 cell line. DVB has the further advantage of being more synthetically accessible 
than variolin B, and so the DVB core structure became the focus of the work described in this 
thesis. 
1.3.3.2 Analogue syntheses 
Anderson and Morris also devised a series of synthetic routes to variolin analogues, with the 
potential to selectively functionalise at the C(2') and/or C(9) positions (Figure 1.14), and 
employed these protocols in the synthesis of a range of non-natural analogues. The analogues 
that were synthesised, along with their bioactivities, are given in Section 3.2.2. 
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Figure 1.14: The synthetic routes devised by Anderson and Morris 
in the synthesis of non-natural vanolin analogues. 
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The brief structure-activity relationship (SAR) investigation carried out by Anderson and Morris 
was extended to the deoxy series as part of the work described in this thesis, with an aim to 
determine the most suitable analogues for further development into polymer therapeutics (see 
Section 3.2.3). 
It should be noted that this SAR work was carried out as part of a much larger SAR effort 
coordinated by Pharma Mar, SA. Their work will be discussed in more detail in Section 3.1. 
1.3.4 Reasons for developing DVB into a polymer therapeutic 
DVB is a compound in the early stages of development as an anticancer therapeutic. It is 
slightly more bioactive and more synthetically accessible than the parent natural product variolin 
B. It possesses appreciable anticancer activity in vitro, and preliminary investigations using 
animal models have begun. One of the most significant shortcomings of this promising 
compound, however, is its low aqueous solubility. The use of solubilising formulations has thus 
far been met with only partial success. 89 The pharmaceutical utility of DVB in its unmodified 
form will therefore almost certainly be limited by this poor solubility. Conjugation with a water 
soluble polymer, such as pHPMA, will greatly increase the water solubility ofDVB. The further 
advantages associated with macromolecular prodrugs, namely improved pharmacokinetics and 
pharmacological profiles, have been discussed in detail in 1.2.2. 
1.4 Aims 
At the beginning of the work described in this thesis, the aims of the work were defined as 
follows: 
1) to further investigate and optimise the synthesis ofDVB; 
2) to extend the brief SAR investigation involving the methoxy and hydroxyvariolin series 
to the deoxy series; 
3) to select the most suitable analogues for further development into polymer-drug 
conjugates, and acyl ate these analogues with the GFLG tetrapeptide biolinker; and, 
4) to use any tetrapeptide-variolin conjugates successfully synthesised in the synthesis of 
polymer-drug conjugates from pMAOS. 
Chapter 2 outlines the optimisation of the synthesis of DVB, as well as the attempted synthesis 
of a DVB-tetrapeptide conjugate. Attempts were also made at synthesising a variolin analogue-
tetrapeptide conjugate, with the variolin being bound through the N(9a) position. Some 
interesting chemistry at the N(9a) position was uncovered during this work. 
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Chapter 3 outlines the synthesis of a small family of DVB analogues, with a tetrapeptide 
conjugate being synthesised from the most suitable of the analogues. 
Finally, Chapter 4 outlines the discovery and characterisation of some unforeseen side reactions 
encountered in the use of pMAOS as an activated polymeric precursor in the synthesis of 
polymer~drug conjugates. 
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CHAPTER 
ACYLATION OF THE VARIOLIN CORE 
2.1 Introduction 
As was discussed in Chapter 1, DVB was to be incorporated in a polymer therapeutic via a 
biodegradable tetrapeptide biolinker. It was therefore necessary to acylate DVB with the 
N-protected tetrapeptide Fmoc-glycyl-L-phenylalanyl-L-leucyl-glycine, 
DVB has two potential points of attachment - the N(9a) and N(2'a) positions. This chapter deals 
first with the synthesis of the variolin core, then with attempts to selectively acylate at each of 
these positions. 
2.2 Characterisation of Compounds 
All new compounds synthesised as part of the work described in this and in following chapters 
were rigorously characterised using a range of techniques (compounds that had previously been 
reported were generally characterised by lH NMR and melting point analysis alone). NMR 
experiments that were routinely performed included 10 lH and DC experiments, and the 2D 
COSY, HSQC-DEPT and CIGAR experiments, The type of information that is afforded by 
these 2D experiments is shown below in Figure 2.1, 
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Figure 2.1: The specific types of bond connectivities detected by COSY 
(red), HSQC (blue) and CIGAR (green) 2D NMR experiments. 
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COSY experiments indicate pairs of adjacent protons. HSQC-DEPT experiments indicate the 
direct connectivity ofproton(s) to the carbon to which they are bonded, as well as establishing if 
a given proton signal is a methylene or a methine/methyl group. CIGAR experiments give 
correlations between protons and carbon atoms separated by two, three or four bonds (with the 
latter being less common). 
All novel compounds synthesised as part of the work described in this thesis were 
unambiguously characterised by a combination of ID and 2D NMR techniques. Around half of 
the most important previously reported compounds were also characterised in this manner. In all 
but one example (which is discussed in Section 2.4.3.1), these three techniques allowed 
unambiguous assignment of all IH and 13C signals in the respective ID NMR spectra. The 2D 
NMR techniques were particularly useful in the structure elucidation of copolymers 4.3 and 4.6, 
discussed in detail in Sections 4.3.2.1 and 4.3.2.6, respectively. 
In addition to characterisation by 2D NMR spectroscopy, all novel compounds synthesised as 
part of this work were routinely analysed by high-resolution mass spectrometry (HRMS) using 
electrospray ionisation (ESI), a technique which employs a 'soft' form of ionisation that leads to 
minimal decomposition of the parent ion, with detection being carried out in the positive mode. 
HRMS analyses were performed in quadruplicate, with a requirement being that the root-mean-
square (rms) of the deviation from the expected value for the four runs be less than 5 ppm for a 
result to be considered confirmative. 
Other routinely used characterisation techniques included melting point determination of 
crystalline solids and FTIR spectroscopy. HPLC and LCMS were also employed at times to lend 
support to proposed structures and/or the purity of samples. 
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2.3 Synthesis of the Deoxyvariolin Core 
The Anderson and Morris route to the deoxyvariolin core structure is shown below in Figure 2.2. 
The final step (an ionic hydrogenation90 involving ring-closing and reduction of the triaryl 
species in one reaction step) was initially performed on the triaryl alcohol 2.4,86 though further 
work on the analogous methoxy system had indicated that this reaction would proceed in better 
yield from the triaryl acetate, 2.5.87 DVB was synthesised in 6 steps in 5.2% overall yield. 
ijYCI ijYX 0 0 79% CI~ 97% He:)) NyN jill NyN .. 
SMa SMa CI N CI N 
2.1: X= 1 2.3 
2.2: X = Li 
56% 
2.4 
134% 
2.5 
2.6 
Figure 2.2: The Morris and Anderson synthetic route to the deoxyvariolin core. 
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Given the need of a ready supply of deoxyvariolin material, it was decided that these synthetic 
protocols would be more closely investigated and hopefully improved. 
2.3.1 Replication of the existing protocols 
The protocols for the synthesis of the iodopyrimidine 2.1 and pyridine acid chloride 2.3 were 
replicated to give the desired products in 80% and 99% yield, respectively. These two reagents 
were then used in the synthesis of triaryl alcohol 2.4 using the protocols developed by Anderson 
and Morris. These protocols involved the addition of 2.3 to the lithio species 2.2, which is 
formed in situ from 2.1. Species 2.2 is relatively unstable and prone to side reactions. The 
exothermic nature of the addition reaction further complicates this troublesome reactivity in 
larger scale syntheses, A specialized piece of glassware was therefore employed - a reactor with 
a coiled side arm for the addition of reag'ents,87 During the reaction the reactor is almost 
completely immersed in a -95°C (MeOHINz) cold bath, so that reagents that are added via the 
side arm are cooled before reaching the reaction solution. 
The protocols specify the careful addition of n~BuLi at 0.5 mLimin to a vigorously stirred 
solution of iodide 2.1, stirring the reaction solution for 20 minutes to allow the complete 
formation of 2.2, then the careful addition of acid chloride 2.3 at a similar rate followed by 
stirring for a further 3-4 h. During the course of the reaction the temperature should remain as 
close to -95°C as possible, and of course, must be kept rigorously dry, This is a difficult 
reaction, but yields of ~55% can be expected if carried out properly. 
The first attempt at this reaction gave only a 26% yield of triaryl alcohol 2.4. The exact reason 
for the low yield was unknown, but was most likely due to flawed experimental technique. It 
was decided to convert this material to triaryl acetate 2.5, with an aim to take the acetate through 
to the ionic hydrogenation step in the hope that the observed improvement in yields for the 
methoxy system would hold true in the deoxy series. 
Triaryl alcohol 2.4 was therefore acetylated with acetic anhydride to give triaryl acetate 2.5 in 
92% yield. 2.5 was then subjected to the ionic hydrogenation protocols, involving triethyl silane 
and TFA, to give core structure 2.6 in 69% yield, thus confirming that the triaryl acetate gives 
much better yields than the triaryl alcohol in both the deoxy as well as the methoxy system. 
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The synthetic protocols described above for the synthesis of 2.4 were repeated, differing only in 
that an acetyl chloride quench was used in place of the methanol quench upon completion of the 
reaction (in analogy to the protocols developed for the methoxy system), to give triaryl acetate 
2.5 in 60% yield. 
2.3.2 Arylation of Weinreb's amide 2.8 
Despite the good yield in this reaction, it was still considered desirable to investigate other 
synthetic approaches employing a more robust triaryl acetate synthetic step. Therefore, a similar 
synthetic route reported by Remuinan et al. was investigated.91 This procedure involves the 
synthesis of the Weinreb's amide 2.8 from acid chloride 2.3, which is then reacted with the 
Grignard species 2.7, formed in situ from iodide 2.1, to give ketone 2.9. 2.9 is then reacted in a 
subsequent step with 2.7 in a reaction quenched with acetyl chloride to give triaryl acetate 2.5 in 
a reported 52% yield over 3 steps (Figure 2.3). 
N MgCI 0 MeO-N~ 87% 2.1 ... NyN I I ~ ... 2.3 
SMe CI N 
2.7 2.8 
80% 
0 
ex)) i) 2,7; ii) AcCI ... 2.5 
NyNCI N~ 74% 
SMe 
2.9 
Figure 2.3: The Remuinan et al. synthetic route to triaryl acetate 2.5. 
Thus, Weinreb's amide 2.8 was synthesised from acid chloride 2.3 in 93% yield. However, the 
reaction of 2.8 with 2.7 (formed in situ from 2.1) did not proceed as cleanly as was hoped. The 
literature protocols specified that Grignard reagent 2.7 was formed from 2.1 at 0 °C then 
transferred via cannula into a solution of 2.8. These protocols were eventually modified slightly, 
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so that 2.7 was formed at -15°C and into this solution was then carefully transferred via cannula 
a solution of 2.8 to give ketone 2.9 in 75% yield. The subsequent step, involving the arylation of 
ketone 2.9 by 2.7, gave mixtures of compounds, of which the desired product 2.5 was only a 
small component (as determined by IH NMR spectroscopy). The crude reaction mixtures 
typically contained 10-20% unreacted starting material 2.9 as well as a large amount of the two 
compounds 2.10 and, to a lesser extent, 2.11 (Figure 2.4). The desired product, 2.5, was isolated 
in 14% yield. 
2.10 2.11 
Figure 2.4: Side products 2.10 and 2.11. 
The presence of both 2.9 and 2.11 in the crude reaction mixtures indicated that the nucleophile 
was consumed by side reactions before the reaction was able to go to completion. This is despite 
using a 2.5 molar excess of the nucleophile. In the synthesis of 2.9 from 2.8, only a 1.25 molar 
excess of 2.7 was required, indicating that the formation of 2.7 from 2.1 was an efficient 
reaction. The difference in the success of the two reactions therefore most likely reflects the 
higher degree of sterlc hindrance in the ketone compared with the Weinreb's amide. It is not 
known why the literature account encountered more success than was seen in this work. 
In order to address the problem of the relatively low reactivity of ketone 2.9, the stonger lithio 
nucleophile 2.2 was investigated. The literature reports the use of Barbier protocols in the 
arylation of 2.9 by 2.2 (specifically, the addition of n-BuLi to a cooled solution of both 2.9 and 
2.1 at -78°C) to give 2.5 in 61 % yield.91 These protocols were therefore repeated to give 2.5 in 
59% yield. 
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2.3.3 Arylation of methyl ester 2.12 
Work being carried out in parallel to the Weinreb's amide investigation involved the arylation of 
methyl ester 2.12 (Figure 2.5) with either 2.2 or 2.7. 
o Meo:o 
CI N 
2.12 
Figure 2.5: Pyridine methyl ester 2.12. 
Ester 2.12 was synthesised from 2.3 in 85% yield. Arylation of 2.12 with three molar 
equivalents of 2.7 gave a messy crude' reaction mixture (as determined by 'H NMR 
spectroscopy) comprised of the 2.12 starting material, ketone 2.9, side product 2.11 and, to a 
lesser extent, product 2.5. Attempts were not made to purify the product from this mixture. 
It appeared that, as in the arylation of 2.9, the stronger Iithio nucleophile 2.2 was required. Thus, 
2.12 was reacted with three molar equivalents of 2.2 using Barbier protocols and the reaction 
quenched with acetyl chloride. Rather than the expected product 2.5, what was instead isolated 
from the reaction mixture, in 90% yield, was the quaternary species 2.13 (Figure 2.6). 
MeO OAe ~ ~Y~CI)lN) 
SMe 
2.13 
Figure 2.6: Quaternary species 2.13. 
It is postulated that 2.13 forms due to the stabilisation of the quaternary intermediate oxyanion 
through coordination by the lithium cation (Figure 2.7). 
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n-8uLi AcCI 
2.13 2.1 + 2.12 
Figure 2.7: Proposed mechanism offonnation of 2.13. 
Treatment of 2.13 with aqueous NaOH caused it to collapse to ketone 2.9. Thus, when a crude 
reaction mixture from the reaction shown in Figure 2.7 was treated with 1 M NaOH at room 
temperature for 2 h and the crude reaction mixture analysed by IH NMR spectroscopy, ketone 
2.9 was seen by to be the only significant nicotinoyl-containing compound. Unfortunately, 
purification of 2.9 was hindered by the coelution of side product 2.10, which forms from 
unreacted 2.2. It is anticipated that a lower stoichiometry of 2.2 in the above reaction (1.2 
equivalents, for example) would be sufficient for the reaction to go to completion and would 
avoid the problems of contamination by 2.10: 
2.3.4 Barbier protocols with acid chloride 2.3 
With the observed successes seen with the application of Barbier protocols in the synthesis of 
triary! acetate 2.5 from 2.9, it was decided to employ these protocols in the synthesis of 2.5 (and, 
for comparative purposes, triary! alcohol 2.4) from acid chloride 2.3 and iodide 2.1 (Figure 2.8). 
2.4 
MeOH 
.. 
2.1 + 2.3 
l ".BuLi 
AcCI 
---I....... 2.5 
Figure 2.8: Syntheses of2.4 and 2.5 from 2.1 and 2.3 under Barbier lithiation conditions. 
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Initial investigations gave promising results, and three small modifications were made: firstly, it 
was best to transfer a solution of the iodide to a cooled solution of the acid chloride immediately 
prior to addition of n-BuLi, rather than letting the two reagents sit together for any length of time 
(during which time side reactions, leading to the formation of what appeared to be h, were seen 
to occur); secondly, a reaction temperature of -96°C gave superior yields than one of -78 °C; 
and, thirdly, 2.2 molar equivalents of the nucieophile were sufficient for the reaction to proceed 
to completion. 
The protocols employing the methanol quench gave an inseparable mixture of triaryl alcohol 2.4 
with a small amount of the biaryl alcohol 2.14 (Figure 2.9). This mixture was refluxed in 
benzene with MnOz to give a mixture of ketone 2.9 and 2.4, the latter of which was then easily 
purified in 40% yield. When the acetyl chloride quench was used, triaryl acetate 2.5 was 
obtained in 50% yield. In some instances an inseparable mixture of 2.5 and biaryl acetate 2.15 
(Figure 2.9) was obtained; this material, however, could be taken through to the next synthetic 
step to give core structure 2.6, which could then be easily purified away from the contaminant 
2.15 in good yield. The formation of 2.14 and 2.15 under similar conditions have been reported 
by Anderson and Remuinan et al., respectively.87,91 
2.14 
OAe 
~ ~y~cIANJ 
SMe 
2.15 
Figure 2.9: Contaminants 2.14 and 2.15. 
While the yields were reasonable, especially considering the more simple reaction protocols and 
much lower nucieophile stoichiometry, the yields were still not as good as expected based on 
analysis of the crude reaction mixtures by lH NMR spectroscopy, which indicated yields of 
around 80%. Furthermore, purifications that involved several chromatographic steps 
consistently gave lower yields, suggested that material was being lost during the 
chromatography. Using DIOL in the place of silica gave no better results. For this reason a 
crude reaction mixture was taken directly through to the core structure synthetic step to give 2.6 
in 50% yield over 2 steps. Given that the ring-closing reaction proceeds in about 70% yield from 
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a clean sample of 2.5, this yield of 50% over 2 steps confirms the high yield suggested by the IH 
NMR results for the synthesis of 2.5 and supports the assertion that material was being lost 
during chromatography. 
Thus, core structure 2.6 was synthesised over 3 steps (with only 1 chromatographic step, and one 
step requiring no purification at all) from commercially available starting materials in 40% 
overall yield. 
2.4 Acylation ofN(9a) 
With core structure 2.6 in hand, and ready access to more if needed, attention could now be 
turned towards the synthesis of acylated analogues of DVB. Rather than investigating the 
acylation of DVB immediately, it was considered desirable to first synthesise analogue 2.16 
(Figure 2.10) to investigate acylations exclusively at the N(9a) position. 
2.16 
Figure 2.10: Analogue 2.16. 
2.4.1 Synthesis of 2.16 
Intermediate 2.17 was synthesised in near-quantitative yield via the synthetic route shown in 
Figure 2.11, a route developed by Anderson and Morris during investigations involving the 
methoxy system.87 Deprotection of the p-methoxybenzylamine (Pl\1B) group from 2.17 with 
neat triflic acid to give analogue 2.16 proceeded without complications in good yield. 
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99% 
N N~ 
q 
Triflic acid 
2.6 2.16 
94% 
OMe 
2.17 
Figure 2.11: The synthetic route to analogue 2.16 from core structure 2.6. 
Analogue 2.16 poses sed an IC so of 3.9 J1M against the P388 cell line. Although this was 
approximately an order of magnitude lower than the bioactivity of DVB (IC5o 0.47 J1M) 
against this particular cell line, it was still considered a worthwhile candidate for further 
development into a polymer therapeutic (see Section 3.2.3.4 for a discussion of in vitro 
bioactivity in the context of this work). It was also a logical choice of analogue for the 
investigation of acylations at the N(9a) position. 
2.4.2 Tetrapeptide biolinker synthesis 
It was necessary to synthesise the tetrapeptide biolinker - FmocGFLG - to be used as the 
electrophile in the acylation of analogue 2.16. Given that the cytotoxins being employed in this 
work were all of synthetic origin, it was desirable to have ready access to comparable amounts of 
the tetrapeptide. Several synthetic routes were therefore investigated. 
2.4.2.1 Solid-phase protocols 
Solid-phase protocols employing Fmoc-protected amino acids92 and Wang-resin93 had previously 
been applied in the synthesis of FmocGFLG.94 HBTU couplings were employed, with Fmoc-
deprotection being carried out using piperidine. These protocols were successfuI1y repeated to 
give the tetrapeptide in 38% overall yield, but it was soon realised that, unlike the natural 
product-based projects for which this synthesis had been developed, the work being carried out 
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here required relatively large amounts of this compound. It was therefore decided to develop 
solution~phase protocols for the simple (and less expensive) gram-scale synthesis of the 
biolinker. 
2.4.2.2 Solution phase protocols employing Fmoc-amino acid chlorides 
Carpino and coworkers have reported the rapid and convenient synthesis of oligopeptides (up to 
residues) in the solution phase using Fmoc-protected amino acid chlorides.95-98 A chloroform 
solution of the carboxyl-protected peptide nucIeophile with a small excess of the Fmoc-protected 
amino acid chloride is vigorously stirred with a 5% aqueous Na2CO) solution. The organic 
fraction (containing all the peptidic material) is then isolated from this biphasic mixture and 
treated with a diamine base, which serves to both cleave the Fmoc goups and react with any 
remaining acid chloride. The mixture is then extracted with pH 5.5 phosphate buffer to 
remove the basic fulvene ad ducts and conjugates, while leaving the less basic free amine 
growing peptide chain in the organic phase for the next coupling cycle. Importantly, 
racemization was not observed during the application of these protocols.95 Figure 2.12 shows 
one of these coupling/deprotection cycles, employing 4-aminomethyl piperidine (AMP) as 
deprotecting agent and nucleophilic scavenger (nucleophilic attack may involve either of the two 
nitrogens, hence the ambiguous structures). 
The Fmoc-amino acid chlorides were easily synthesised from their respective amino acids by 
reaction with thionyl chloride,95 with the exception of Fmoc-L-leucine acid chloride, which was 
successfully synthesised but used as a thick gum, as repeated attempts at recrystallisation were 
unsuccessful. The tetrapeptide was then synthesised via the above protocols, albeit in only low 
overall yield - a yield of 28% (24% if the glycine benzyl ester synthetic step is included) was 
achieved once, with yields of 10-15% being typical. 
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R2 ~ H2NAyo~ 
o ! CHCI,Iaq Na,C03 
+ 
1 pH = 5.5 buffer wash 
R1 0 H'NJy~0o~ 
o Rz V 
Figure 2.12: One cycle of a solution phase synthesis of oligopeptides 
using Fmoc-protected amino acid chlorides. 
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A closer look at the first two steps revealed the reason for the poor yield. Firstly, it had been 
observed during IH NMR spectroscopic analysis of the acid chlorides that Fmoc-L-Ieucine was 
much more electrophilic than the other two amino acid chlorides (in contrast to Fmoc-glycine 
and Fmoc-L-phenylalanine acid chlorides, relatively large amounts of the free acid of Fmoc-L-
leucine were observed in NMR spectra of this acid chloride due to traces of water in the CDCb 
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NMR solvent).* Hydrolysis during the coupling reaction involving Fmoc-L-leucine acid chloride 
therefore represented a significant loss of material. Secondly, diketopiperazine formation 
following deprotection of the dipeptide (Figure 2.13) was also thought to be occurring, though 
efforts were not made to purify the diketopiperazine. 
Figure 2.13: Presumed diketopiperazine formation from LGOBn. 
Due to this unsatisfactory first couplingldeprotection cycle, giving 50% yield at best, it was 
decided to use more conventional solution-phase protocols in the synthesis of the tetrapeptide. 
2.4.2.3 Conventional solution-phase protocols 
The tetrapeptide was synthesised in the C-N direction, with the C-terminal glycine residue being 
protected with a benzyl ester group. Fmoc-protected amino acids were used. The first coupling, 
between the benzenesulfonate salt of glycine benzyl ester and Fmoc-L-Ieucine, was carried out 
with DCCIHOBT, with the dipeptide being easily separated from the DCU side product by silica 
chromatography. The Fmoc group was cleaved from FmocLGOBn by stirring with 
1: 1 AMP/THF for five minutes and the deprotection adduct removed by washing with pH = 5.5 
phosphate buffer (these manipulations were carried out as quickly as possible in an attempt to 
minimise diketopiperazine formation). To the reaction solution was then immediately added 
Fmoc-L-phenylalanine acid chloride and 5% aqueous Na2C03 solution, the biphasic solution 
stirred vigorously at room temperature, and the product purified by silica chromatography. 
AMP-deprotection protocols were again employed in the deprotection of the Fmoc group, an 
EDCI/HOBT coupling used in the reaction between the resulting tripeptide and Fmoc-glycine, 
and the tetrapeptide benzyl ester purified on silica. The benzyl ester was cleaved by palladium-
• Synthesis of leucine methyl ester from the acid chloride with dry methanol gave a product free of the acid, 
indicating that the acid chloride starting material was of high purity. 
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catalysed hydrogenolysis (though it had been reported under similar conditions,99 no cleavage of 
the Fmoc group was observed during this step) and the FmocGFLG purified by precipitation 
from THF with hexanes. It should be noted that no evidence of racaemisation was observed 
when crude reaction mixtures were analysed by thin layer chromatography on silica, nor when 
purified peptides were characterised by NMR spectroscopy. The finalised synthetic route, 
involving seven synthetic steps, three chromatographic steps and with an overall yield of 33%, is 
given below in Figure 2.14. 
benzyl alcohol, 
Senzenesulfonic acid o rP) ~~~OH • H2Nlr°~ 86% 
i) AMP/CHCI3 :.\r~JoBn Ii) pH :: 5.5 buffer wash 
o 
I Fmoc-L-PheCI, 
64% ~ CHCI3, aq NaZC03 
FmocGFLG 
Pd/C, H2 
I) AMP/CHCI3 
.. 
i~ buffer wash 
o 0 
900f< I Fmoc+leuclne, 
o ~ DCC, HOST, TEA 
Figure 2.14: Finalised solution-phase synthetic route to FmocGFLG. 
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While more laborious, this synthetic route has the advantage of being robust, using a minimal 
amount of electrophile at each step, producing relatively clean product and enabling the efficient 
scale up to potentially gram~quantities. 
With the biolinker in hand, attention could be turned towards the synthesis of a variolin-biolinker 
conjugate. 
2.4.3 Acylation of 16 with the biolinker 
2.4.3.1 Dec coupling 
A DCC coupling between analogue 2.16 and FmocGFLG gave conjugate 2.18 (Figure 2.15), 
which precipitated out ofsolution during the course of the reaction. Conjugate 2.18 was isolated 
by filtration in 28% yield, with a small amount of contamination by DCU, 
2.18 
Figure 2.15: Conjugate 2.18. 
Analysis by IH NNIR spectroscopy showed all the expected peptide and variolin signals. Of 
particular note was a signal at 12.87 ppm for the 9-NH proton, and a chemical shift of -4.5 ppm 
(partially obscured by another signal) for the C-terminal glycine methylene group, which was 
significantly different from the value of 3.73 ppm seen with the free tetrapeptide. However, 
2D NMR was unable to conclusively prove the structure of 2.18, as key CrGAR correlations 
between the tetrapeptide and variolin core were not observed. This uncertainty was resolved by 
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HRMS, however, which gave a strong signal for a compound of correct mass, with no 
observable free tetrapeptide or variolin. 
The synthesis of this compound using what is ultimately an anhydride electrophile at 4 °C 
showed that the N(9a) position was somewhat different from other 2~aminopyrimidines, which 
require more agressive conditions ~ for example, refluxing with acetic anhydride lOo•102 or using 
acid chloridesJ03-J06 - before acylation will proceed. The left hand side of Figure 2.18 gives the 
proposed mechanism for the acylation of N(9a), though it is not known why this reaction 
proceeds so much more readily than with other 2-aminopyrimidines. 
Attempts to purify conjugate 2.18 away from the DCU impurity were hindered by 
decomposition, to give what appeared to be analogue 2.16 by tIc analysis. Furthermore, 
treatment with piperidine, in an attempt to cleave the Fmoc group, led to complete 
decomposition to give analogue 2.16 (and, presumably, the tetrapeptide GFLG). This low 
stability of the N(9a)-acyllinkage needed to be investigated more closely. However, due to the 
awkward solubility and relatively high polarity of conjugate 2.18, it was decided to investigate 
the stability further using a simple model system employing the acetyl moiety in place of 
FmocGFLG. 
2.4.4 Acylation ofN(9a) with Acel 
The reaction of analogue 2.16 with one equivalent of AcCI, in the presence of a slight molar 
excess of TEA, gave a mixture of the variolin starting material 2.16, the monoacetyl derivative 
2.19 and the diacetyl derivative 2.20 (Figure 2.16), This result was not unexpected, as the 
formation of derivative 2.20 under similar conditions has already been reported,91 and the 
diacetylation of other 2-amino pyrimidines101,102 is also known. Attempts to push this 
diacetylation reaction through to completion were unsuccessful, however, as is evidenced by the 
results from the reaction of 2.16 with five equivalents of AcCl, again, with a small molar excess 
of TEA (Table 2.1). Reactions were carried out at room temperature for 48 hours, and the 
variolin products purified by flash chromatography on silica. 
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2.19 2.20 
Figure 2.16: AcetyJated variolin derivatives 2.19 and 2.20. 
Relative proportions of va rio lin products (%)[a) 
2.16:AcCI Recovery (%)[a] 2.16 2.19 2.20 
1: 1 62 53 7 40 
1 :5 61 o 59 41 
[a] Based on recovered variolin material following flash chromatography on silica. 
Table 2.1: The ratio of compounds recovered from the acetlyation of 2.16 with Ace!. 
Subsequent attempts to push the formation of 2.20 through to completion were unsuccessful. 
During the chromatography on these reactions, it was noticed that derivative 2.19 appeared to be 
decomposing back to 2.16 while on the silica. This was surprising, given the reported stability of 
other 2_acylaminopyrimidines. I03,104,I06,107 For this reason the two reactions were repeated, 
stirring the reaction solutions at room temperature for 19 hours, and removing a 30 f!L aliquot 
for immediate concentration in vacuo and analysis by IH NMR spectroscopy. In the NMR 
spectra of these mixtures, the three variolin products, presumably with minimal decomposition, 
could be quantified relative to each other by comparing the peak integral ratios of the acetyl 
methyl signals of derivative 2.19 (appearing at 2.676 ppm) and derivative 2.20 (both methyls 
were coincident and appeared at 2.41 ppm) with the S-methyl signal (which was coincident for 
all three compounds, 2.16, 2.19 and 2.20, and appeared at 2.685 ppm) (Figure 2.17). The results 
are presented in Table 2.2. 
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U6, 2.19, and 2.20 SCH, 
2.20 COCH, (x2) 
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Figure 2.17: The methyl region from a IH NMR spectrum of a crude reaction 
mixture from the acetylation of2.16 with I eq AcCl. 
Relative proportions of va rio lin products (%) 
2.16:AcCI 2.16 2.19 2.20 
1: 1 43 19 38 
1:5 o 57 43 
Table 2.2: The ratio of va rio lin compounds in the acetylation 
of 2.16, as detennined by I H NMR spectroscopy. 
43 
ppm 
The NMR results confirmed what had been previously observed; namely, that regardless of the 
amount of AcCl present, the diacetyl derivative 2.20 is formed at about 40%. Higher 
stoichiometries of AcCllead to a higher conversion of 2.16 to 2.19, but most of this monoacetyl 
derivative doesn't react any further. To test this assertion, a sample of 2.19 was stirred with 
AcCl at room temperature for 22 h. Removal of an aliquot followed by immediate concentration 
in vacuo and analysis by lH NMR spectroscopy indicated that no acetylation had occurred (that 
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is, 2.20 was not present). Flash chromatography on silica gave the starting material 2.19 with 
81 % recovery, 
As a further test, a solution of 2.20 and 2.16 stirred at room temperature for 5,5 hours gave no 
2.19, as determined by IH NMR spectroscopy. These results, taken together, prove that the 
product ratios given in Table 2.1 and Table 2.2 are not equilibrium concentrations. 
The second conclusion is speculative and not so obvious, and that is that the acetylation of 2.19 
to give 2.20 goes via a reaction catalysed by 2.16. This assertion comes from the fact that the 
only obvious difference between the reactions in which 2.20 was produced and the failed attempt 
at acetylating 2.19 was the presence of 2.16 in the former examples. Figure 18 shows the 
proposed mechanism for the formation of 2.20, catalysed by 2.16, It is proposed that analogue 
2.16 is acetylated by AcCI at the N~8 position to give intermediate 2.21. This intermediate has 
not been detected, and it is not known how long~lived it is. Intermediate 2.21 may then undergo 
either an intramolecular acyl-migration to give 2.19, or it may be subjected to an intermolecular 
attack by a second molecule of 2.19 to give the diacylated species 2.20, and in the process 
regenerating the catalyst 2.16. This mechanism is purely speculative, and has been formulated 
based only on the experimental results already given, It is not known why species 2.21 acylates 
2.19 to give 2.20 while AcCI does not. 
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Figure 2.18: Proposed mechanism for the 2.16-catalysed synthesis of 2.20 from 2.19. 
Conclusive proof of the catalytic involvement of 2.16 would require the use of N15 -labelled 
variolin reagents, This type of investigation, however, was considered beyond the scope of this 
project. Instead, a few simple experiments were done in an attempt to lend support to the 
proposed mechanism. The first of these involved stirring derivative 2.19, analogue 2.16 (1 eq), 
AcCI (5 eq) and TEA (5.5 eq) at room temperature for 13 h. Analysis of an aliquot of the crude 
reaction mixture by IH NMR spectroscopy revealed that there was no remaining 2.16 starting 
material, with a ratio of 2.19 to 2.20 of 75:25. Given that 2.19 will not be acylated in the 
absence of 2.16, and 2.16 alone will give ~40% 2.20 in the reaction with excess AcCI, it can be 
inferred that some intermolecular catalysis has occurred, that is, if the 2.19 starting material was 
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not acylated and did not participate in the fonnation of 2.20, then 40% acylation of 2.16 would 
be expected to give a final ratio of 2.19 and 2.20 of 80:20. The observed ratio was 25% higher 
than that expected for the hypothetical reaction in which no 2.19 starting material reacts to form 
2.20, which is considered to be above the margin of error for the experiment It is therefore 
proposed that the presence of2.16 allowed the 2.19 starting material to be acylated to give 2.20. 
A second experiment involved repeating the above experiment, with the difference that the 
biswthiomethyl core structure 2.6 was substituted for analogue 2.16. No fonnation of 2.20 was 
observed in this experiment, indicating that core structure 2.6 does not fonn an acylating species 
in the same way as analogue 2.16 forms 2.21. 
A final investigation into this reactivity involved a time course experiment. This involved the 
reaction of analogue 2.16 with AcCI (5 eq) and TEA (5.5 eq), with aliquots periodically being 
removed, diluted with THF, injected onto the HPLC and analysed at 256 nm. For each run the 
peak areas of 2.16, 2.19 and 2.20 were measured and directly compared with each other (for the 
purpose of this quick experiment, the extinction coefficients of the three compounds at the 
specified wavelength were considered to be comparable). The changing proportions of the three 
variolin compounds during the first 20 minutes is shown below in Figure 2.19, 
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Figure 2.19: An HPLC~based time course investigation for the acetylation of2.16 with AcC!. 
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It can be clearly seen that the reaction is complete in about the first 10 minutes. At 5 minutes 
80-85% of 2.16 has reacted, with -30% 2.20 and -55% 2.19 having been fonned. In the next 
five minutes the remaining 2.16 is all but completely consumed with an increase in the relative 
concentration of 2.20 of 10-15%, while the relative concentration of2.19 is seen to increase only 
slightly. This is presumed to be due to the fact that 2.19 is being consumed (to fonn 2.20) 
almost as quickly as it is being fonned (from 2.16). In the final 10 minutes, following complete 
consumption of 2.16, no more 2.20 (whose rate of formation at any time is seen to be a function 
of the concentration of 2.16) is formed~ in fact, a small amount of hydrolysis of 2.20, to give 
2.19, is observed, presumably through traces of water that were introduced by the repeated 
removal of aliquots with the same syringe (see Section 2.4.5 for a discussion of the 
decomposition of 2.20 to 2.19). These results are entirely consistent with the proposed 
mechanism shown in Figure 2.18. 
2.4.5 Stability of derivatives 2.19 and 2.20 
Varying levels of instability of both monoacetate 2.19 and diacetate 2.20 had been observed, 
with both breaking down to give 2.16 (and 2.20 first breaking down to give 2.19, which 
accumulates under basic conditions), and so it was decided to look more closely at this. The first 
investigation was simple - successively larger amounts of TF A (chosen because of its use in 
reversed phase purification) or piperidine (chosen because of its use in Fmoc-deprotection) were 
added to solutions of 2.19 or 2.20 in THF and the solutions periodically analysed by tic. Efforts 
were not made to exclude water. Results are given below in Table 2.3 and Table 2.4. 
[TFA] (v/v) 0.1% l.0% 10% 
Time (min) 30 120 30 120 30 120 
2.19 decomposition ~rtial partial complete 
2.20 decomposi . nil minimal partial complete 
Table 2.3: Degradation of2.19 and 2.20 to 2.16 in TFA/THF solutions. 
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[Piperidine] (v/v) 0.1% 1.0% 10% 
Time (min) 30 120 30 120 30 120 
2.19 decomposition minimal minimal partial partial complete 
2.20 decomposition complete 
Table 2.4: Degradation of2.20 to 2.19, and 2.19 to 2.16 in piperidinelTHF solutions. 
Both 2.19 and 2.20 readily break down to 2.16 (as indicated by tic) within 30 minutes in 
10% (v/v) solutions ofTFA or piperidine. This is in contrast to most 2-amidopyrimidines, which 
typically require much more vigorous conditions for the removal of acyl groups.l07 2.20 breaks 
down to 2.19 very quickly in the presence of piperidine, whereas it shows significantly higher 
stability towards TF A, breaking down to 2.16 only at higher concentrations. 2.19, while not as 
stable as 2.20 towards TF A, is significantly more stable towards piperidine, more stable, in fact, 
than it is towards TF A. The order of decreasing stability, then, is 2.20 (TFA) > 2.19 (piperidine) 
> 2.19 (TFA) > 2.20 (piperidine). This is an interesting result, and so will be discussed here in 
more detail. 
One would expect 2.20 to be less stable than 2.19 simply due to the higher reactivity of imides 
over amides. However, this is not the case for the decomposition in acidic conditions. There are 
most probably several important factors explaining these differences in stability between the two 
in both acid and base, which are outlined below. 
The probable mechanism of the aminolysis of2.20 by piperidine is given in Figure 2.20. 2.20 is 
shown with the acetyl groups out of the plane of the ring (a steric requirement). Decomposition 
is proposed to proceed via a direct nucleophilic attack on an acetyl carbonyl, followed by 
expulsion of the resonance-stabilised anionic variolin leaving group. (What is not shown in 
Figure 2.20 is that this resonance stabilisation may also involve the delocalisation of the negative 
charge into the variolin core structure, in an analogous fashion to that shown in Figure 2.22.) In 
support of this mechanism of decomposition is the observation that only minimal degradation of 
2.20 was seen to occur during chromatography on silica with eluants containing 0.1 % (v/v) TEA. 
TEA, while being a stronger base than piperidine, is not nucleophilic. 
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Figure 2.20: Nucleophilic attack on 2.20 to give 2.19 under basic conditions. 
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Aminolysis of 2.19 is also proposed to proceed via a direct nucleophilic attack at the acetyl 
carbonyl, where a strongly hydrogen-bonded 9-NH proton (as is evidenced by the IH NMR 
spectrum of this compound) ensures that the acetyl moiety lies in the plane of the ring. The 
tetrahedral intermediate will then break down to give an anionic variolin leaving group, which 
will in turn be protonated to form 2.16 (Figure 2.21). 
2.16 
Figure 2.21: Aminolysis of 2.19 to give 2.16. 
As has already been pointed out, this sort of lability is not normally observed in 2-aminoacyl 
pyrimidines. It is proposed, therefore, that the reactivity of 2.19 can be attributed to the stability 
of the anionic variolin leaving group, a species in which the negative charge may be delocalised 
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across 2 different nitrogens (Figure 2.22). The observed aminolytic lability of 2.19 also indicates 
that the 'degree' of aromaticity of the bottom pyrimidine ring is less than that of more 
conventional 2-aminopyrimidines (including the 'top' pyrimidine ring of DVB see Section 
2.5.3), and so resonance stabilisation (with the associated loss of aromaticity) is less 
energetically costly. 
Figure 2.22: Resonance stabilisation of the anionic variolin leaving group. 
A proposed mechanism for nucleophilic attack on 2.19 under acidic conditions first involves 
protonation of the variolin core. There are a total of five nitrogens in 2.19 that could be 
protonated, and under acidic conditions the protonated forms of all will be in equilibrium with 
one another. Figure 2.23 shows that protonation of N-8 will activate the acetyl group for 
nucleophilic attack due to hydrogen bonding between the acidic proton and the carbonyl oxygen. 
Following nucleophilic attack to give the tetrahedral intermediate, N-8 may then participate 
again in the acceptance of the same proton from the hydroxyl group in a concerted 
decomposition reaction that leads to expulsion of 2.16. Alternatively, decomposition may 
proceed like that shown in Figure 2.21 with the expulsion of a resonance-stabilised anionic 
variolin leaving group (Figure 2.22), Again, the surprising reactivity of this compound 
presumably reflects the lower 'degree' of aromaticity, and therefore higher energy, of the bottom 
ring system (that is, when compared with more conventional 2-aminopyrimidines), 
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Figure 2.23: Acid-catalysed hydrolysis of 2.19. 
In the experiment described above (TF A-catalysed decomposition) the nucleophile was water, 
traces of which would have entered the THF reaction solution during the course of the reaction. 
The observation that 2.20 is hydrolysed more slowly than 2.19 under acidic conditions can be 
explained by the assertion that a protonated form of 2.20 is not able to form the type of hydrogen 
bond (between the proton on N-8 and the carbonyl oxygen) shown in the structure on the left 
hand side of Figure 2.23 due to steric clash between the methyl of the other acetyl group and 
N-l. Put another way, the steric clash with N-l forces the acetyl moieties of 2.20 out of the 
plane of the ring, which disallows the carbonyl oxygens to act as hydrogen bond acceptors for 
the protonated N(8)-H hydrogen bond donor. 
As derivative 2.19 was a better model for the type of polymer therapeutic conjugates that were 
the target of this work, its stability in aqueous solution was investigated more closely. Thus, 
solutions of2.19 (22~) in 3:1 DMSO/aqueous buffer solutions were left at 30°C, and aliquots 
periodically removed and analysed by HPLC at 256 nm. The peak areas for 2.16 and 2.19 were 
measured and directly compared (no adjustment was made for the likely difference in extinction 
coefficients at the specified wavelength). The results for three separate reactions at pH = 5.0, 7.4 
and 9.3 are given below in Figure 2.24. 
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Figure 2.24: The pH-dependent decomposition of 2.19 to 2.16 in aqueous solutions. 
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At physiological pH, 3% degradation had occurred after 50 h, whereas 63% and 69% 
degradation had occurred at pH =:; 5.0 and 9.3, respectively. This result was double checked by 
repeating the experiment, using THF in the place of DMSO, and analysing the solutions only 
once, after 43 h. The results are given below in Table 2.5. 
pH % Decomposition* 
5.0 30 
7.4 2 
9.3 90 
* Detennined by comparing the peak areas of 2.19 with 2.16. 
Table 2.5: Decomposition of2.19 in aqueous THF solutions of varying pHs. 
These results were similar to the earlier findings, albeit with a larger observed difference in 
decomposition between pHs 5.0 and 9.3. 
The observed acid-catalysed bond cleavage could be useful in the context of polymer 
therapeutics - a polymer carrying analogue 2.16, directly bound via N(9a), will be stable in the 
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blood plasma (pH -7.4) but unstable in the relatively acidic lysosomal environment (pH -4.8), 
thus leading to intracellular liberation of free 2.16. Furthermore, the interstitial medium of 
tumours is often acidic (due to secretion of lactic acid by cancer cells in what is often an hypoxic 
environment),5 so that the drug may even be liberated from the polymer backbone in the 
interstitial space. Diffusion of small molecules in the interstitium will be much faster than that 
of macromolecules,s thus allowing the drug to reach its target more rapidly (see Section 1.1.2.1). 
Efforts were therefore turned towards the synthesis of a pHPMA~based polymer therapeutic 
carrying analogue 2.16 directly bound to the polymer backbone. 
2.4.6 Reaction of 16 with pMAOS 
Several attempts were made to synthesise polymer therapeutic 2.22 via the protocols shown in 
Figure 2.25. 
2.16 
2.22 
Figure 2.25: Attempted synthesis of polymer therapeutic 2.22. 
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During the workup of the reaction solutions following the first step, however, it became obvious 
that analogue 2.16 was not bound to the polymer backbone. Analyses using IH NMR 
spectroscopy confirmed this. The most likely explanation was that 2.16 was being lost from the 
polymer intermediate due to attack by IA2P at the methacrylate carbonyl of variolin-bearing 
polymer units. However, purification of the polymer intermediate following the first step 
showed that most of the variolin starting material was not polymer bound, even before the 
addition of IA2P. It was therefore considered desirable to develop a simple small-molecule 
model system to investigate this reaction more closely. 
2.4.7 A model system for 2.22 syntheses 
The simple pMAOS analogue N-hydroxysuccinimidyl pivalate, 2.23, (Figure 2.26), a known 
compound, 108 was synthesised from pivaloyl chloride and N-hydroxysuccinimide (NBS). 
Reaction of analogue 2.16 with ten equivalents of 2.23 gave mixtures of the desired product 2.24 
(Figure 2.26) and the two starting materials, favouring the starting materials ~2: 1. A temperature 
of 100°C was needed for the reaction to proceed in reasonable time. The observation that the 
reaction couldn't be pushed to completion (temperatures of 130°C led to the decomposition of 
the variolin starting material), taken together with the fact that the two starting materials were 
always seen in the IH NMR spectrum of the crude reaction mixtures, suggested that an 
equilibrium was being established (Figure 2.26). 
+ ... ... 
2.16 
2.24 
Figure 2.26: The equilibrium between 2.16, 2.23, 2.24, and NHS. 
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The possibility that an equilibrium was being established was investigated by heating 2.24 with 
one equivalent of NHS under the same conditions as for its formation (water was carefully 
excluded), IH NMR spectroscopic analysis clearly showed the presence of both the variolin 
starting material and the products 2.16 and 2.23, favouring the products -3:1, thus confirming 
the proposed equilibrium. All three compounds were isolated by flash~chromatography on silica. 
The discovery that analogue 2.16 had comparable leaving group ability to NHS (possible acid 
catalysis by NHS not withstanding) indicated that the proposed protocols for the synthesis of a 
polymer therapeutic carrying analogue 2.16 directly bound to the polymer would not be suitable. 
Specifically, it was realized that the second synthetic step involving two equivalents of lA2P 
would certainly lead to aminolysis of the variolin~polymer bond. This rationale would also hold 
true for a more "conventional" polymer therapeutic construct carrying a variolin-tetrapeptide 
conjugate, Attempts to synthesise a polymer therapeutic carrying a deoxyvariolin analogue, 
bound via the N(9a) position, were therefore abandoned, and attention was instead focussed on 
the N(2'a) position, 
2.5 Acylation ofN(2'a) 
2.5.1 Synthesis of N(9a)-protected DVB 
Bis-PMB-protected DVB, 2.26, was synthesised according to protocols developed by Anderson 
and Morris,85,87 Thus, oxidation109 of core structure 2.6 to give the bis-sulfoxide derivative, 2.25, 
followed by reaction withp-methoxybenzylamine (PMB), gave 2.26 in 72% yield over two steps 
(Figure 2.27), 
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Figure 2.27: Synthesis of2.26 from 2.6. 
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The selective deprotection of the 2'-PMB group from a bis~PMB-protected variolin analogue had 
already been demonstrated by Anderson and Morris in the methoxyvariolin series,87 and so 
similar protocols were applied in this work in the mono-deprotection of analogue 2.26. Thus, 
2.26 was heated in neat TF A at 45°C for 24 h to give analogue 2.27 in 83% yield (Figure 2.28). 
24 h 
2.26 
2.27 
Figure 2.28: Synthesis of 2.27 from 2.26. 
The bioactivity of 2.27 against the P388 cell line was found to possess an ICso of 5.4 ~, around 
10 times less bioactive than DVB. Incorporation of this analogue into a polymer therapeutic was 
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therefore pursued, but considered a less important target than a polymer therapeutic carrying 
DVB bound via the N(2'a) position. 
2.5.2 Acylation of2.27 
As has been already mentioned (Section 2.4.3.1) the acylation of 2-aminopyrimidines usually 
requires relatively strong conditions, such as boiling in acetic anhydride or reacting with acid 
chlorides. It was not surprising, therefore, to discover that the DCCIHOBT, EDCIIHOBT and 
HBTU coupling systems did not lead to coupling between 2.27 and FmocGFLG. 
Attention was therefore turned towards acid chloride chemistry. Attempted synthesis of 
FmocGFLG acid chloride from the reaction of FmocGFLG with oxalyl chloride, however, led to 
consumption of the tetrapeptide in an unidentified side reaction before the variolin nucleophile 
was added (see below, Section 2.6.2.1). A proposed synthetic route, then, involved the synthesis 
of a 2.27-glycine conjugate, 2.29 (Figure 2.30) followed by acylation of this intermediate with 
FmocGFL. This variolin tetrapeptide conjugate, following Fmoc deprotection, could then be 
reacted with pMAOS to give a polymer therapeutic carrying analogue 2.27. Alternatively the 
PMB group could first be deprotected to give a DVB-tetrapeptide conjugate, which would then 
be reacted with pMAOS to give a DVB-carrying polymer-drug construct of type 1.1 (polymer 
cross-linking via the N(9a) ofDVB would be avoided due to the lability of this bond, as has been 
outlined above in Section 2.4.7). 
Analogue 2.27 was reacted with one equivalent of Fmoc-glycine acid chloride in a reaction 
which gave a mixture of variolin compounds, including the starting material (as determined by 
tlc). Increasing the stoichiometry of the acid chloride to four equivalents appeared to do little in 
the way of pushing the reaction to completion, with variolin starting material remaining upon 
completion of the reaction. The desired monoacylated product, 2.28, was isolated from one of 
the reaction mixtures in 14% yield (Figure 2.29). 
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Figure 2.29: Synthesis of 2.28 from 2.27. 
It is not known why this reaction did not proceed more cleanly, nor why starting material 
remained in solution despite large excesses of the electrophile. Decomposition of 2.27 on the tic 
plates would not have been occurring to any significant extent (see Section 2.5.3). The side 
products were not isolated and characterised, with this work being abandoned before further 
efforts were made towards its optimisation (see Section 2.5.3). 
2.5.3 Stability of N(2'a) .. acyllinkage 
The stability of the N(2'a)-acyl linkage was investigated. A solution of monoacylated variolin 
2.28 in 5% TFAlDMSO showed no appreciable decomposition after 5 hours at room temperature 
when analysed by HPLC (2.28 elutes at 15.1 minutes using the standard gradient elution 
protocols). The N(2'a)-acyl linkage is therefore much more stable towards acid than the 
N(9a)-acyllinkage. 
The experiment was repeated with TEA in the place of TF A - decomposition was observed by 
HPLC, but was presumed to be due to Fmoc deprotection. This decomposition gave a variolin 
compound eluting at 9.8 minutes (using standard gradient elution protocols), presumed to be 
2.29 (2.27 elutes at 11.4 minutes), and a compound eluting at 20.9 minutes, presumed to be one 
of two Fmoc-deprotection fulvene species' (Figure 2.30). Fmoc deprotection by TEA has been 
previously reported. liD 
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Figure 2.30: Proposed 2.28-deprotection products detected by HPLC. 
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In support of these proposed structures, 2.28 was stirred in 20% piperidine/THF for 15 minutes 
then analysed by HPLC to show the same two compounds eluting at 9.8 minutes and 21 minutes, 
respectively. Despite this promising result, 2.29 was not isolated nor further characterised, due 
to results that are described below. 
In a parallel investigation 2.28 was stirred in neat triflic acid for 2 h, the variolin material 
purified using a CIS cartridge, and the crude mixture analysed by HPLC. Perhaps not 
surprisingly, cleavage of the N(2'a)~acyl linkage had accompanied PMB deprotection to give 
DVB (eluting at 7.2 minutes). 
Alternative PMB-deprotection strategies had been investigated by Anderson and Morris, and had 
proven problematic. Rather than revisit this chemistry, it was decided to pursue the acylation of 
DVB directly. The logic behind this was that, while acid chloride electrophiles had been shown 
to acyl ate both N(9a) and N(2'a), the N(9a)-acyl group(s) could then be selectively cleaved in the 
presence of the N(2'a)-acyl groups. 
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2.6 Acylation ofDVB 
2.6.1 DVB Synthesis 
Efforts were initially focussed towards scaling up the synthesis of DVB developed by Anderson 
and Morris.s7 PYIB-deprotection of 2.26 with neat triflic acid gave DVB in reasonably high 
purity as a yellowlbrown solid. Several strategies were tried in the purification of this material, 
but most were hindered by the relatively high polarity and low solubility of DVB. Eventually, 
protocols were established whereby a small amount ofDIOL was added to a -2 mglmL solution 
of the crude DVB in THF. This slurry was then diluted slowly and with vigorous swirling with 
-1.5 eq volumes of hexanes, leading to the coating of the DIOL with DVB. This yellow slurry 
was then loaded onto a DIOL column and the DVB eluted with 2% MeOHlCH2Clz, The DVB 
eluted slowly, over 20-30 fractions (-10 column volumes), but was obtained in high purity 
nonetheless with a yield of 88%. The IC50 of this material was found to be 0.47 ~ against the 
P388 cell line. 
2.6.2 Acylation with acid chlorides 
2.6.2.1 Tetrapeptide acid chloride 
Acylation of DVB by FmocGFLG acid chloride was attempted. Oxalyl chloride was added to a 
solution of FmocGFLG in THF - the evolution of gas was observed, indicating that the acid 
chloride had been formed. The presumed acid chloride was worked up and then reacted with 
DVB. However, analysis of the crude reaction mixture by HPLC (using the standard gradient 
elution protocol) showed only two compounds - DVB (eluting at 7.3 minutes) and an unknown 
compound eluting at 18.5 minutes (the FmocGFLG starting material elutes at 15.3 minutes) and 
possessing an Fmoc chromophore. This material was partially purified on silica, and analysis by 
lH NMR spectroscopy showed it to be pepddic (though clearly not the FmocGFLG starting 
material); specifically, Fmoc aromatic and leucine methyl signals were unambiguously 
identified. 
While the FmocGFLG acid chloride decomposition side product was not characterised, it was 
clear that the electrophiIe was being consumed by some side reaction. For this reason it was 
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decided to investigate an alternative synthetic pathway. Fmoc~glycine acid chloride was already 
in hand, and so it was decided to acylate the relatively unreactive N(2'a) position with this 
electrophile, deprotect the Fmoc group, then acylate again with FmocGFL using conventional 
solution-phase peptide coupling protocols (an EDCI coupling, for example). The N(9a) position 
would also acylate at each of the two steps, but the resulting bond could be easily cleaved with 
acid or base, while preserving the N(2'a)-peptide linkage (Figure 2.31). 
DVB 
FmocGlyCI 
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Figure 2.31: Proposed synthetic pathway to 2.31. 
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It was anticipated that purification of analogue 2.30 would be difficult, given the high polarity of 
both 2.30 itself and the side products from the deprotection reaction (specifically, glycine). It 
was envisioned that 2.31 would be purified by reversed-phase semi preparative HPLC. 
Deprotection of the Fmoc group of 2.31 in a piperidine/THF solution followed by addition of 
hexanes to give the free amine conjugate as a precipitate would be expected to proceed without 
complication. 
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2.6.2.2 FmocGFL tripeptide synthesis 
Conventional solution-phase protocols were again employed in the synthesis of the tripeptide 
FmocGFL. Initial attempts to synthesise the tripeptide in a C-N direction were again met with 
problems of decomposition during the dipeptide deprotection step. While the deprotection side-
product wasn't characterised, it could be clearly seen as a separate set of signals in the lH N1v1R 
spectrum of the crude reaction material, and was again presumed to be the diketopiperazine 
derivative (Figure 2.32). Approximately 30% of the starting material had cyclised following 
deprotection. 
FmocPhe, DCC, HOST, TEA 
lIIr 
90% 
+ 
1 0% PIPeridln~ITH~ 30m/, 
H 0 N~osn 0y 
Figure 2.32: Diketopiperazine fonnation in C-N dipeptide solution-phase synthesis. 
It was therefore decided to synthesise the tripeptide in an N-C direction. The synthetic route 
developed is shown below in Figure 2.33. The dipeptide intermediate FmocGF could have been 
synthesised by a more direct route involving the reaction between phenylalanine and 
Fmoc-glycine acid chloride, though concerns regarding the ease of purification of this compound 
led to the slightly more laborious route being taken. The synthesis proceeded without 
complication (though, the synthesis of the L-phenylalanine benzyl ester proceeded in only 26% 
yield), to give the desired tripeptide FmocGFL in 5 steps and 46% overall yield. 
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Figure 2.33: N~C tripeptide solution-phase synthesis, 
2.6.2.3 Acylation ofDVB by Fmoc~glycine acid chloride 
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During the synthesis of the tripeptide, an investigation involving the acylation of DVB by 
Fmoc-glycine acid chloride was also being carried out. The reaction between DVB and one 
equivalent of Fmoc-glycine acid chloride gave predominantly one monoacylated derivative, as 
determined by LCMS, As a quick test of the identity of this acylated derivative, a small amount 
of TF A was added to the crude reaction mixture, which was then left at room temperature for ten 
minutes before being analysed again by HPLC, The HPLC trace showed that that the conjugate 
had completely broken down to DVB and Fmoc-glycine, indicating that the acylated compound 
was most probably the N(9a)-acylated conjugate 2.32 (Figure 2.34), This assertion that the 
N(9a) position had been acylated in preference to the N(2'a) position was consistent with the 
observed differences in the ease of acylation of these sites (see Sections 2,4,3.1 and 2,5.2), The 
result also confirmed an earlier result obtained with 2'-thiomethyl analogue 2.16 indicating that 
the N(9a) position will only be acylated once by the Fmoc-glycine acid chloride electrophile, It 
is not known why diacylations do not occur with this electrophile, but it may be due to the 
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increased steric hindrance around the carbonyl electrophilic centre (compared with acetyl 
chloride). 
~ 
N\, N 
NH 
Fmoc-Nr-( 
H 0 
2.32 
Figure 2.34: 2.32, the kinetic product from the reaction between DVB and Fmoc-glycine acid chloride. 
As expected, the reaction between DVB and Fmoc-glycine in an EDCI-mediated coupling also 
gave only 2.32. It was hoped that a solution of this analogue heated to sufficiently high 
temperatures may rearrange to give 2.33 (see Figure 2.35). It was envisioned that this reaction 
would go via an intermolecular attack by N(2a) of one variolin molecule on the acyl carbonyl of 
2.32, to give a molecule of DVB and 2.33, the latter of which would not be expected to react any 
further. At temperatures > 1 00 °C, however, decomposition of 2.32 occurred without the 
formation of any 2.33. It is not known what exactly was taking place, but the most likely 
possibility is that Fmoc deprotection by the basic variolin core was occurring (see Section 3.2 for 
a comparable result) to give glycine residues that would react as nucleophiles in preference to the 
variolin 2'-NHz group. This idea was not explored in any more detail. 
DVB acylation reactions involving higher stoichiometries of the acid chloride electrophile were 
carried out. Analysis by HPLC of the crude reaction mixtures consistently showed that a 
mixture of products had been formed, and DVB starting material was always observed (despite 
the use of anhydrous techniques that had been shown to be effective in other systems employing 
acid chlorides). LCMS was able to show that two separate monoacetylated and one diacetylated 
conjugate had been formed, indicating that the N(2'a) position was being acylated, though not to 
completion. 
It is not known why these acylation reactions were so awkward, neither proceeding to 
completion nor giving a single product, regardless of the stoichiometry of the electrophile. One 
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possibility is that protonation of the variolin nucleophile by liberated HCI may diminish its 
nucleophilicity. An excess of TEA had been included in the reaction mixture to address this 
possibility, but the relative basicities of TEA and DVB are not known. In part response to this 
issue, pyridine was employed as the solvent in the place of THF in the hopes that it would act as 
a proton "sink". This solvent had two further advantages - it would disfavour the fonnation (or 
at least the survival) of the N(9a)-acyl linkage, and it was a superior solvent for DVB, allowing 
-10 fold higher concentrations (ie, 10 mg/mL DVB). The only potential drawback was the 
possibility of Fmoc deprotection by pyridine, though subsequent results suggested that this was 
not a significant problem. 
Thus, several reactions were carried out in pyridine with three equivalents of the acid chloride 
electrophile with or without a slight excess of TEA and with or without DMAP. The fonnation 
of compounds 2.32 (Figure 2.34), 2.33 and 2.34 (Figure 2.35) was observed (as detennined by 
LCMS and the TFAlHPLC test outlined above), though the reactions consistently gave mixtures 
of compounds, including the DVB starting material and Fmoc-glycine. Furthennore, despite the 
use of careful and well established anhydrous techniques, reproducibility was poor. 
2.33 
~ 
N N~ 
NH Fmoc-'N~ 
H 0 
2.34 
Figure 2.35: Acylation products 2.33 and 2.34. 
From one reaction, involving three equivalents of the electrophile with catalytic amounts of 
DMAP, was isolated 2.33 in 3% yield (after multiple silica columns). 2.34 was also isolated in 
partial purity, which did not allow complete and unambiguous structure elucidation, but did 
show the key 9-NH and 2'-NH proton signals in the correct position and integrating to one proton 
each when examined by IH NMR spectroscopy, thus confinning that the two acyl groups (as 
determined by MS) were shared between both positions. 
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The best results obtained were from an experiment involving three equivalents of the electrophile 
and five equivalents of TEA in pyridine (though reproducibility problems should again be 
emphasised) . The HPLC results from the analysis of the crude reaction mixture are given below 
in Figure 2.36 and Figure 2.37. 
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Figure 2.36: UV profiles ofDVB (red), 2.33 (green) and Fmoc-glycine (blue) . 
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Figure 2.37: HPLC trace of a crude acetylation reaction mixture, run with the standard 
gradient elution protocols at 260 nm (blue) and 360 nm (red) . 
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Figure 2.36 gives the UV profiles of DVB, Fmoc-glycine and 2.33 (the profiles are not 
standardised, ie, comparisons of the relative values of the extinction coefficients at any given 
wavelength for the three different compounds are potentially misleading). It can be seen, then, 
that HPLC runs examined at 260 nm will show the presence of all Fmoc- and variolin-containing 
compounds, while examination at 360 nm (which is the optimum wavelength when 2.32 and 
2.34 are also considered) will show only the variolin material. This distinction between the two 
wavelengths is precisely what is shown in Figure 2.37. 
It can be seen (particularly by examination of the top, red trace in Figure 2.37) that a significant 
amount ofDVB remains unreacted (exactly how much is uncertain, as extinction coefficients for 
the relevant variolin compounds have not been measured). Of the DVB that did react, the N(2'a) 
position was the favoured site of acylation, presumably due to cleavage of most of the 
N(9a)-amide bonds that had formed. Large amounts of Fmoc-glycine were also seen. It is not 
known what the material eluting between 18 and 19 minutes was, other than that it contained an 
Fmoc chromophore; LCMS analysis performed in positive mode did not give any useful 
information, and attempts were not made at isolating this material. The possibility of it being an 
Fmoc-deprotection fulvene species is seemingly discounted by the absence of any significant 
amounts of Fmoc-deprotected glycine-variolin conjugates, which would be expected to elute 
around 6-8 minutes (the identity of the DVB peak was confirmed by LCMS). 
It is possible that an equilibrium exists. It is difficult to explain why the N(2'a)-acylation did not 
go to completion. The possibility that this group became protonated as the reaction proceeded is 
an unlikely one, given the large amount of amine base present. Another possibility is that the 
pyridinium acyl salt was not a strong enough acylating agent to allow the acylation of this 
position. This, taken together with the possibility of an equilibrium between the pyridinium acyl 
salt and the variolin N(9a)-acylated species' (the former of which would immediately decompose 
following injection onto the HPLC), would explain the presence of the DVB starting material 
and Fmoc-glycine. However, this would also imply that any N(2'a)-acylation that had occurred 
had been carried out by the acid chloride before it had reacted with the pyridine solvent, which 
also seems unlikely. 
Regardless of the reasons, the acylation of DVB was found to be a messy (and presumably 
complicated) reaction, with poor reproducibility. Factors which may affect the reaction include 
the possible protonation of the variolin core as the reaction proceeds, possibly modified 
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reactivity of either the N(9a) or N(2'a) position upon acylation of the other, and possible 
involvement ofDVB acylation intermediates in intermolecular acyl transfers. 
When it had been established that the acylation ofN(2'a) ofDVB would not go to completion, a 
crude reaction mixture, similar to that shown in Figure 2.37, was treated with piperidine in the 
hopes that all the variolin compounds would be converted to DVB and 2.30 (Figure 2.31). The 
mixture was analysed by HPLC to give a trace that was indeed much simpler than that shown in 
Figure 2.37. A large peak at 10.3 minutes, corresponding to the piperidine-fulvene Fmoc-
deprotection adduct, was seen, as well as three variolin compounds. One of these was DVB 
(eluting at 7.3 minutes), while the other two eluted at 6.7 and 6.8 minutes. It is not known what 
these two compounds were. 
It was realized at this stage that purification was going to be very difficult, given the reaction 
mixture containing DVB, the two unknown variolin compounds and glycine, all of which were 
very polar molecules. This was further complicated by the awkward solubility of the variolin 
compounds. An initial attempt to remove the glycine by coating ClS with the organic material 
and washing with saturated aqueous NaHC03 solution proved unsuccessful. This work was 
therefore abandoned in favour of more immediately promising lines of investigation (see 
Chapter 3), and was not revisited due to results presented in Chapter 4. 
2.7 Conclusions and Future Work 
The DVB synthetic protocols developed by Anderson and Morris were further refined so that 
DVB was synthesised on the sub-gram scale from commercially available starting materials in 
six steps (only three of which required chromatography) in 25% overall yield. The key 
developments were the application of Barbier protocols in the synthesis of triaryl acetate 2.5, 
taking the crude reaction mixture from this step directly through to the next step (synthesis of 
core structure 2.6), and employing DIOL-based protocols in the purification ofDVB. 
A convenient synthesis of ketone 2.9 was also developed, which is a potentially useful 
compound for the synthesis of deoxyvariolin analogues. 
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The 2'-thiomethyl DVB analogue 2.16 proved to be a useful compound when investigating the 
reaction of the 9-NH2 group with electrophiles, These investigations were extended to DVB, 
where it was shown that acylation proceeds first at the N(9a) position, with anhydrides 
possessing sufficient electrophilicity to allow this reaction to proceed to completion, The more 
electrophilic acid chlorides are needed to acylate at the N(2'a) position, which is consistent with 
the relatively low nucleophilicity of other 2-aminopyrimidines. 
The N(9a)-acyllinkage is stable at neutral pH but cleaved in acidic or basic environments. This 
would suggest that polymer therapeutics carrying DVB bound via an acyl group at the N(9a) 
position could give intralysosomal site-specific liberation of the cytotoxin. Synthetic routes to 
polymer therapeutics of this type could capitalise on the preferred acylation at the N(9a) position 
over the N(2'a), but would need to employ very mild synthetic conditions to preserve this 
delicate linkage. One possibility would be the reaction of a pHPMA-based copolymer carrying a 
specified stoichiometry of tetrapeptide-bearing methacryl units. Conjugation of DVB with these 
units using anhydride activation would probably be most suitable (EDCI has been successfully 
used in one such polymer therapeutic synthetic reaction),z6 
Ultimately, acylation of an N(9a)-protected DVB analogue is probably the preferred synthetic 
route to an N(2'a)-acylated variolin conjugate, given the messy and awkward acylation of DVB. 
Synthesis of 2.29 was a promising result, however alternative PMB-deprotection protocols need 
to be explored. Alternatively, a different protecting group could be utilised. 
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CHAPTER 3 
DEOXYVARIOLIN ANALOGUES 
3.1 Research Carried Out by Pharma Mar, SA 
As was mentioned in Section 1.3.3.3, the variolin analogue production carried out in the 
laboratory of Dr Jonathan Morris at the University of Canterbury (UoC) was part of a larger 
investigation being performed at Pharma Mar, SA (a Spanish Pharmaceutical company that 
focuses on marine natural products). The work carried out at the University of Canterbury 
(UoC) is outlined in Section 3.2, while this Section gives an overview of the work carried out at 
Pharma Mar. It should be noted that this unpublished work is of commercial sensitivity, and so 
the details given here are necessarily sparse. 
As part of the work carried out at Pharma Mar, around 200 analogues have been synthesised, 
with most being related to DVB (159) and a smaller number based on variolin B (70). Of these 
analogues, 35% possessed bioactivity in the 10-6_10-7 M range, with none showing significantly 
better activity than variolin B or DVB. Solubility of analogues is an ongoing problem, though 
the stability of va rio lin Band DVB in aqueous solutions is very good. 89 
3.2 Research Carried Out at the DoC 
In parallel to the research being carried out at Pharma Mar, the synthetic work carried out in the 
group of Dr Jonathan Morris at the UoC was performed by two researchers - Dr Regan 
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Anderson, a PhD student at the time, followed by the author of this thesis. Dr Anderson worked 
primarily with the methoxy and hydroxy series (see Section 3.2.2),87 while the work described in 
this thesis was involved with the deoxy series (see Section 3.2.3). Before the results are 
presented, however, the rationale behind the selection of the target analogues should first be 
given. 
3.2.1 Rationale for target analogues 
When the variolin analogue synthetic work began, it was thought likely that variolin B exerted 
its bioactivity through DNA intercalation (though, as is outlined in Section 1.3.2, it is now 
known that both variolin Band deoxyvariolin Bare CDK inhibitors).67 Attention was therefore 
turned towards other intercalators for clues as to the sort of structural modification that may 
enhance the bioactivity of the variolins. 
Two such intercalators are N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (DACA), a 
compound that has progressed to phase IT clinical trials, and TAS-I03, another anti tumour agent 
that is also in clinical trials (Figure 3.1). 1ll,1l2 Both are dual Topoisomerase IIII poisons, 
stabilising the Topo-DNA complex, thus leading to accumulation of DNA strand breakages and, 
ultimately, apoptosis. 1I3•116 Both can be superficially described as planar heterocyclic 
compounds bearing N ,N-dimethylaminoalkylarnido/amino moieties. A crystal structure of 
DACA bound to a DNA oligomer shows the tertiary amine involved in an important hydrogen 
bond to the N(7) of a guanine residue. ll3 
TAS-103 
Figure 3.1: DACA and TAS-I03, two DNA intercalators. 
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These results led to the idea that the bioactivity of variolin B may be enhanced through the 
inclusion of an NN-dimethylaminoalkylamine moiety. Further reasons for pursuing this type of 
analogue was the anticipated improved solubility afforded by the basic dimethylamino moieties 
(which would be protonated at the physiological pH of ~7.4), and the observed improvement in 
nuclear localisation of small molecules bearing multiple positively charged nitrogens. 1l7 
3.2.2 Analogue syntheses performed prior to this thesis 
As was outlined in Section 1.3.3.3, Anderson and Morris synthesised a range of variolin 
analogues in the methoxy and hydroxy series. Several of these analogues incorporated 
N,N-dimethylaminoalkylamines at the C(9) position, though the SAR investigation was not 
extended to the C(2') position. The analogues are given below in Table 3.1, along with their ICso 
values against the P388 cell line. 
It can be seen that DVB and variolin B are by far the two most bioactive analogues. The next 
most bioactive analogues (3.1 and 3.2, which are roughly an order of magnitude less bioactive 
than the parent compound, variolin B) bear an NN-dimethylaminopropaneamine group, and so 
this moiety was chosen for further investigations involving the deoxy series. Analogues 3.6 and 
3.7 were intermediates in the synthesis of 3.9 and 3.10, respectively (see Section 2.3.1 for the 
details of the analogous synthesis in the deoxy series), and analogue 3.8 was synthesised from 
the bis-PMB-protected analogue (see Section 2.4.1· for details of the analogous synthesis in the 
deoxy series). 
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Compound X Y Z IC50 (IJM)* 
DVB NHz NHz R 0.47 
variolin B NHz NHz OR 0.65 
3.1 NH(CRZ)3NMeZ SMe OMe 8.3 
3.2 NH(CRZ)3NMeZ SMe OR 10.0 
3.3 NHz NHz OMe 12.1 
3.4 NH(CRz)zNMez SMe OMe 26.8 
3.5 NH( CRz)zNMez SMe OR 32.9 
3.6 NR(Pl\1B) SMe OMe >54 
3.7 NR(PMB) SMe OR >56 
3.8 NH(PMB) NHz OR >60 
3.9 NHz SMe OMe >74 
3.10 NHz SMe OR >77 
* Against the P388 ccUlinc. 
Table The methoxy- and hydroxyvariolin analogues synthesised by Anderson. 
3.2.3 Analogues synthesised by the author 
As has already been mentioned, the SAR work initiated by Anderson and Morris was extended 
to the deoxy series as part of the work described in this thesis. Synthesis of alkyldiamine 
analogues in the deoxy series was considered worthwhile for two reasons. Firstly, it would allow 
a direct comparison with the compounds synthesised by Anderson, and, secondly, it could lead to 
a bioactive analogue bearing a primary alkylamine that could be conjugated with the tetrapeptide 
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biolinker en route to a polymer-drug construct. This latter point became particularly relevant 
after shortcomings were discovered with the acylation (and stability) at the N(9a) and N(2'a) 
positions of the variolin core (see Sections 2.3,2.4 and 2.5). 
The deoxyvarioIin analogues were synthesised according to protocols developed and employed 
in the methoxy- and hydroxyvariolin series by Anderson and Morris (Section 1.3.3.3, Figure 
1.15, Table 3.1). These pathways are based on the difference in reactivity between the two 
pyrimidine C(2) positions. Specifically, the C(9) position of the key intermediate, 2.6, is more 
reactive with respect to nucleophilic substitution than the C(2') position. Selective substitution 
by amines at C(9) of2.6 can therefore be carried out at high temperatures (~100 °C) without any 
observable reaction at C(2'). Similarly, oxidation of both thiomethyl groups of 2.6 to give the 
bis-sulfoxide derivative, 2.25, allows selective substitution at C(9) at room temperature in a few 
minutes, whereas higher temperatures (~100 DC) are needed before substitution at C(2') will 
proceed. The application of these reaction pathways to the deoxyvariolin series are summarised 
in Figure 3.2. 
2.6 
I RNH2 
• 100°C 
A 
m-CPBA RNH2 
JIll> 
room temp. 
2.25 
B 
Figure 3.2: Synthetic routes to deoxyvariolin analogues. 
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Analogues of type A were therefore synthesised by heating core structure 2.6 with an excess of 
the nucleophilic amine. Analogues of type B were synthesised by first oxidising 2.6 with 
m-CPBA to give the bis-sulfoxide, 2.25, then heating this compound with an excess of the amine 
nucleophile. Finally, analogues of type C were synthesised by reacting 2.25 with one equivalent 
of the first amine nucleophile at room temperature (giving substitution exclusively at the 
C(9)-position) to give mono-sulfoxide intermediate 3.11, followed by the addition of an excess 
of the second nucleophile and heating the reaction to 100°C. Intermediates were generally not 
purified. 
The following Sections deal with the application of these pathways in the synthesis of twelve 
deoxyvariolin analogues. 
3.2.3.1 Dimethylaminopropaneamine analogues 
The analogues incorporating the N,N-dimethylaminopropaneamine moiety that were synthesised 
include 3.12, 3.13, 3.14 and 3.15. The structures, yields and bioactivities of these compounds, 
along with those of their intermediates 3.16, 3.17, 3.18 and 3.19, are given in Table 3.2. The 
syntheses proceeded without complication, with purification being carried out using reversed 
phase C18 . A discussion of the bioactivities of these analogues is given in Section 3.2.3.4. 
3.2.3.2 Methoxyanalogues 
The 2'-methoxy analogue 3.20, as well as the two intermediates 3.18 and 3.21 were also 
synthesised, using sodium methoxide as a nucleophile. See Table 3.2 for their structures, yields 
and bioactivities, and Section 3.2.3.4 for a brief SAR discussion. 
3.2.3.3 Diamine analogues 
Given the favourable bioactivities of 3.1, 3.2 and 3.12, taken together with the difficulties 
encountered in the synthesis of a variolin-tetrapeptide conjugate from analogues 2.16, 2.27 and 
DVB (see Chapter 2), the analogues 3.22, 3.23 and 3.24 (Figure 3.3) became logical targets. It 
was expected that these analogues would be easily conjugated with the tetrapeptide biolinker, 
given the presence of only one nucleophilic amine. Furthermore, and in contrast to the 9-NH2 
and 2'-NH2 groups of DVB, the reactivity of the alkylamine moiety, and the stability of the 
resulting amide linkage, would be expected to be that of other simple primary amines and 
amides, respectively. 
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3.22 3.23 3.24 
Figure 3.3: Synthetic targets for incorporation into polymer-drug conjugates. 
Initial attempts at synthesising these analogues were performed in parallel, with the nucleophilic 
amines being used straight from the bottle without any attempts made to dry the reagents first. 
This casual experimental technique was due to the fact that water contamination had not 
presented itself as a problem with N,N-dimethylaminopropaneamine as the nucleophile. In the 
reactions involving the diaminoalkanes, however, water contamination led to the isolation of the 
degradation product 3.25 (Figure 3.4) from the reaction mixtures. A proposed mechanism of 
formation of 3.25 is given in Figure 3.4. The key steps in the decomposition are the two 
successive imine hydrolyses, followed by a high-temperature decarbonylation reaction. The 
extent of formation of 3.25 varied between the three reactions, with degradation in the ethylene-
and propylenediamine systems being complete after 20 h at 100 °C, and that in the 
butanediamine system being only partial (~40% under the same reaction conditions). This 
difference may reflect the more favourable formation of 5- and 6-membered rings over the 
7-membered ring, respectively, during the decomposition. It may also reflect the different 
amounts of water contamination in each of the three nucleophilic reagents (1,2-diaminoethane 
and l,3-diaminopropane are liquids at room temperature, whereas 1,4-diamino butane is a 
crystalline solid). 3.25 possessed an IC50 of 35 ~ against the P388 cell line. 
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Figure 3.4: Proposed mechanism of fonnation of 3.25. 
Given the difficulty in handling polar compounds such as 3.22, 3.23 and 3.24, it was necessary to 
rigorously exclude water from the reaction mixtures in order to avoid any formation of 3.25 and 
thus greatly simplify the workup/purification process. The propylene~ and butylenediamines 
were dried by azeotropic distillation using toluene in a Dean-Stark apparatus. The 
ethylenediamine was not dried successfully by this methodology, probably because its boiling 
point (118 °C) exceedsd that of toluene by only 7°C. All three amines were also converted to 
their hydrochloride salts and recrystallised from H20IEtOH. Conversion of the salts back to the 
free bases, and isolation of the anhydrous free bases, however, was difficult, and so this 
methodology was abandoned. Due to the difficulty in obtaining 1,2-diaminoethane as an 
anhydrous solution, the synthesis of 3.22 was not pursued. Moreover, results obtained by 
Chapter 3: SYnthesis and Acylation ofDeoxyvariolin Analogues 
. 
78 
Anderson and Morris in the hydroxy and methoxy series suggested that this analogue would 
show inferior bioactivity to 3.23 (see compounds 3.1, 3.2, 3.4, and 3.5, Table 3.1). 
Using dry toluene solutions of I,3-diaminopropane and I,4-diaminobutane, analogues 3.23 and 
3.24 were successfully synthesised without any discemable decomposition (based on IH NMR 
spectroscopic analysis of the crude reaction mixtures). A large excess of the nucleophile was 
used to avoid dimer formation. A I5-fold excess was initially employed, but that was 
subsequently reduced to 5-fold in the diaminopropane reaction without any observable dimer 
formation. Purification was difficult due to the high polarity of both compounds (with 3.23 and 
3.24 being moderately water soluble). Both LH20 and DIOL chromatography were employed 
with limited success. Kugelrhor distillation at 120°C, 0.03 mm Hg allowed the efficient 
removal of any unreacted nucleophile with no observable decomposition of the variolin product. 
This allowed both analogues to be produced in high purity in near-quantitative yield. Further 
experimentation led to the discovery that 3.23 could be isolated in high yield and purity by 
washing a solution of the analogue in dichloromethane with saturated aqueous brine solutions 
(the solubility of3.23 in saturated aqueous brine solution is poor). 
3.2.3.4 Analogue bioactivities 
The bioactivity and yield data for the twelve analogues whose syntheses are briefly discussed 
above, along with the six analogues (DVB, 2.6,2.16,2.17, 2.26 and 2.27) whose syntheses were 
discussed in chapter 2, are summarised in Table 3.2. 
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% Yield (# 
Compound X Y ICso (~)* of steps)** 
DVB NH2 NH2 0.47 63 (3) 
3.19 NH(p:MB) NH(CH2)JNMe2 2.1 68 (3) 
3.15 NH2 NH(CH2)3NMe2 2.5 22 (4) 
3.20 NH2 OMe 3.6 18 (4) 
2.16 NH2 SMe 3.9 93 (2) 
2.27 NH(P:MB) NH2 5.4 60 (3) 
3.23 NH(CH2)3NH2 SMe 5.7 94 (1) 
3.13 NH(CH2)3NMe2 NH(CH2)3NMe2 6.0 63 (2) 
3.17 NH(CH2)3NMe2 NH(P:MB) 8.3 63 (3) 
3.12 NH(CH2)JNMe2 SMe 11 98 (1) 
3.14 NH(CH2)3NMe2 NH2 17 38 (4) 
3.24 NH(CH2)<tNH2 SMe 21 99 (1) 
3.18 NH(P:MB) SOMe >28 63 (2) 
3.16 NH(CH2)3NMe2 SOMe >28 Not taken 
2.17 NH(P:MB) SMe >29 99 (1) 
3.21 NH(P:MB) OMe >30 61 (3) 
2.26 NH(P:MB) NH(P:MB) >34 72 (2) 
2.6 SMe SMe >37 NA 
* Against the P388 cell line. 
** The yield and number of steps are given from the key intermediate 2.6. 
Table 3.2: A range of deoxyvariolin analogues and their bioactivities. 
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The immediate conclusion that can be drawn from these SAR results is that all the modifications 
at C(9) and/or C(2') of DVB that were investigated led to at least a five~fold decrease in 
bioactivity, with all but two of the synthetic intermediates showing a decrease in bioactivity of at 
least two orders of magnitude. Surprisingly, the next most bioactive analogue after DVB was 
3.19. There are no obvious patterns or general structure~activity relationships that can be 
inferred from the results, with one result seemingly contradicting a conclusion that might be 
drawn from another. Also, an error margin of roughly a factor of two is present in the bioassay, 
so small differences in bioactivity should be discounted. 
The fact that the P388 cell line was the only one investigated represents a further shortcoming of 
these results, as is evidenced in the results obtained by Pharma Mar, SA in their SAR work with 
the variolins. In their 2003 patent,91 for example, they report the bioactivity of a range of around 
100 different analogues against up to 17 different cell lines. In short, the cytotoxicities of a 
single analogue often vary. significantly betwyen different cell lines, sometimes in excess of an 
order of magnitude, and different cell lines show different degrees of relative sensitivity to 
different analogues. 
Furthermore, while bioassays such as the P388 in vitro assay are invaluable in SAR work such as 
this, they do possess some important shortcomings, particularly with respect to this project. The 
assay conditions are necessarily contrived, and so do not accurately mimic in vivo human 
physiology (where pharmacokinetics and pharmacological profiles become important). This 
alone may affect the results significantly. However, in this investigation a more serious 
shortcoming exists: namely, that the cytotoxins presented in Table 3.2 were submitted to the 
bioassay as the free drugs, whereas the aim of this project is to incorporate cytotoxins into 
polymer-drug constructs. As was discussed in Section 1.2, this will drastically alter the 
mechanism of drug delivery to the intracellular site of action, which could in turn affect the 
relative bioactivities of the deoxyvariolin analogues. 
Despite these shortcomings of the bioassay, however, the information is still useful and strongly 
suggestive. An important result was that analogue 3.23 possessed reasonable bioactivity (more 
so than 3.24), and so it was chosen as a suitable drug for development into a polymer-drug 
construct. Though the bioactivity was less than what is generally accepted as being required of 
anticancer drugs (nanomolar levels), the tumour-targeting and improved pharmacological profile 
afforded by conjugation onto a polymer should offset this relatively low bioactivity when used in 
vivo. 
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It is noteworthy that this analogue was synthesised from commercially available starting 
materials in 4 steps (with only one chromatographic step) in 38% overall yield. 
3.3 Acylation of 3.23 
As discussed in Section 1.2.3.2, the polymer-drug constructs that were the ultimate goal of this 
work were to be synthesised by the reaction of pMAOS with appropriate nucleophiles, which 
included tetrapeptide-drug constructs. Conjugate 3.26 was therefore an immediate synthetic 
target (Figure 3.5). 
Figure 3.5: Conjugate 3.26. 
An EDCI-mediated coupling between FmocGFLG and 3.23 gave the protected conjugate, 3.27 
(Figure 3,6). DIOL chromatography allowed the efficient purification of this compound, 
whereas LH20 chromotography led to unsatisfactory results, 
Figure 3.6: Conjugate 3.27. 
Chapter 3: Synthesis and Acylation ofDeoxyvariolin Analogues 82 
Attempts at removing traces of solvent from the sample by heating under reduced pressure 
(75 °C, 0.03 mm Hg, 20 h) led to decomposition of 3.27 to 3.26, with the concomitant formation 
of a material that showed low solubility in all solvents investigated, including MeOH, DMSO, 
THF, CH2Ch and hexanes. Given its low solubility, this material was unable to be characterised, 
though is presumed to be the polymer 3.29, formed from the dibenzofulvene 3.28, which is in 
tum the product of Fmoc deprotection (Figure 3.7). The unpredictable polymerisation of 3.28 is 
well known. 98 FmocGFLG had previously been seen to be stable under the conditions that led to 
the decomposition here, and so intermolecular catalytic participation by the basic variolin 
heterocyclic core is proposed to be the reason for the observed decomposition . 
.. 
3.28 3.29 
Figure 3.7: Fonnation of3.29. 
The mixture of desired product and presumed polymer was taken directly through to the Fmoc-
deprotection step. Deprotection was carried out in a 2.5% piperidine/THF solution. Addition of 
hexanes led to precipitation of the desired product, which was isolated by filtration to give the 
desired product with a small amount of contamination by 3.29. This mixture was then dissolved 
in THF and filtered to remove the polymeric contaminant. The deprotection step was presumed 
to be quantitative, with the desired product 3.26 being obtained in 62% yield over 2 steps (that is, 
from 3.23). The product was of sufficiently high purity (see Figure 3.8) to negate the need for 
any further purification. This was fortunate, as it would be difficult to purify 3.26 by 
chromatography (laborious reversed phase preparative HPLC would almost certainly have been 
required). 
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Figure 3.8: lHNMR spectrum of3.26 ind6-DMSO 
The bioactivities of 3.27 and 3.26 are very similar (see Table 3.3), and retain over half the 
bioactivity of the parent compound, analogue 3.23. This is less than the error margin for the 
bioassay, which is considered to be -2-fold. This result suggests either that the conjugate itself 
is appreciably bioactive, or that the tetrapeptide motif is being 'efficiently cleaved 
intralysosomally by cathepsin proteases. While further investigations are required to determine 
which of the two is correct, the former explanation is the most likely, 
Table 3.3 gives the structures and bioactivities of some of the acylated variolin compounds that 
were synthesised as part ofthe work described in this chapter and in Chapter 2. 
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f' 
N~ 
N 
"N-R2 R1 
Compound RI R2 ICso (pM)* 
3.27 (CH2)3NHGLFGFmoc H 9.0 
3.26 (CH2)3NHGLFG H 9.9 
2.19 Ac H 12.6 
2.20 Ac Ac 16.1 
2.24 CO(t-Bu) H >8.0 
2.18 GLFGFmoc H >13.8 
'" Against the p388 cell line 
Table 3.3: Bioactivities of some acylated deoxyvariolins. 
Interestingly, conjugate 2.18 (whose synthesis is described in Section 2.3.3.1) is less bioactive 
than conjugate 3.27, despite analogue 2.16 being more bioactive (IC5o 3.9 pM) than analogue 
3.23 (IC5o == 5.7 pM). This may simply reflect the aforementioned error margin, though the 
exact bioactivity of 2.18 is not known. By virtue of its larger size and higher polarity, conjugate 
2.18 would most likely enter the cells via the lysosomal pathway. It has already been postulated 
(see Section 2.3.5) that the lysosomal environment would facilitate the degradation of 2.18 to 
2.16, though the observed in vitro bioactivity of this compound would suggest otherwise. 
Analogues 2.19 and 2.24 (and, to a lesser extent, 2.20) are related compounds, in that they are 
derived from 2.16 by acylation at N(9a). These small molecules, however, are most likely 
transported directly across the cell membrane in the in vitro bioassay. Given the lability of the 
N(9a)-amide bond (discussed in Section 2.3.5), it is unclear whether the bioactive agents are the 
compounds themselves, or the degradation product 2.16. More data are necessary to determine 
why the bioactivity of 2.18 is so much lower than that of 2.16, and how it compares with the 
bioactivities of 2.19, 2.20 and 2.24. 
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With 3.26 in hand, and demonstrable bioactivity of this conjugate in vitro, attention was focussed 
on the incorporation of this compound into a polymer-drug construct. Efforts toward this goal 
are described in the following chapter. 
3.4 Conclusions 
The synthetic protocols developed by Anderson and Morris were successfully employed in this 
work in the synthesis of thirteen deoxyvariolin analogues from the key intermediate 2.6. 
Substitution by amines at C(9) of 2.6 gave the desired products in near quantitative yield. 
Syntheses which first required the oxidation of 2.6 to 2.25 proceeded in 60-65% yield, while 
PMB-deprotection reactions give yields of 30-50% (perhaps reflecting, at least in part, the small 
scale that these reactions were often carried ou't on). 
All analogues synthesised displayed inferior bioactivity to DVB in the P388 in vitro bioassay. 
There were no obvious structure-activity relationships, with steric bulk at both positions being 
tolerated to different degrees between different analogues. Both primary amines of DVB appear 
to be required for sub-micromolar bioactivity. The inclusion of N,N-dimethylaminopropane-
amine moieties affected the bioactivity adversely, and in a comparable manner to the methoxy 
and thiomethoxy moieties at the C(2') position (with the surprising exception of analogue 3.19), 
and to the amino, p-methoxybenzylamine and alkyldiamine moieties at the C(9) position. It is 
now known that DVB is not an intercalator, and so incorporation of these moieties in hindsight 
would not necessarily be expected to improve the bioactivity. 
Analogue 3.23, a synthetically accessible DVB analogue incorporating a diaminopropane 
moiety, was approximately an order of magnitude less bioactive than DVB. While its bioactivity 
was relatively low, the improved pharmacokinetics and pharmacological profile afforded by 
polymer therapeutics made this analogue a reasonable candidate for incorporation into a 
polymer-drug conjugate. Given the presence of a single aliphatic amine, conjugation of 3.23 
with the tetrapeptide biolinker proceeded without complication. The conjugate, 3.27, could be 
easily purified by DIOL chromatography, which eliminated the need for chromatographic 
purification of 3.26, the Fmoc-deprotected conjugate. 
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CHAPTER 4 
POLYMER CHEMISTRY 
4.1 Introduction 
With conjugate 3.26 in hand, efforts towards the synthesis of a polymer therapeutic via the 
Godwin and Brocchini protocols began. The first step was the synthesis of a sample of pMAOS 
possessing suitable molecular weight characteristics. Before this is described, however, some 
important background information regarding the measurement and quantification of the molar 
mass distribution within a polymer sample will be given. 
4.1.1 Polydispersity (PD) 
As was outlined in Section 1.2.2.3, the improved pharmacokinetics afforded by polymer 
therapeutics can be attributed to their molecular size. It is important to consider, then, not just 
the average molar mass of a polymer sample, but also the molar mass distribution within that 
sample. The breadth of this distribution can be approximated and represented by a single value -
the polydispersity (PD) of a sample. 
PD will be defined shortly, but first a brief summary of the methods used in the measurement of 
the molar mass characteristics of a polymer sample is needed. Analysis of polymer samples by 
the size exclusion-based technique Gel Permeation Chromatography (GPC) will produce a curve 
that gives the mass fraction of the sample, Wi, at any given molar mass, MI (it should be noted 
that what is actually measured is the molecular size, which may vary between different types of 
polymers of the same molar mass). In order to describe the general characteristics of such a 
curve, at least in terms of its breadth and height, a PD value can be assigned. This PD value is a 
function of two types of molar mass averages, defined below. 
The number-average molar mass (Mn) is defined1l8 as 'the sum of the products of the molar 
mass of each fraction multiplied by its mole fraction', ie, 
where Xi is the mole fraction of molecules of molar mass Mi and is given by the ratio of N/ (the 
number of molecules in a discrete size fraction i) to the total number of molecules. 
The weight-average molar mass (Mw) is definedl18 as 'the sum of the products of the molar mass 
of each fraction multiplied by its weight fraction', ie, 
where Wi is the mass of molecules of molar massMi divided by the total mass of the sample. 
Having obtained the above values for a given sample by GPC analysis, the PD of that sample is 
calculated by dividing the weight-average molar mass by the number-average molar mass, ie, 
Thus, a polymer sample comprised of molecules of uniform molar mass, or one showing 
monodispersity, will have PD 1.0. Most polymer samples, however, will be comprised of 
molecules of varying sizes, and as this breadth of molar mass distribution increases, so too will 
the PD value. 
It should be noted that the interpretation of GPC traces to give PD values is somewhat 
subjective, and so different researchers may arrive at different PD values for similar polymer 
samples. Furthennore, no rigorous investigation into the relationship between PD and 
therapeutic efficiency has been carried out. As a guideline, however, a PD of < 1.3 was 
considered desirable for the first generation of polymer therapeutics of type 1.1 that were the 
target of this study, which would ensure that bioactivity would be closely related to the Mn. 
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4.2 pMAOS Synthesis 
Having decided that pMAOS would be employed as the activated polymeric precursor, it was 
necessary to synthesise a sample of pMAOS of low PD. pMAOS is synthesised by the 
polymerisation of methacryloxy succinimide, as shown in Figure 4.1. 
Figure 4.1: Synthesis ofpMAOS from MAOS. 
The main challenge presented by this reaction, then, was to control the polymerisation process to 
give a polymeric product oflow PD. 
4.2.1 Atom Transfer Radical Polymerisation (ATRP) 
4.2.1.1 The literature account 
As was outlined in Sections 1.2.3.2, Godwin et al. reported that controlled polymerisation 
protocols (specifically, ATRP, outlined below) can be employed in the synthesis of pMAOS to 
give polymer samples of low PD.6o The investigators reported a range of syntheses of pMAOS 
under differing conditions, one of which gave a product with Mn :::: 29 kDa and PD :::: 1.14. 
Similar results were reported by Monge and Haddleton.62 In terms of PD values, subsequent 
work toward the synthesis of pMAOS via other types of controlled polymerisation did not 
improve on this result,119 and so it was decided that these protocols would be employed in this 
work. 
The copper-mediated ATRP protocols (Figure 4.2) that were employed utilised an alkyl bromide 
initiator and copper bromide/2,2'-bipyridine complex 'catalyst'. The catalyst cycles between the 
Cu(I) and Cu(II) oxidation states, with bromide concomitantly being associated with either the 
growing polymer chain or the inorganic copper salt, respectively. In this way, the growing 
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polymer chain spends only a fraction of the time as a reactive free radical. This effectively 
lowers the concentration of this species relative to the acrylamide monomer, which ultimately 
will favour the polymerisation reaction over competing chain termination events (which occur 
when two growing polymer chains react with one another). 
Initiation 
Br·R' + eulBr 
initiator catalyst 
[Br'R' = .'>10"'] 
R,~Br 
+ eulBr 
R 
Propagation 
R,~Br 
\R lR 
n 
+ eulsr 
... 
.... 
... 
... 
... 
... 
• R' + eullBr2 
~ 
R 
R'~. + 
R 
R'~· \R )f 
n 
monomer 
eullBr2 
monomer 
Figure 4.2: The mechanism ofthe copper-based A TRP system. 
4.2.1.2 Experimental results 
MAOS was synthesised via a DCC coupling between methacrylic acid and NHS to give the 
activated ester monomer, free of DCU. This monomer was polymerised by ATRP under 
protocols similar to those reported60 to give pMAOS, which was then analysed by GPC. A 
summary of the GPC results and comparison with those from the literature is given in Table 4.1. 
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Experiment Yield (%) 
Literature60 96 
Observed 66 
lJ [a] 
1V1target 
17600 
13400 
29000 1.14 
24900 1.87 
[a] Target molecular weight calculated by lV/target = ([m]d[i]o) X Mrm X yield, where [m]o = initial 
concentration of the monomer, [i]o = initial concentration of the initiator and Mrm == the MW 
of the monomer. 
Table 4.1: Published and observed results for the synthesis ofpMAOS by ATRP. 
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The difference between the two sets of results is pronounced, with the PD of the sample 
synthesised in this work being much higher than in the published results. There were a few 
differences between the published protocols and those employed here: the initiator used in the 
literature was 2~hydroxyethyl 2~bromoisobutyrate, whereas ethyl 2-bromoisobutyrate was used 
, in this work; an initiator:catalystmonomer ratio of 1: 1: 100 was reported in the literature, 
whereas the work described here used a ratio of 1:1:110, and the literature report specified a 
reaction time and temperature of 1 o~ 15 minutes at 100°C, while reaction conditions of 90°C for 
four hours were used here. While these discrepancies could be expected to give some deviation 
from the reported results, they would not account for the large difference in PD values. In fact, 
lower temperatures have been reported to improve the polymerization process for this particular 
system ,62 
These ATRP protocols were explored in more detail in a separate investigation carried out by 
Uma Adash. In her investigation, eleven separate syntheses of pMAOS by ATRP under 
differing conditions were carried out; the lowest PD obtained in this investigation was 1.68, with 
most values being close to or exceeding 2. 
In light of these results, other controlled radical polymerisation protocols were investigated. 
4.2.2 RAFT synthesis 
In a parallel study, and as an alternative to ATRP, Adash investigated controlled radical 
polymerisation of MAOS by Reversible Addition-Fragmentation chain Transfer polymerisation 
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(RAFT). This investigation yielded more favourable results, and so these protocols were utilised 
as part of tms work. 
4.2.2.1 Background information 
RAFT is the same in principle as ATRP insofar as the growing polymer chain spends only a 
fraction of the time as a free radical. RAFT, however, employs dithioacids in the place of the 
metal-based system used in ATRP. In a typical RAFT synthesis AIBN is used as initiator and a 
dithioacid derivative, or RAFT agent, 'caps' the growing polymer chain in an equilibrium 
reaction favouring the capped chain over the free radical. The RAFT agent employed in this 
work was 2-(2-cyanopropyl)dithiobenzoate, 4.1 (Figure 4.3). 
As is shown below in Figure 4.3, not just the AIBN initiator but also the RAFT agent itself will 
initiate polymerisation reactions. It is therefore the combined stoichiometries of the initiator and 
the RAFT agent (which is usually present in a high excess relative to the initiator) which 
determine the number of initiation events, and therefore the Marget. It should also be pointed out 
that, though not shown in the diagram, the carbon-centred radical species is also able to 
participate in chain-elongation polymerisation reactions, and will do so to a greater extent as the 
RAFT agent is consumed by initiation events. 
NC~('\N~ 
frNv/'CN ---",:::--,\---,lIIo-)o r CN I) monomer 
CN 
NC.\) '''~6-t-
I~ 
~ 
4.1 
Figure 4.3: The mechanisms of initiation in a RAFT polymerisation. 
Chapter 4: Polvmer Chemistry 92 
The number of free radicals within the system at anyone time is determined by the concentration 
of the initiator. Upon completion of all the initiation events, these free radicals will be centred 
on either growing polymer chains or a trigonal intermediate, 4.2, incorporating the RAFT agent 
and two growing polymer chains (Figure 4.4). 
... R:r6SS'~ 
'7
1 ~ 
4.2 
... T 
R1. R2 ::: growing polymer chains 
Figure 4.4: The equilibrium between free radical species during a RAFT synthesis. 
Obviously, chain elongation can only proceed when a free radical is centred on a growmg 
polymer chain. From this it follows that a highly controlled polymerisation will be one where 
the equilibrium reactions shown above are highly facile, with the equilibrium concentrations 
strongly favouring the trigonal intermediate 4.2. 
It has been reported that RAFT protocols may be employed in the synthesis of pMAOS with 
PD<l.3 .120,121 
4.2.2.2 Experimental results 
pMAOS synthesised by Adash via the protocols of Schilli et al.,120 using a 1 :57 ratio of RAFT 
agent to monomer, possessed a much more favourable molecular weight profile (see Table 4.2) 
than that synthesised by ATRP. 
Experiment A A [a] 1V1target Yield (%) !Vin (gmol-1) 
RAFT 2600 90 30000 1.36 
[a] Target molecular weight calculated by Mtargct = {[m]o!([i]o+[r]o)} x Mrm x yield; where [m]o = 
initial concentration of the monomer, [i]o = initial concentration of the initiator, [r]o = initial 
concentration of the RAFT agent and Mrm = the MW of the monomer. 
Table 4.2: Molecular weight data of a pMAOS sample synthesised by RAFT. 
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While the observed Un was far from the Mtarget, the average molecular weight of 30 kDa and PD 
value of 1.36 were considered acceptable (though the PD was less than ideal) for the use of this 
polymer in the synthesis of a first generation of polymer therapeutics. The synthesis was 
therefore repeated to obtain sufficient quantities of polymer to proceed to the next stage of 
investigations, namely, polymer therapeutic syntheses. 
4.3 Reactivity ofpMAOS 
4.3.1.1 Application of the literature protocols 
The following reaction (Figure 4.5) was attempted. The copolymer intermediate was not 
isolated, rather it was formed and reacted in situ, in accordance with the reported protocols. 
pMAOS 
0.1 eq conjugate 3.26 
DMSO, 60 eC, 2h 
Copolymer 
~eq 1A2P 
/ eo eC,3h 
Figure 4.5: The attempted synthesis of a variolin~containing polymer therapeutic. 
The reaction mixture was purified directly by LH20 size exclusion chromatography, during 
which time the yellow colour (characteristic of variolins) was seen associated with both the high 
and low molecular weight fractions. In all, seven fractions were collected, concentrated and 
analysed by a combination of IH NMR spectroscopy and MS(ESI). 
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Disappointingly, the yellow polymeric material was shown by IH NMR spectroscopy (by 
comparing the variolin N(9a)H signal with the various polymer signals) to contain less than 2 
mol% variolin material, rather than the expected 10 mol%. Of the remaining material, one of the 
late-eluting, low Mr fractions was shown by NMR and MS to be reasonably pure conjugate 3.26, 
though the amount recovered was estimated to be only a fraction of that used in the reaction. 
The remaining fractions were mixtures of low Mr compounds, some of which contained 
unidentified variolin material that was not conjugate 3.26. 
The fact that only a fraction of the variolin conjugate had ended up on the polymer was 
surprising, especially given that a reaction time and temperature in the first step exceeding the 
literature protocol by 45 minutes and 10 ec, respectively, had been used." The low recovery of 
unreacted conjugate 3.26 indicated that this material was probably being consumed through a 
competing side reaction(s). Heating a DMSO solution of the conjugate under the same reaction 
conditions but in the absence of polymer led,to no decomposition, suggesting that the polymer 
was participating in the side reactions. 
Further attempts at the synthesis of a polymer therapeutic via these protocols all gave similar 
results. Furthermore, isolation and NMR analysis of the polymer intermediate in these reactions 
showed an unidentified broad polymeric peak at ~2.5 ppm, and NMR analysis of the polymeric 
products following the second step consistently gave polymer backbone signals integrating 
higher than expected relative to the polymer side-chain lA2P signals (an explanation of these 
results is given below in Section 4.3.2). It was therefore decided that the two-step reaction 
would be further investigated with a model system, using only lA2P as the nucleophile. 
4.3.2 Reaction of pMAOS with lA2P 
(The work described in this Section was carried out in collaboration with Dr Sean Devenish, Dr 
Devenish's contributions are indicated wherever relevant.) 
Investigations involving the reaction of pMAOS with lA2P revealed two unexpected side 
reactions (see Sections 4.3.2.1 and 4.3.2.5) that, taken together, explain the failure of the 
• The Uterature60 protocols used conditions of 50°C and 1.25 h, while this experiment was run at 60°C for 2 h. 
polymer therapeutic synthetic attempts, and explain the anomalies seen in the NMR spectra of 
the polymeric intermediates and products. 
4.3.2.1 Ring-opening of the succinimide residues 
Reactions of pMAOS with lA2P at differing temperatures consistently gave a polymeric product 
which, when analysed by IH NMR spectroscopy, displayed the same non-pHPMA polymer peak 
at ~2.5 ppm (specifically, 2.4 ppm in d6-DMSO (see Figure 4.9) and 2.6 ppm in drmethanol) 
that was mentioned above. All other signals were in the correct positions for a pure sample of 
pHPMA 
The identity of this signal at ~2.5 ppm was revealed through 2D NMR experiments, which were 
performed by Dr Devenish. An HSQC-DEPT experiment indicated that this peak corresponded 
to a pair of methylenes with carbon chemical shifts of 28.2 and 30.8 ppm (Figure 4.6). In a 
CIGAR experiment, correlations were obserVed from 2.6 ppm to two carbonyl resonances at 
170.3 and 173.5 ppm (see Figure 4.7; the two DC correlations at 80.3 and 83.5 are fold-backs 
from 170.3 and 173.5 ppm, respectively). 
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Figure 4.6: HSQC-OEPT NMR spectrum, taken in C0300, of copolymer 4.3. 
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Figure 4.7: CIGAR NMR spectrum, taken in CD30D, of copolymer 4.3. 
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Taken together, these results are consistent with pMAOS having undergone some degree of ring-
opening reaction of N-hydroxysuccinimide (NHS) to give succinamide moieties, with the 
resulting non-equivalent pairs of methylene and carbonyl groups. This ring-opening is proposed 
to occur through attack by IA2P at an imide carbonyl to give copolymer 4.3 (Figure 4.8), rather 
than the expected complete displacement ofNHS through attack at the ester carbonyl. 
1A2P 
o 
o~ 
yYH 
OH 
4.3 
Figure 4.8: Formation of copolymer 4.3 from the reaction ofpMAOS with lA2P. 
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This ring-opening of NBS-activated esters by amines has been reported previously in reactions 
in which either the active ester carbonyl group or the incoming nucleophile is sterically 
congested.122.123 There is also strong evidence to suggest that the steric bulk around the activated 
ester carbonyls of pMAOS appreciably decreases the displacement of NHS by amine 
nucleophiles. 124 Ring-opening of NBS by primary amines has also been reported to proceed to 
completion at room temperature in less than 1 h,125 and has been reported as an efficient way of 
synthesising N-(O-carbamoyl)-succinamides from O-succinimidyl carbamates. 126 
Given below is a fully assigned IH NMR spectrum of copolymer 4.3 (x 0.62, Y 0.38; Figure 
4.9). It is important to note that this spectrum has been taken in d6-DMSO, to allow detection of 
the amide and hydroxamate protons, while the 2D spectra presented above were taken in 
d4-methanol. This difference in NMR solvents results in small differences in chemical shifts of 
equivalent signals. Also, the assignment of the two sets of lA2P signals (eg, H-12 vs H-12') is 
speculative and based on peak broadnesses, .with peak broadness decreasing with increasing 
distance from the polymer backbone. Signals were initially assigned by comparison with spectra 
of pure pHPMA, and were confirmed by the 2D NMR experiments. 
() 
I 0:; 
8 9 
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o NH 14'!d12 13 
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Figure 4.9: Fully assigned IH NMR spectrum of copolymer 4.3 in d6"'DMSO. 
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This initial work was carried out using pMAOS synthesised by ATRP, and so catalysis of this 
ring-opening reaction by traces of copper was considered a possibility, 127 This hypothesis was 
discounted, however, when RAFT-synthesised samples of pMAOS were shown to react in 
exactly the same fashion. 
Three representative examples of the reaction of pMAOS with lA2P are given in Table 4.3. 
Reaction solutions were directly purified by LH20 size-exclusion chromatography (SEC), and 
the polymeric material examined by IH NMR spectroscopy. 
Expt. Temp. CC) Time (h) lA2P (mol eq) Yield (%) % Ring-opening[a] 
1 40 7 1.0 84 60-65 
2 40 25 1.0 85 
3 50 3 91 60-65 
[a] As detennined using IH NMR spectroscopy - the integral of the succinarnidyl methylene peak was 
quantified relative to the IA2P methylene signal. Obtaining accurate integrals was often compromised by 
uneven baselines, and so percentages are given as multiples of 5, in accordance with this margin of error. 
Table 4.3: The extent of ring-opening in the reaction ofpMAOS with lA2P, 
Ring-opening, then, dominated the type of nucleophilic attack by lA2P at the temperature that 
was reported to afford polymer therapeutics of type 1.1. Lower reaction temperatures made little 
or no difference to the extent of ring-opening, and the copolymer product was stable in solution 
following its formation. Undisplaced NHS was not observed in any of the IH NMR spectra. 
4.3.2.2 Hydroxamic acids isolated and characterised 
It was expected that these ring-opened hydroxamate moieties would be displaced from the 
polymer backbone by a second attack of lA2P (PKa hydroxamic acids ~ 9), though at a slower 
rate than the displacement of NHS (pKa - 8). Indeed, hydroxamate-activated esters have been 
used in the acylation of amines. 128,129 
Table 4.3 (above) shows that when one equivalent of nucleophile was used, the extent of ring-
opening was consistently 60-65%. However, when higher stoichiometries of the amine 
nucleophile were used, less ring-opening was observed in the polymeric product. The reason for 
this was presumed to be due to expulsion of the hydroxamate leaving groups, formed in situ, by a 
second nucleophilic attack by lA2P at the still-activated ester carbonyl. In support of this 
hypothesis, longer reaction times and higher temperatures were seen to give copolymers bearing 
less ring-opened material, presumably through an exacerbation of this loss of ring-opened 
material from the polymer backbone by a second nucleophilic attack Table 4.4 gives the results 
from three representative reactions. One can infer from these results that the expUlsion of the 
hydroxamate leaving group from the polymer backbone is indeed a slower reaction than the 
expulsion/ring-opening of the NBS residues. 
Expt. Temp. eC) Time (h) lA2P (mol eq) Yield (%) % Ring-opening[a1 
1 45 3.5 1.2 87 55·60 
2 50 3 2.0 82 55 
3 50 16 2.0 90 10 
[a] As detennined using I H NMR spectroscopy - the integral of the succinarnidyl methylene peak was 
quantified relative to the lA2P methylene signal. Obtaining accurate integrals was often compromised by 
uneven baselines, and so percentages are given as multiples of 5, in accordance with this margin of error. 
Table 4.4: The exient of ring-opening with an excess of lA2P. 
Examination of the low-molecular weight material obtained from these reactions (following 
LH20 SEC) revealed a number of ring-opened succinamide derivatives, as well as the expected 
NBS. The two main ring-opened compounds were purified and characterized by Dr Devenish, 
and shown to be the and Z-isomeric hydroxamic acids 4.4 and 4.5 (Figure 4.10).94 
H 0 HO'N~N~ 
o H OH 
OH 0 
HN~N~ 
o H OH 
4.4 4.5 
Figure 4.10: Hydroxamic acids 4.4 and 4.5. 
Importantly, the chemical shifts for the succinimidyl methylenes were 2.18 and 2.33 for 
hydroxamic acid 4.4 and 2,38 (both coincident) for hydroxamic acid 4.5 in d6-DMSO, which is 
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in close agreement with the value of 2.4 ppm seen with copolymer 4.3 (see Figure 4.9), lending 
further support to the proposed structure of this compound. 
4.3.2.3 How are hydroxamic acids 4.4 and 4.5 formed? 
The isolation of hydroxamic acids 4.4 and 4.5 from the reaction mixtures was taken as evidence 
for the proposed structure of copolymer 4.3, however, the possibility that these compounds had 
been formed from free NBS in solution, following its liberation from the polymer backbone, 
could not be discounted. Indeed, both 4.4 and 4.5 were recovered from a reaction involving only 
NBS and 1A2P in methanol at 40°C (in an experiment performed by Dr Devenish that emulated 
a literature report).130 
In order to resolve this ambiguity a pure sample of copolymer 4.3, which had no NBS groups as 
determined by IH NMR spectroscopy, was reacted with 1A2P. Following LH20 SEC, the 
isolated low molecular weight material was examined by IH NMR spectroscopy and seen to 
contain the hydroxamic acids 4.4 and 4.5 (it should be noted that these compounds had partly 
reacted further to give related compounds that were not characterized). As there was no source 
of NBS in this experiment, 4.4 and 4.5 must have initially been conjugated to the polymer 
backbone, as in structure 4.3. This was taken as final proof of the structure of 4.3. 
Having proved structure 4.3, attempts must be made to explain why the ring-opening reaction 
was so pronounced in this system, yet not in others to the same extent. The reason is presumably 
related to steric hindrance at the ester carbonyl centre. To test this idea, a solution of 
N-hydroxysuccinimidyl pivalate (2.23; see Section 2.3.7) was heated with two equivalents of 
1A2P in DMSO at 55°C for three hours. Analysis of the crude reaction mixture by MS (positive 
mode) revealed the expected amine product (which dominated the spectrum), while no ring-
opened hydroxamate ester material was observed. The products were isolated using a CI8 
cartridge, and the material shown, through the use of IH NMR spectroscopy, to be exclusively 
the amide product. 
This result shows that the quaternary a-centre alone does not account for the presumed steric 
hindrance of the pMAOS carbonyl centers. It is proposed, then, that the polymer conformation 
in solution exacerbates this steric hindrance, leading to extensive ring-opening of the 
succinimide residues. 
4.3.2.4 Can copolymer 4.3 replace pMAOS in the synthesis of polymer therapeutics? 
The observation, described in Sections 4.3.2.2 and 4.3.2.3, that copolymer 4.3 still represented 
an activated polymer backbone led to the idea that 4.3 could be used in place of pMAOS in the 
synthesis of polymer-drug constructs of type 1.1 (via the reaction scheme shown in Figure 4.5). 
Therefore, pMAOS was reacted with lA2P to give copolymer 4.3 in situ (assumed to be 60-65% 
ring-opened), conjugate 3.26 (0.1 eq) was added, the reaction stirred at 70 °C for 22 h, then 
1A2P (2 eq) added and the reaction stirred for an additional 17 h at 70 °C. The reaction mixture 
was purified by LH20, and the high molar mass and low molar mass material (both yellow in 
colour) collected for characterisation. 
The polymeric material was examined by IH NMR spectroscopy. It was difficult to obtain 
reliable integrals, due to an uneven baseline, but a comparison of the peak integrals for the 9-NH 
proton of the variolin component of conjugate 3.26 with the polymeric 1A2P methylene signal 
suggested that the polymer was carrying 5 mol% variolin (this result was later refined to 2.5% 
based on results, described in Section 4.3.2.5, which revealed further structural characteristics of 
the polymer - namely, the presence of glutarimide moieties). It was decided that this result 
should be checked by UV quantification. 
UV analysis of a standard solution of conjugate 3.26 in DMSO gave an extinction coefficient at 
410 nm (8(410 nm» of 20 000 Lmorlcm"l. The UV absorbance at 410 nm of a 250 JlglmL solution 
of the polymeric material, performed in triplicate, gave an average Ac410 nm) = 1.02. From this, a 
concentration for polymer-bound conjugate 3.26 of 51 ~ was inferred, which gave a molar 
loading of 3.3% for the conjugate (this result was later refined to 2.5%, based on results 
described in Section 4.3.2.5, which revealed further structural characteristics, and therefore the 
correct molar mass, of the polymer). This was, in hindsight (that is, after the values had been 
adjusted due to the aforementioned refined copolymer molecular formula that included 
glutarimide units - see Section 4.3.2.5), in good agreement with the NMR result. At the time, 
however, an ambiguity remained (5 mol% vs 3.3 mol%), and so it was decided to investigate the 
low molar mass material in an attempt to quantify the amount of conjugate 3.26 in this fraction. 
Analysis by IH NMR spectroscopy, not surprisingly, showed the low Mr fraction to be 
comprised mainly of ring-opened succinamide material, a small amount of NHS, and a small 
amount of conjugate-like material. The mixture was complex, however, so no reliable 
information regarding the amount or identity of the conjugate-like material could be gleaned. 
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The UV profile of this low molar mass material was typical of variolin~containing material, 
however due to the complexity of the mixture UV quantification was considered unreliable. 
Investigations using HPLC were therefore pursued. 
Injections of solutions of conjugate 3.26 (3.4 x 10-9 mol) onto the HPLC, run with the standard 
gradient elution protocols and analysed at 248 nm, gave average peak areas of 1.03 x 1012 
AU.min.mor l . Dissolution of the low molar mass material from the attempted polymer 
therapeutic synthesis in DMSO (3 mL), followed by a 1: 100 dilution and injection of 100 J.iL of 
the resulting solution onto the HPLC (in triplicate) gave a series of five peaks, all with 
conjugate-like chromophores, eluting between 10 and 12.5 minutes. One of these peaks, eluting 
at 10.2 minutes and comprising less than 5% of the total peak area of the region, was confirmed 
by sample spiking to be conjugate 3.26. The combined peak areas of all the conjugate-like peaks 
. 
was 4400 AU.min. Assuming that the extinction coefficients for these compounds at 248 nm 
were the same as for conjugate 3.26,* then 85% of the conjugate starting material could be 
accounted for by these unidentified compounds iIi the low Mr faction. This was in excess of the 
expected value, though only by 10% (given a molar loading of 2.5% on the polymeric material). 
This discrepancy may be explained by a change in extinction coefficients for the conjugate side-
products, by other non-conjugate-derived impurities also eluting from the HPLC column at 
10-12 minutes (a distinct possibility, given the complexity of the region), or simply by the error 
margin of the investigation. The result nonetheless corroborates the conclusion that only a 
fraction of the conjugate 3.26 starting material, probably ~2.5%, ended up on the polymer 
backbone. 
None of the four conjugate-like side products identified by HPLC were characterised (LCMS 
analysis gave insufficient information for even speculation). Their appearance was attributed to 
the relatively high reaction temperature and long reaction times needed. Subsequent results 
(reported in Section 4.3.2.5) led to this line of work being abandoned, rendering the 
characterisati on of these compounds redundant. 
Although TEA has been reported to decrease the rate of acylation of amines by hydroxamate 
esters,129 the attempted polymer therapeutic synthesis from copolymer 4.3 was repeated with the 
• A reasonable assumption, based on the observation that the UV absorbancy of the reaction mixture was seen to 
change only slightly during the course of the reaction, as is discussed below. 
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inclusion of TEA, in an attempt to minimise the unwanted side reactions. Unfortunately, the 
glutarimide~forming side reaction (described in Section 4.3.2.5) was seen to occur at 
prohibitively high levels. These experiments did, however, show that a reaction time of seven 
hours at 45 DC was sufficient to give complete reaction of conjugate 3.26, with ~70% of the 
conjugate ending up on the polymer backbone. Most of the variolin material remained polymer~ 
bound during the subsequent reaction with lA2P. 
A further important result was that the UV absorbance at 410 nm of a reaction solution did not 
change significantly during the course of a reaction, strongly suggesting that the extinction 
coefficient of conjugate 3.26 was not significantly altered by conjugation onto a polymer 
backbone up to a concentration of at least 7 mol% substitution. This validated the method for 
quantification of va rio lin material on a polymer backbone by UV spectrophotometry. 
As was alluded to above, in an attempt to reduce conjugate 3.26 consumption through unwanted 
side reactions, subsequent polymer therapeutIc synthetic attempts were carried out employing 
lower reaction temperatures. Examination of the polymeric products by IH NMR spectroscopy, 
however, consistently gave spectra with anomalous integrals; specifically the polymeric lA2P 
oxymethine signal integrated too high when compared with the lA2P methylene signal, and both 
were less than expected when compared to the backbone signals. Reexamination of the spectra 
obtained from the higher temperature reactions showed the same discrepancies. Furthermore, 
some of the polymeric products were eventually found to be water insoluble. 
These observations were investigated more closely, again employing a model system using only 
IA2P as nucleophile. What was discovered is described in Section 4.3.2.5, and would lead to the 
abandonment of the synthesis of polymer therapeutics from copolymer 4.3. 
Before moving on and discussing the nature of this second side reaction, it should also be noted 
here that none of the polymeric constructs synthesised possessed demonstrable bioactivity (that 
is, an IC50 value against the P388 cell line of<125 !tg/mL). 
4.3.2.5 Hydroxamate expulsion to git'e glutarimide moieties 
The formation of water~insoluble polymers from the reaction of pMAOS with primary amines 
was reported by Ringsdorf in his 1975 paper.17 In this paper, he briefly mentions that the 
reaction of pMAOS with ethanolamine gave the expected water~soluble polymer when the 
reaction was carried out below 40 cC, but water~insoluble polymers resulted when the reaction 
was carried out at temperatures greater than 40 cC. The insoluble polymers were presumed to be 
cross-linked polymers, fonned by the reaction of alcohol groups of polymer-bound ethanol amide 
moieties with unreacted NHS ester groups. No further experimental or characterisation details 
were given. Ethanolamine is a close structural analogue of lA2P, and so this report was seen to 
corroborate the findings described above. However, it was considered desirable to investigate 
the water-insoluble polymers more closely in order to confinn their structure. 
When copolymer 4.3 was heated in DMSO with lA2P the polymeric product was insoluble in 
water, and displayed the integral anomalies described above when examined by lH NMR 
spectroscopy (see Figure 4.14). Importantly, however, the NMR spectra contained lA2P 
hydroxyl signals that were larger than would have been expected had significant amounts of 
ester cross-links been formed. This result strongly challenged the explanation previously offered 
for the formation of these insoluble polymers, and so 2D NMR experiments were again 
employed to elucidate the structure of this polymer. 
An HSQC-DEPT experiment (Figure 4.11) revealed a very broad set of methylene signals that 
had previously escaped attention spread across ~0.5 ppm (~3.4-3.9 ppm) and partially obscured 
by the oxymethine signal (3.8-4.0 ppm) (see Figure 4.14). The l3C shift of the associated 
carbons suggested that these signals were lA2P methylene groups. Further support for this 
assignment carne from a COSY experiment (Figure 4.12), which showed a correlation from this 
broad region to the oxymethine signal. 
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Figure 4.11: HSQC-DEPT spectrum of copolymer 4.6, taken in CD30D. 
3.0 -
3.1 -, 
3.2 
3.3 
3.4 
3.5 
3.6 -
4.1 
rr..,....TT-.-r-t-,....,T·.,-.,.·-t~-r--rr-.,..-,-rT-..-r" , I ' , ,...,.T~~,....."...,..'-·-r--rr-..,-'.-,.....r.,... 
4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 
F1 (ppm) 
Figure 4.12: COSY spectrum of copolymer 4.6, taken in CD30D. 
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Taken together, these data indicated that a copolymer containing lA2P residues in both amide 
and imide functionalities, copolymer 4.6, had been formed (Figure 4,13), The formation of 4.6 is 
proposed to occur through ring-closing attack of amides on (presumably) neighboring 
hydroxamate-activated esters to form N-substituted glutarimides, 
4.6 
Figure 4.13: Fonnation of copolymer 4.6 from copolymer 4.3, 
The IH NMR data were consistent with this proposed structure, with the oxymethine protons of 
the glutarimide and HPMA moieties being coincident and partially overlapping the very broad 
signal from the lA2P methylene protons of the N-substituted glutarimide (see Figure 4.14), 
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Figure 4.14: Fully assigned IH NMR spectrum of copolymer 4.6 in d4~methanol. 
To further prove this structure, a pure sample of ring-opened copolymer 4.3 in d6-DMSO was 
heated at 70°C in the absence of lA2P and the reaction followed by iH NMR spectroscopy. The 
liberation of hydroxamic acids 4.4 and 4.5 was clearly observed during the course of the 
experiment, and after completion copolymer 4.6 was isolated from the reaction mixture. 
It was found that this ring-closing reaction dominated any attempts to convert copolymer 4.3 to 
pHPMA. When 4.3 (-65% ring-opened) was heated in 50% lA2PIDMSO at 45°C for 24 hours, 
copolymer 4.6 was isolated with an HPMA:glutarimide ratio of -1: 1, indicating that -50% of the 
hydroxamate displacement from 4.3 had occurred through intramolecular attack. 
Glutarimide formation during the aminolysis of pMAOS has been previously reported; 
specifically, 1-5% glutarimide formation was reported to occur at ambient temperature, with no 
observable formation at temperatures of 50-60 °C.6i It is likely that the researchers were in fact 
observing the presence of ring-opened material in their iH NMR spectra, though no NMR 
characterisation data were given, and so further comment can not be made here regarding this 
report. 
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4.3.2.6 Implicationsfor thefailed polymer therapeutic syntheses from pMAOS 
It was now clear why the efforts toward a synthesis of a polymer therapeutic carrying conjugate 
3.26 using pMAOS as the polymeric precursor (described in Section 4.3.1.1) were unsuccessful. 
The majority of the yellow variolin-containing material had ended up in the low Mr fraction 
following LH20 SEC, with less than 2 mol% remaining on the polymer. It is now known that 
the two reactions shown in Figure 4.15 would have represented a significant loss of variolin 
material from the polymer. 
-:B::t-
o,?&o 
3.26-NH2 
4.7 
1 
Figure 4.15: Competing side-reactions during the attempted synthesis, using 
pMAOS, of a polymer therapeutic incorporating conjugate 3.26. 
The material, 4.7, that was expelled from the polymer backbone in the third and final step of the 
above reaction scheme is shown below in Figure 4.16. 
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o H 0 HOHN~NJN 
o H 
4.7 
Figure 4.16: Leaving group 4.7, 
Attempts at identifying leaving group 4.7 in the low Mr fraction of the attempted polymer 
therapeutic syntheses were met with only partial success - analysis by LCMS showed a 
compound of the expected molar mass, though apparently at significantly lower concentrations 
than would have been expected, The most likely reason for this is that 4.7 was presumed to have 
reacted further to give other unidentified compounds (an idea taken from the observation that 
hydroxamic acids 4.4 and 4.5 were isolated from complex reaction mixtures comprised of other 
similar compounds), 130 
4.3.2.7 Replication of the GodwiniBrocchini experiment 
In a final attempt to utilize pMAOS, it was decided that the reaction conditions previously 
reported to provide the HPMA copolymer 1.3 (see Section 1.2.3,2) would be replicated exactly,60 
Firstly, N-glycyl-glycyl-~-naphthylamide hydrochloride, 4.8 (Figure 4,17), was synthesised from 
~-naphthylamine via conventional solution-phase peptide synthetic protocols in 44% yield over 
four steps, 
H 0 r(YYNITN~NH2' Hel 
~ 0 H 
4.8 
Figure 4.17: The drug substitute, 4.8, used in the reported model synthesis of a polymer therapeutic, 
This material was then used in the reaction shown in Figure 4.18, 
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4.8 (0.1 eq), TEA (0.2 eq) 1A2P 
pMAOS )IIro 1.3 
DMSO, 50°C, 2.5 h 50°C, 1.25 h 
Figure 4.18: An exact replication of the reported protocols for the synthesis 
of the HPMA copolymer 1.3, bearing 10 mol% 4.8. 
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The crude reaction mixture was analysed by HPLC, using the standard gradient elution 
protocols, and shown to contain small amounts of two low Mr chromophore-containing 
compounds (eluting as sharp peaks), with the majority of the chromophore being polymer-bound 
and eluting as a broad peak from 9- 15 minutes. Of the two low Mr com pounds, one eluted at 
8.5 minutes and was shown by sample spiking to be unreacted conjugate, and the other eluted at 
10.1 minutes, and was presumed to be leaving group 4. 9 (Figure 4.19). 
o H 0 H HOHN~N~Nf(N~ 
o H 0 ~
4.9 
Figure 4.19: Leaving group 4.9. 
Purification of the reaction mixture by LH20 SEC gave a polymeric product and a low Mr 
fraction. Examination of the polymeric product by lH NMR spectroscopy showed that the 
polymer contained 60-65 mol% ring-opened materiaL Comparing the integrals for the H-l of the 
naphthylamide moiety with the polymer backbone and lA2P methyl signals suggested that the 
polymer was carrying 9-10 mol% conjugate 4.8. This was in agreement with the HPLC result 
obtained with the crude reaction mixture. Examination of this material by FTIR showed poorly-
defined absorbances throughout the spectra, with a complete absence of the NHS-ester carbonyl 
peak at 1735 cm-1 (the latter result was consistent with the disappearance of the active ester peak 
reported in the literature),6o,62 
The subsequent reaction of this polymeric material in the presence of lA2P at 50°C for 2 d gave 
a copolymer with an HPMA:glutarimide ratio of ~2: 1. Integrals also suggested that the polymer 
was carrying 5-6 mol% conjugate 4.8. The isolated copolymer was again examined by FTIR 
spectroscopy, which again showed only poorly-defined absorbances throughout the spectra, with 
no strongly distinguishing signals from that of the copolymer isolated after the first step of the 
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reaction. Fonnation of copolymers of type 4.3 and 4.6, therefore, cannot be readily observed by 
IR spectroscopy. 
4.3.3 Reaction ofpMAOS with benzylamine 
A 2004 paper, coauthored by Monge and Haddleton, describes the synthesis of pMAOS by 
copper-mediated ATRP.62 Polymers with!Vin - 4000 gmor l and PD < 2.0 were synthesised, and 
then used in the synthesis of poly(N-benzyl methacrylamide). The displacement reaction was 
carried out at 50°C for five hours - the reaction was followed by IR spectroscopy and was 
stopped upon the complete disappearance of the NBS-activated ester carbonyl peak at 1736 cm-I. 
The reaction solution was concentrated in vacuo and the polymer reportedly purified by 
precipitation from DMSO with methanol. A IH Nl\IIR spectrum given in the paper of the 
polymeric product at first glance appears to be pure poly(benzyl methacrylamide), free of any 
ring-opened succinimidyl moieties. 
It is obvious that this polymer contains no significant amounts of ring-opened material. 
However, close inspection reveals the likely presence of some glutarimide material. While 
integral ratios are not given, a manual measurement of the peak areas (ie, cutting out and 
weighing each peak) suggested that the polymer was comprised of both amide and glutarimide 
moieties. The hypothesised N-substituted glutarimide benzyl methylene signal is a slightly 
raised region -0.4 ppm upfield of the amide benzyl methylene signal. Given the small size and 
broadened nature of this signal reliable integrals could not be obtained, however a rough estimate 
would suggest that the glutarimide:benzyl methacrylamide ratio was -1: 10. 
In order to confirm this assertion, it was decided that the reaction would be replicated. Thus, a 
solution of pMAOS and benzyl amine was stirred at 50°C for five hours. The reaction was 
performed in triplicate. One reaction was purified immediately by LH20 SEC, and the other two 
were left under reduced pressure (0.03 mm Hg) at room temperature for seven days to remove 
the liquid reagents. This was in accordance with the Monge and Haddleton protocols, though 
neither times nor temperatures were given in their paper for this concentration process. Of the 
latter two, one was purified by LH20 chromatography, while the second was dissolved in a 
minimal amount of DMSO then diluted 100-fold with methanol. No precipitation occurred in 
this final experiment; furthermore, methanol had successfully been used as the eluant during the 
LH20-based purification of the polymeric material from the first two reactions. It is not known 
why this discrepancy between what was reported and what was observed exists. 
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The polymeric material from the first reaction (ie, that which was immediately purified) was 
analysed by IH NMR spectroscopy and shown to be a copolymer carrying both ring-opened 
succinimide and glutarimide material (Figure 4.20). The assignment of the glutarimide benzyl 
methylene signal at 4.7 ppm was supported by an HSQC-DEPT NMR experiment. This signal is 
in the same position as the presumed glutarimide methylene signal seen in the IH NMR spectrum 
given in the Monge and Haddleton paper. 
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Figure 4.20: IH NMR spectrum, taken in d6-DMSO, of the polymeric 
product from the reaction ofpMAOS with benzylamine. 
The amount of ring-opened material observed was less than expected. This may reflect different 
conformations in solution (and therefore different degrees of steric hindrance) of the polymer 
intermediates between the 1A2P and benzylamine substitution reactions. Conversely, the 
amount of glutarimide formation is higher than expected. No explanation can be given for this, 
although Section 4.4.1.2 (below) does show that the ring-closing reaction can be relatively facile 
in some systems. 
Analysis of the polymer isolated from the second reaction (that is, after seven days under 
reduced pressure) showed it to be fairly similar to that shown above, with the only difference 
being that it carried less ring-opened material and more benzyl methacrylamide. The ratio of 
glutarimide : benzyl methacrylamide : ring-opened units in this polymer was about 1 : 7 : 1. 
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Therefore, during the seven days under reduced pressure slightly less than half of the 
hydroxamate moieties were displaced by a subsequent attack of benzyl amine. Very little (if any) 
glutarimide formation occurred during this time, which is consistent with earlier observations 
suggesting that this reaction is less pronounced at lower temperatures. 
While no ring~opened material was seen in the polymer made by Monge and Haddleton, a likely 
explanation for this is that hydroxamate material was indeed formed, but subsequently expelled 
upon attack by benzylamine during the sample concentration phase. (The temperature at which 
this concentrating step was carried out is not given.) The amount ofring-closing that can be seen 
in their polymer sample is comparable to that found in this work. 
Another possibility is that that the pMAOS samples that were made and used in their work were 
from 3.6 to 4.5 kDa. This is around 7 times smaller than the RAFT-synthesised polymer used in 
the work described here (Mn ~ 30 kDa). It is possible that the smaller molecules may adopt a 
different conformation in solution, so that steric hindrance around the ester carbonyls is 
minimised. This idea was not investigated further, however. 
4.4 Other Activated Polymers 
With conjugate 3.26 still in hand, it was decided that other activated methacrylic homopolmers 
would be investigated, in the place of pMAOS, as possible precursors to polymeric constructs of 
type 1.1 in the type of reaction shown in Figure 4.5. 
4.4.1 Poly(p~nitrophenyl methacrylate) (pNPMA) 
Given than p-nitrophenol-activation is currently employed in the conventional synthetic route to 
polymer therapeutics (see Section 1.1.3.1), it was decided that a pNPMA homopolymer (Figure 
4.21) would be investigated as a possible substitute for pMAOS in the protocols being employed 
in this work. 
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Figure 4.21: pNPMA 
4.4.1.1 Synthesis 0/ pNPMA 
pNPMA homopolymer was synthesised by Adash from p-nitrophenyl methacrylate via 
conventional free radical poiymerisation. GPC analysis was not performed on this sample, 
which was synthesised with an Mtnrget of 20 kDa and was presumed to be of high PD. 
4.4.1.1 Reaction o/pNPMA with 1A1P 
The reactivity of pNPMA was investigated using lA2P as the nucleophile. A solution of the 
polymer (97 ~), lAZP (2 eq) and TEA (1.5 eq) in DMSO was stirred at 45°C for 48 hours, and 
aliquots were periodically removed and analysed by HPLC using the standard gradient elution 
protocols at a wavelength of 315 nm. p-Nitrophenol eluted as a sharp, well-defined peak at 
1l.6 minutes (this was confirmed by sample spiking). Peak areas were measured and compared 
to those obtained with a standard solution ofp-nitrophenol (6.5 x lOll AU.min.mor1) in order to 
quantify the amount of leaving group displacement. The results are given below in Figure 4.22. 
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Figure 4.22: Liberation ofp-nitrophenol from pNPMA upon reaction with lA2P. 
After 48 h 89% of the p-nitrophenol had been displaced from the polymer backbone, as 
determined by HPLC. At this time the polymeric material was purified by LH20 SEC and 
examined by IH NMR spectroscopy. The NMR spectrum clearly showed that a large amount of 
glutarimide formation had taken place, and also confirmed that -10 mol% of the p-nitrophenol 
residues remained polymer-bound. Figure 4.23 gives the structure of the copolymer product, 
along with the ratios of the three different structural units. 
Figure 4.23: The polymeric product from the reaction ofpNPMA with lA2P. 
The large amount of glutarimide formation further confirmed the proposed structure of the 
glutarimide moiety, with 2D NMR experiments run on this polymer again giving the key 
correlations. This increase in glutarimide formation in pNPMA compared with pMAOS may be 
due to either the increased electrophilicity of the p-nitrophenyl-activated ester compared with the 
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NBS-activated ester, a possible different polymer conformation in solution, or a combination of 
both. 
In light of the large amount of observed glutarimide formation, this line of investigation was 
abandoned. 
4.4.2 Poly(methacryloyl chloride) (pMAC) 
A 1998 paper reported that poly-methacryloyl chloride (pMAC) gave superior results to pMAOS 
in the synthesis of polyamides, 131 Adash had begun work towards the synthesis of samples of 
pMAC of low PD (work that is still being undertaken at the time of writing), and so this polymer 
was investigated as a possible precursor in the synthesis of polymer-drug constructs of type 1.1. 
4.4.2.1 Synthesis ofpMAC 
The synthesis of pMAC by conventional polymerization protocols has been reported; AIBN was 
used as the initiator, and temperatures of 60-65 °C for 2-3 days gave yields of 89_95%.131,132 
Several attempts were made at synthesising pMAC by these protocols, with generally poor 
results. Eventually, a synthesis carried out in toluene at 85°C for 21 hours gave a polymeric 
product in 28% yield (based on weight recovery, and later refined to 29% based on a presumed 
acid chloride/free acid copolymer structure see below). Longer reaction times did not improve 
on this yield. Examination of this material by IH NMR spectroscopy showed only one set of 
signals, which were in the correct position for the pMAC backbone signals. These signals were 
very 'spikey', however, suggesting that low Mr material had been formed, most probably well 
short of the Mtarget of 5.5 kDa, or 53 monomer units. The spikey appearance of the backbone 
signals may have also reflected some degree of hydrolysis of the acid chloride moieties, possibly 
in the NMR solvent (CDCb). It was therefore decided that a subsample of this polymer would 
be converted to the methyl ester analogue poly-methyl methacrylate (pMMA) in order to 
quantify the amount of reactive acid chloride groups remaining on the polymer chain. 
Thus, a dry solution of the freshly-made pMAC in a mixture of pyridine, methanol and THF was 
heated to reflux under argon for three days. The polymeric product was purified by precipitation 
from tetrahydrofuran with methanol in a disappointing 24% yield, Examination of this material 
by IH NMR spectroscopy again gave 'spikey' backbone signals, indicative of a copolymer 
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and/or low Mr material, with a methyl ester signal integrating to around two protons (relative to 
the backbone signals). This suggested that -30% hydrolysis had occurred at some point, either 
during the synthesis of pMAC or the subsequent synthesis of pMMA (the monomer starting 
material, methacryloyl chloride, was shown by IH NMR spectroscopy to be pure, ie, free of 
methacrylic acid). Hydrolysis during polymer synthesis became the most likely explanation 
when this value of ~30% was confirmed in a separate substitution reaction involving the much 
stronger nucleophile 1A2P (see below, Section 4.4.2.2). 
4.4.2.2 Reaction ofpMAC with lA2P 
Despite the suspected low quality of the pMAC sample, it was decided that reaction of this 
polymer with 1A2P would be investigated. pMAC is more electrophilic than pNPMA and 
pMAOS (and even more so than the ring opened copolymer 4.3), and so it was anticipated that 
this polymer, even if it was -30% hydrolysed, would show a significant degree of glutarimide 
formation. 
A sample of pMAC was reacted with five equivalents of 1A2P under dry conditions at 70°C for 
16 hours. The polymer that was isolated was examined by IH NMR spectroscopy and shown to 
be comprised ofmethacrylic acid, HPMA and glutarimide units in a ratio of3:5:1 (Figure 4.24). 
This interpretation was based solely on the peak integrals; the glutarimide 1A2P methylene 
signal is not obvious, but this is considered reasonable given the large area over which it is 
spread. 
Given the presumed ~30% methacrylic component of this polymeric product, and given that this 
value is the same as that seen in the pMMA synthetic reaction from the same starting material, it 
can be inferred that the pMAC starting material was most probably ~30% hydrolysed. It is not 
known why this hydrolysis occurred, as all attempts were made, using well-established 
anhydrous protocols, to rigorously exclude water from the polymerisation reaction. 
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Figure 4.24: lH NMR spectrum ofthe polymeric product from the reaction 
ofpMAC (presumably 30% hydrolysed) with lA2P. 
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The amount of glutarimide formation would indicate that around 10% of the available acid 
chloride moieties were attacked by a neighbouring HPMA amide in the glutarimide~forming 
reaction. This level of glutarimide formation was less than what was expected, given the amount 
of glutarimide formation that was seen with the pMAOS and pNPMA One possible explanation 
is that the polymer starting material was sufficiently hydrolysed so that there were few HPMA 
residues adjacent to methacryloyl chloride residues as the substitution proceeded, however it is 
considered unlikely that this alone could account for the relatively low amount of observed 
glutarimide formation. Another more likely possibility is that the more sterically hindered acid 
chloride carbonyl favours intermolecular attack by the smaller 1A2P rather than the 
intramolecular reaction with the larger amide group. A third consideration is that polymer 
conformation in solution may significantly affect the relative rates of the two types of 
nucleophilic attack. Furthermore, the presumed lower molar mass of the pMAC molecules used 
in this investigation may have affected this conformation. 
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4.5 Conclusions and Future Work 
The use of polymethacryloyl active esters as precursors to polymethacrylamides is precluded by 
formation of unwanted side-products, It has been clearly demonstrated that attack on pMAOS 
by primary amine nucleophiles proceeds not just at the NHS-activated methacrylate carbonyl, 
but also at the succinimidyl carbonyls, This ring-opening reaction is seen to be slightly favoured 
over the NHS-displacement reaction, This type of NHS ring-opening has been previously 
reported as a reasonably facile reaction, and it is thought to be so pronounced in the pMAOS 
system due to steric hindrance at the methacrylate carbonyl centre, presumably due at least in 
part to the polymer conformation in solution, 
The resulting ring-opened hydroxamate moieties were shown to be displaced from the backbone 
by subsequent nucleophilic attack However, this displacement was seen to occur not just 
through intermolecular attacks by primary amine nucleophiles, but also by intramolecular attack 
by neighboring amide moieties to form N-substituted glutarimide moieties, This glutarimide-
forming reaction was shown to be unavoidable, proceeding at an equal rate to the intermolecular 
attack at 70 °e, for example, The copolymer products typically displayed very poor water 
solubility. 
It is not known why these reactions have not been reported to date. It is possible that the size of 
the polymer chains has a significant effect in terms of steric hindrance around the NHS-activated 
carbonyls. The idea that polymer length may have an important influence on pMAOS 
conformation in solution and therefore the way that this polymer reacts with amine nucleophiles 
is purely speculative, and has yet to be further investigated. 
The Godwin et al. paper60 presents IR data but no NMR data, and the work described in Section 
4.3.2.7 shows that the formation of copolymers 4.3 and 4.6 would not be easily detected in 
experiments monitored by IR spectroscopy alone. It is not known whether the polymeric 
products reported in this paper were fully characterised by NMR spectroscopy. 
As an alternative to pMAOS, pNPMA was investigated, The use of this polymer, however, was 
also precluded by the formation of glutarimide moieties at levels greatly exceeding those seen 
with pMAOS. It is not known how universal this phenomenon of glutarimide formation is with 
poly(activated methacrylate) homopolymers, but these results suggest that the problem may be 
encountered with other activated polymeric precursors of this type. 
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Surprisingly, pMAC chloride showed much less glutarimide formation, though the synthesis of 
this material was thought to be hampered by hydrolysis, and the Mn of this material (which was 
likely to be much lower than the Mtarget) was not measured. This result therefore needs to be 
corroborated with pMAC of high quality, though the hydrolytic lability of this polymer may limit 
its application in the synthesis ofpolymer~drug constructs of type 1.1. 
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CHAPTER 5 
AIMS REVISITED 
As has already been outlined in Section 1.4, at the beginning of the work described in this thesis, 
the aims of the work were defined as follows: 
1) to further investigate and optimise the synthesis ofDVB; 
2) to extend the brief SAR investigation involving the methoxy and hydroxyvariolin series 
to the deoxy series; 
3) to select the most suitable analogues for further development into polymer~drug 
conjugates, and acylate these analogues with the GFLG tetrapeptide biolinker; and, 
4) to use any tetrapeptide~variolin conjugates successfully synthesised in the synthesis of 
polymer-drug conjugates from pMAOS. 
The first of these aims was successfully fulfilled, with the overall yield for the six-step DVB 
synthesis being improved from 5.2% to 25%. The experimental details for this improvement are 
given in Chapter 2. 
The second aim was also successfully fulfilled, with the N,N-dimethylaminopropaneamine 
moiety being selectively incorporated into DVB at either the C(9) and/or the C(2') positions. A 
2' -methoxy analogue and two 9-alkyldiamine analogues were also synthesised. The biological 
data obtained for the deoxyvariolin analogues closely resembled that obtained by Anderson for 
the analogous compounds in the methoxy- and hydroxyvariolin series'. This work is described 
in Chapter 3. 
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The third objective, synthesis of variolin-tetrapeptide conjugates, was met with only partial 
success. By far the most bioactive analogue (at least in terms of the in-house P388 murine 
leukaemia bioassay) was DVB, but efforts to synthesise a tetrapeptide conjugate of this 
compound were unsuccessfuL Experiments carried out with the 2' -SMe deoxyvariolin analogue 
2.16 and the N(9a)-PMB DVB analogue 2.27 helped to shed some light onto this troublesome 
reactivity. Specifically, it was found that N(9a) is acylated more rapidly than N(2' a), but that the 
resulting N(9a)-acyl linkage is of inadequate stability to survive both the Fmoc-deprotection 
protocols and the polymer-drug synthetic protocols being employed in this work. 
Having established that N(9a)-acylation gave compounds of insufficient stability, attention was 
turned towards acylating DVB at the N(2'a) position. Attempts at acylating N(2'a) of DVB 
quantitatively with Fmoc-glycine acid chloride were unsuccessful. It is not known why this 
reaction would not go to completion, though interference by water contamination can be ruled 
out. Purification of the resulting mixture of va rio lin compounds was prohibitively difficult. 
N(9a)-PMB DVB analogue 2.27 was acylated by Fmoc-glycine acid chloride at N(2'a) and the 
product purified (albeit in low yield), but it was found that attempted PMB-deprotection using 
the established protocols (involving stirring in neat triflic acid) resulted in cleavage of the 
N(2'a)-acyllinkage. 
In order to circumvent the difficulties encountered in the acylation of N(9a) and/or N(2'a) of 
DVB, deoxyvariolin analogue 3.23 was instead chosen for development into a polymer-drug 
construct. While possessing roughly an order of magnitude lower bioactivity than DVB, this 
analogue possessed only one primary aliphatic nucleophilic amine. Conjugation (and subsequent 
Fmoc-deprotection) of this analogue with the tetrapeptide biolinker proceeded without 
complication to give conjugate 3.26 in a total of six steps with 23% overall yield (from 
commercially available starting materials. 
With conjugate 3.26 in hand, the fourth aim of the project, namely, synthesis of polymer-drug 
conjugates from pMAOS, was addressed. Despite the numerous literature accounts of the 
aminolysis of pMAOS, attempts to synthesise a HPMA-based polymer drug conjugate of type 
1.1 incorporating deoxyvariolin analogue 3.23 from pMAOS proved unsuccessful. Subsequent 
investigations involving only IA2P as nucleophile uncovered two unforeseen side reactions. 
Specifically, attack by lA2P at the succinimidyl carbonyls was resulting in ring-opening of the 
NBS groups (with 60-65% ring-opening typically being observed), and a subsequent attack by 
HPMA amide nitrogens on neighbouring hydroxamate-activated esters was leading to 
N-substituted glutarimide formation. This glutarimide formation was shown to be a surprisingly 
facile and unavoidable reaction. Furthermore, the polymeric products displayed poor water 
solubility. These two side reactions ultimately precluded the synthesis of polymer-drug 
constructs from pMAOS. 
One solution to the problem of glutarimide formation seen with the aminolysis of 
poly(methacrylic activated esters) may be found through the use of N-methylated nucleophiles, 
such as N-methyl IA2P. However, the biological profiles of the resulting polymers, for 
example, poly(N-methyl-N-(2-hydroxypropyl)methacrylamide], are yet to be determined. 
A more reasonable approach would be to simply employ the copolymerisation protocols that 
have been shown to be successful in various publications in recent decades (see Section 1.2.3.l 
for a discussion of these protocols). Specifically, the well-established PKl-type synthetic 
protocols could be employed to give an HPMA-based copolymer carrying analogue 3.23. 
Alternatively, this polymer-drug conjugate could be made by the copolymerisation of HPMA 
with a methacryloyl-tetrapeptide-variolin monomer (which should be readily accessible via the 
acylation of 3.26 with methacryloyl chloride). Importantly, deoxyvariolin analogue 3.23 would 
be expected to be stable under the polymerisation conditions. 
Incorporation of the more bioactive DVB onto a polymer backbone is desirable. Of the two 
possible points of attachment, the N(2' a) position of DVB would give the more stable conjugate. 
Synthesis of pHPMA-based prodrugs of this type would first necessitate the synthesis of an 
appropriately acylated DVB analogue. Given that the pMAOS methodology is seriously flawed, 
a copolymerisation involving HPMA and a methacryloyl-tetrapeptide-DVB conjugate would be 
necessary, Synthesis of the appropriate DVB-bearing monomer would initially require the 
efficient synthesis of N(2'a)-acylated DVB analogues. Given the difficulties encountered with 
the acylation of DVB, this goal is probably best achieved through the acylation of an N(9a)-
protected DVB analogue with Fmocglycine acid chloride. PMB has already been shown to be an 
unsuitable protecting group for this synthetic route, given the harsh conditions needed for 
deprotection, Alternative protecting group strategies therefore need to be investigated. The 
allyloxycarbonyl (Alloc) group is one such possibility, 
Finally, the low stability of the deoxyvariolin N(9a)-acyllinkage, particularly in acidic solutions, 
could be capitalised on in the synthesis of polymer-drug constructs incorporating DVB bound via 
the N(9a) position. The acidic environment of tumour interstitia and of lysosomes would be 
expected to facilitate the liberation of DVB bound in this manner from the polymer backbone. 
Such constructs could conceivably be synthesised by the well~established PKl-type synthetic 
protocols, employing DVB as the nucleophilic drug. An EDCI-mediated coupling between DVB 
and an HPMAImethacryloyl~tetrapeptide copolymer is a variation on this theme that should also 
give the desired product. The polymer product from these two analogous synthetic routes would 
give a construct from which DVB would be liberated via cathepsin-mediated and acid-catalysed 
hydrolysis. 
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CHAPTER 6 
EXPERIMENTAL 
.1 General Methods 
Nuclear Magnetic Resonance Spectroscopy 
All proton detected NMR spectra were obtained on a Varian Inova 500 spectrometer at 23°C, 
operating at 500 MHz. Carbon detected NMR spectra were recorded on a Varian Unity 300 
spectrometer at 23°C and operating at 75 MHz. Other NMR experiments described in this thesis 
viz COSY and the reverse detected HSQC and CIGAR experiments were obtained on the Inova 
500 spectrometer at 500 MHz. Chemical shifts in this thesis are described in parts per million 
(ppm), on the b scale, and were referenced to appropriate solvent peaks: CDCh referenced to 
Si(CH3)4 at bH 0 ppm eH) and CHCh at be 77.0 ppm (DC); d4-methanol referenced to CHDzOD 
at bH 3.30 ppm eH) and CD30D at be 49.3 ppm (DC); and d6-DMSO referenced to 
CD3(CHDz)SO at bH 2,50 ppm eH) and (CD3)zSO at be 39.6 ppm (l3C). IH NMR spectra were 
recorded using an acquisition time (AT) of 0.878 s and a relaxation delay (Dl) of 2 s, COSY 
experiments were typically recorded using an AT of 0.137 s and a Dl of 1.0 s. HSQC-DEPT 
experiments with the Pulsed Field Gradient system were generally run with an AT of 0.133 s, a 
Dl of 1.0 sand JC-H of 130-165 Hz. CIGAR experiments with the Pulsed Field Gradient system 
were run with an AT of 0.303 s, a Dl of 1.0 s, J = 140 Hz and a nJeH of 8.0 Hz. 
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High Pressure Liquid Chromatography 
The High Pressure Liquid Chromatography (HPLC) work described in this thesis was performed 
on a Shimadzu VP system. The complete setup involved a Shimadzu LC-10AC VP liquid 
chromatograph coupled to an SIL-lOA VP autoinjector, aCTO-lOA VP column oven set to 
40°C, and a SPD-M10A VP diode array detector. This system was controlled by Shimadzu 
CLASS-VP (Version 5.023) software. A Shimadzu degasser (DGU-14A) was utilised for the 
degassing of all solvents used in this machine. 
The column used was a Phenomenex ODS(3) column (250 x 4.6 mm, 60 A, 5 Ilm APD, 
1 mLlmin). 
The solvents used were mixtures of either acetonitrile (BDH HiperSolv™ 'Far UV' grade) or 
methanol (BDH HiperSolvTM grade) with water (purified using a MilliQ deionising system). 
The aqueous phase was acidified with 0.05% TFA (Scharlau, synthesis grade). 
The standard gradient elution protocols are given below: 
Time (min) B conc. (%)* 
0 10 
2 10 
14 75 
24 75 
26 100 
30 100 
32 10 
40 10 
;{< This refers to the concentration of acetonitrile in the eluant 
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Gel Permeation Chromatography 
GPC analysis of pMAOS samples was conducted at Ian Wark Laboratories, CSIRO, Clayton, 
Victoria, Australia. The samples were dissolved in DMF and filtered prior to the analysis. They 
were analysed using a series of four Styragel columns HT2, HT3, HT4 and HT5 and an oven 
temperature of 80°C. The eluants used were DMF and 0.05 M LiBr at a flow rate of 1.0 
mLimin. A Dawn EOS light scattering detector with Optilab DSP interferometer (both set at 690 
nm) was used. 
Mass Spectrometry 
Mass spectrometric analyses were performed on a Micromass LCT spectrometer equipped with 
an electrospray ionisation (ESI) probe. Samples were analysed at a probe voltage of 3200 V at 
150°C with a nebuliser gas flow of 160 L/hr and desolvation gas flow of 520 Llhr with the 
source temperature at 80°C. The cone voltage was typically 20 V. The solvent flow from a 
syringe pump in direct injection mode was 20 ~/min. 
UV·Vis Spectroscopy 
UV~Vis measurements were taken on a Hewlett Packard HP 8452A Diode Array Spectrometer. 
Samples were placed in 10 mm quartz glass cuvettes (Stama). 
IR spectroscopy 
IR measurements were taken on a Shimadzu FTIR-8201 PC Spectrometer. Spectra of solids 
were obtained by the diffuse reflectance method using KBr. Spectra of oils were obtained in a 
solution of CDCh using a CaF2 solution cell. 
Melting Points 
Melting points were obtained on a Reichert microscope hot~stage and are uncorrected. 
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Column Chromatography 
Analytical thin layer chromatography (TLC) was conducted on aluminium-backed Merck 
Kieselgel KG60F254 silica sheets (0.2 mm thickness). Plates were visualised by both short- and 
long-wavelength UV light. For compounds possessing the pyrido[3',2':4,S]pyrrolo[1,2-
c]pyrimidine core, long-wave UV light was particularly useful. Staining was occasionally 
carried out using either potassium permanganate dip (3 g KMn04, 20 g K2C03 and S mL S% aq 
NaOH in 300 mL H20) or phosphomolybdic acid dip (10% w/v phosphomolybdic acid III 
EtOH). 
Flash chromatography was routinely carried out using Merck silica 60 (40-63!l) following the 
procedure of Still and coworkers. 133 Where stated, neutralised silica was prepared by stirring the 
silica as a slurry in CH2Ch with 0.1 v/w equivalents of triethylamine, then, following loading 
into a column, washing with 3-5 column volumes of the eluant. Reversed phase C18 
chromatography was carried out using Bakerbond CI8 (40 !lm preperative LC packing), which 
was recycled by successive washes with 1% TF AlDMSO, MeOH and CH2Clz. Bakerbond speThl 
Octadecyl (CIS) disposable solid phase extraction columns (40 mm APD, 60 A) of a SOO mg/3 
mL size were also occasionally employed for small samples. DIOL chromatography was carried 
out with J.T.Baker DIOL (40 !lm prep LC packing), which was recycled by successive washes 
with 1% TF AlDMSO, MeOH and CH2Ch. Preparative size-exclusion chromatography (SEC) 
was carried out using Sephadex LH-20 (Pharmacia Biotech AB). GPC analyses were performed 
at the Key Centre for Polymer Colloids, University of Sydney, Australia by Uma Adash, using a 
series of four Styragel columns HT2, HT3, HT4 and HTS and an oven temperature of 80°C. 
The eluant was DMF + O.OS M LiBr at a flow rate of 1.0 mLlmin. A Dawn EOS light scattering 
detector with Optilab DSP interferometer (both set at 690 nm) was used. 
Solvents were all of commercial grade and distilled once in glass distillation apparatus except 
MeOH, which was distilled twice. Hexanes consisted of the fraction boiling at SO-70 0c, 
'Flash' columns were run under oxygen-free N2 gas pressure (O.S kPa). 
Following chromatography, synthetic products were analysed by IH NMR spectroscopy in order 
to ascertain their purity. Unless otherwise stated, this purity was close to 100%. 
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P388 (Murine Leukaemia) in vitro Bioassay 
Compounds were assayed for cytotoxicity where applicable using the in-house P388 MTT 
antitumour assay, with samples being submitted as solutions in either MeOH or 
2: 1 MeOH/CH2Cb, The antitumour assay is the most sensitive assay for cytotoxicity, It consists 
of a 2·fold dilution series of the sample of interest followed by incubation for 72 h with P388 
cells. The concentration of sample required to reduce the P388 cell growth by 50% (compared to 
control cells) is determined using the absorbance values obtained when the yellow MTT 
tetrazolium dye is reduced by healthy cells to the purple MTT formazan. The result is expressed 
as the IC5o, usually either in ng/mL or jlM. 
Solvents and Reagents 
Reagents and solvents used in reactions were purified according to well·established 
procedures. 134 All technical grade solvents were distilled prior to use. Methanol was distilled 
twice. Ethanol stabiliser was removed from chloroform by washing with water then distilling 
from calcium chloride. Tetrahydrofuran and diethyl ether were distilled from sodium 
benzophenone ketyl immediately prior to use. Toluene, dichloromethane, pyridine and 
triethylamine were distilled from calcium hydride. Acetic anhydride was distilled from 
phosphorous pentoxide. 1,2-Dichloroethane was distilled from phosphorous pentoxide and 
stored over 4 A sieves under an atmosphere of nitrogen. Acetyl chloride was distilled from 
quinoline (10% v/v) immediately prior to use. Both N,N-dimethylformamide and 
dimethylsulfoxide were sequentially dried over two batches of freshly activated 4 A sieves (2 x 
24 h), before finally being stored over a third batch of freshly activated 4 A sieves. To remove 
residual dimethylamine, DMF was evacuated (~O.l mm Hg) for at least 15 min prior to use. Dry 
methanol was obtained by distillation from Mg(OMe)2 and stored under an atmosphere of 
nitrogen. Solutions of n-BuLi in hexanes were titrated in diethyl ether with 2·butanoi, using 
1,1O-phenanthroline as an indicator. m-Chloroperbenzoic acid was washed with pH = 7.5 
phosphate buffer and recrystallised from dichloromethane. Concentrated aqueous ammonia 
solution was of analytical grade, and was stated to contain ~25% ammonia, density = 0.91 g/mL. 
Water-sensitive reactions were performed in flame-dried glassware under an atmosphere of dry 
argon or nitrogen. Reaction temperatures refer to the external bath or oven temperature. Where 
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stated, "concentrated in vacuo" will generally refer to removal of solvents on a Buchi rotary 
evaporator, followed by removal of traces of solvent using a high vacuum pump. 
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6.2 Experiments Described in Chapter 2 
4-Iodo-2-(methylsulfanyl)pyrimidine 2.1 135 
4-Chloro-2-(methylsulfanyl)pyrimidine (14.00 g, 87.2 mmol) was added to hydroiodic acid 
(100 mL, 731 mmol) with vigorous stirring, and left to stir at rt for 3 days. Large lumps were 
regularly broken up using a glass rod during this time. The suspension was filtered, and the 
precipitate washed with water. The brown solid was then dissolved in CH2Clz (200 mL) and 
washed with sat aq NaHC03 solution (200 mL), 5% aq Na2S203 solution (200 mL), sat brine 
solution (200 mL), dried with Na2S04 and filtered. The solvent was removed in vacuo, and the 
crude material thus obtained recrystallised from hexanes to afford the pure iodide as large white 
needles (15.49 g, 70% yield). Concentration in vacuo of the mother liquor followed by 
recrystallisation of the residues from hot hexanes gave more of the above (2.12 g, 80% total 
yield). 
Mp: 49-50 °C (hexanes) (lit 52-53 oC).135 
IH NMR (500 MHz, CDCh): 82.54 (s, 3H, SCH3), 7.41 (d, J = 5.4 Hz, IH), 8.00 (d, J = 4.9 Hz, 
IH). 
2-Chloronicotinoyl chloride 2.3136 
o o HO:n 
CI N 
CI:O 
CI N 
2-Chloronicotinic acid (4.02 g, 26 mmol), thionyl chloride (10.0 mL, 0.137 mmol) and dry DMF 
(0.2 mL, 2.6 mmol) were stirred at reflux under argon for 24 h. After cooling, thionyl chloride 
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and DMF were removed in vacuo, and the product purified by Kugelrohr distillation (120 °C, 
0.03 mm Hg) to afford the acid chloride as a white crystalline solid (4.45 g, 99% yield). The 
solid was stored under argon and used within 1 day of distillation. 
Mp: 38-41 °C, sweats at 34°C (lit 39-44 °C).137 
In NMR (500 MHz, CDCb): 6 7.44 (dd, J '=" 4.9, 7.8 Hz, 1H), 8.40 (dd, J 2.0, 8.3 Hz, 1H), 
8.59 (dd, J::::: 2.0, 4.9 Hz, IH). 
(2-Chloropyridin-3-yl)bis-[2-(methylsulfanyl)pyrimidin-4-yl]methanol 2.4 
o 
+ CI~ 
CI N 
a) Non-Barbier protocols: 87 
The reactor was charged with iodide 2.1 (9.23 g, 7.9 mmol) and THF (350 mL), and cooled to 
-95°C (MeOHINz). A solution of n-BuLi in hexanes (1.65 M, 22.18 mL, 36.6 mmol) was 
carefully added to the stirred solution over 45 min, while maintaining the solution at -95°C. The 
reactor coil was carefully washed with THF (5 mL), and the solution stirred at -95°C for 30 min. 
To the deep redlbrown solution was added a solution of acid chloride 2.3 (2.16 g, 12.3 mmol) in 
THF (20 mL) over 40 min. After 4 h at -95°C the reaction was left stirring for 10 h, during 
which time it wanned slightly to -93°C. The solution was then allowed to warm to rt and 
washed with sat aq NH4CI and extracted with EtOAc (500 mL, 250 mL, 100 mL). The organic 
extractions were pooled, filtered, concentrated in vacuo to a volume of ~400 mL, washed with 
sat brine solution (400 mL), dried with MgS04, filtered and concentrated in vacuo. The crude 
material thus obtained was purified by repeated flash chromatography on silica, eluting with 1:1 
EtOAc/hexanes, to afford the triaryl alcohol as an orange foam [1.32 g, ~95% pure (as 
determined by 1H NMR), 26% yield]. 
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b) Barbier protocols: 
A solution of iodide 2.1 (1.58 g, 6.3 mmol) in THF (17 mL) was transferred via cannula to a pre~ 
cooled solution of acid chloride 2.3 (500 mg, 2.8 mmol) in THF (8 mL) at -96°C. A solution of 
n-BuLi in hexanes (1.70 M, 3.68 mL, 6.3 mmol) was then added dropwise over 10 min with 
vigorous stirring. The dark red/brown solution was stirred at -96°C for a further 2 h then 
methanol (400 ~) was added over 1 min. The deep red solution was stirred at rt for 2 h, then 
diluted with CB2Clz (75 mL), washed with sat aq NaHC03 solution (100 mL), sat brine solution 
(100 mL), dried with Na2S04, filtered and concentrated in vacuo. The crude material thus 
obtained was dissolved in benzene (15 mL), Mn02 (1.0 g 11.5 mmol) added, and the black 
suspension heated at reflux for 2 h. Filtration through a celite plug followed by concentration in 
vacuo gave an oil which was purified by flash chromatography on silica, eluting with 50% 
EtOAclhexanes, to afford the triaryl methanol as an orange solid (521 mg, 95% pure, 40% yield). 
Mp: 55-58 °C (lit 54-58 OC).87 
IH NMR (500 MHz, CDCh): (52.49 (s, 3H, SCH3), 6.33 (s, lB, OH), 7.17 (dd, J = 4.4, 7.8 Hz, 
lH, B-5), 7.23 (dd, J:= 2.0, 7.8 Hz, lB, B-4), 7.40 (d, J 4.9 Hz, lB, H.5'), 8.38 (dd, J = 2.0,4.4 
Hz, lB, B-6), 8.57 (d, J = 4.9 Hz, lH, B-6'). 
(2-Chloropyridin-3-yl)bis-[2-(methylsulfanyl)pyrimidin-4-yl]methyl acetate 2.5 
a) From triaryl alcohol 2.4: 
To a solution of triaryl alcohol 2.4 (497 mg, 1.27 mmol), DMAP (10.0 mg, 82 ~mol) and TEA 
(265 ~, 1.90 mmol) in CH2Ch (6 mL) was added acetic anhydride (239 ~, 2.53 mmol) and the 
solution heated at reflux for 20 h. The solution was allowed to cool to rt and concentrated in 
vacuo. The crude material thus obtained was purified by repeated flash chromatography on 
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silica, eluting with 1: 1 EtOAc/hexanes, to afford the title compound as an off-white amorphous 
solid (506 mg, 92% yield). 
b) Non-Barbier lithiation protocols: 87 
o 
+ CI:O 
CI N 
The reactor was charged with iodide 2.1 (2.00 g, 7.9 mmol) and THF (100 mL), and cooled to 
-95°C (MeOH!N2). A solution of n-BuLi in hexanes (1.58 M, 5.03 mL, 7.9 mmol) was 
carefully added to the vigorously stirred solution over 15 min, while maintaining the solution at 
-95°C. After 30 min, a solution of acid chloride 2.3 (465 mg, 2.6 mmol) in THF (0.47 mL) was 
added to the dark mixture over 7 min. After 4.5 h at -95°C, the reaction was quenched with 
Acel (566 ~, 7.9 mmol) and allowed to warm overnight. The solution was diluted with CH2Clz 
(100 mL), washed with sat aq NaHC03 solution (200 mL), sat brine solution (200 mL), dried 
with MgS04, filtered and concentrated in vacuo. The crude material thus obtained was purified 
by flash chromatography on silica, eluting with 1: 1 EtOAc/hexanes, to afford the triaryl acetate 
as an orange foam (724 mg, 95% pure, 60% yield). 
c) Grignard arylation o/ketone 2.9:91 
+ 
To a stirred solution of iodide 2.1 (743 mg, 2.95 mmol) in toluene (18 mL) at 0 °C was added a 
solution of i-PrMgCI in diethyl ether (1.36 M, 2.17 mL, 2.95 mmol) dropwise over 8 min. The 
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resulting brown solution was stirred at 0 °C for 1 h, then transferred via cannula over 5 min to a 
similarly cooled solution of ketone 2.9 (313 mg, 1.18 mmol) in toluene (12 mL), and the solution 
stirred at 0 °C for 15 min. AcCI (294 !-iL, 4.12 mmol) was added over 1 min, and the solution 
allowed to warm to rt overnight. At this time sat aq NaHC03 solution (30 mL) was added and 
the biphasic solution extracted with EtOAc (3 x 15 mL). The organic extractions were 
combined, dried with NaZS04, filtered and concentrated in vacuo. The crude material thus 
obtained was subjected to repeated flash chromatography on silica, eluting with 1:1 
EtOAc/hexanes, to give the triaryl acetate in low purity as an orange/brown oil (147 mg, 50% 
pure, 14% yield). 
d) Barbier lithiation protocols from ketone 2.9:91 
To a vigorously stirred solution of iodide 2.1 (2.16 g, 8.6 mmol) and ketone 2.9 (1.14 g, 
4.3 mmol) in THF (25 mL) at -78°C was added a solution of n-BuLi in hexanes (1.52 M, 
5.64 mL, 8.57 mmol) over 15 min. The brown solution was stirred at -78°C for 15 min, AcCI 
(1.22 mL, 17.1 mmol) added dropwise over 2 min and the dark red solution stirred at rt for 3 h. 
The solution was diluted with CH2Clz (100 mL), washed with sat aq NaHC03 solution (100 mL), 
sat brine solution (100 mL), dried with Na2S04, filtered and concentrated in vacuo to give a dark 
orange/brown oil. This crude material was purified by flash chromatography on silica, eluting 
with 1: 1 EtOAc/hexanes, to give the triaryl acetate, contaminated by a small amount of the biaryl 
acetate, as an orange foam (1.23 g, 90% pure, 59% yield). 
e) Barbier lithiafion protocolsfrom acid chloride 2.3 (with bimyl acetate 2.15 formation): 
o 
+ CI~ 
CI N 
To a vigorously stirred solution of acid chloride 2.3 (163 mg, 0.93 mmol) and iodide 2.1 
(700 mg, 2.8 mmol) in THF (9 mL) at -78°C was added a solution of n-BuLi in hexanes 
(1.52 M, l.83 mL, 7,93 mmol) dropwise over 5 min. The dark brown solution was stirred at 
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-78°C for 30 min, then acetyl chloride (330 J..LL, 4.6 mmol) added over 2.5 min. The deep red 
solution was stirred at rt for 3 h, then diluted with CH2Cl2 (30 mL), washed with sat aq NaHC03 
solution (20 mL), sat brine solution (20 mL), dried with Na2S04, filtered and concentrated in 
vacuo. The crude material thus obtained was purified by flash chromatography on silica, eluting 
with 1: 1 EtOAclhexanes, to give an inseparable mixture of the triaryl acetate and biaryl acetate 
in a ratio of 10:1 (291 mg, 90% pure, 65% yield of the triarylacetate). 
Biaryl acetate 2.15 had the following spectroscopic properties (some signals, as reported in the 
literature, are coincident with the triarylacetate signals):91 
lH NMR (500 'MHz, CDCb): 0 2.22 (s, 3H, COCH3), 2.45 (s, 3H, SCH3), 7.04 (s, IH, H7), 7.11 
(d, J = 5.2 Hz, 1H, H-5'), 7.27 (coincident, 1H, H-5), 7.83 (dd, J = 1.7, 8.1 Hz, IH, H-4), 8.39 
(coincident, 1H, H-6), 8.53 (d, J = 4.8 Hz, 1H, H-6'). 
,f) Barbier lithiation protocols from acid chloride 2.3 (without bialyl acetate 2.15 formation): 
A solution of acid chloride 2.3 (1.04 g, 5.9 mmol) in THF (10 mL) was transferred via cannula to 
a pre-cooled solution of iodide 2.1 (3.30 g, 13.1 mmol) in THF (40 mL) at -96°C. A solution of 
n-BuLi in hexanes (1.60 M, 8.17 mL, 13.1 mmol) was then added dropwise over 20 min with 
vigorous stirring. The dark red/brown solution was stirred at -96°C for a further 2h then acetyl 
chloride (2.11 mL, 30 mmol) was added over 5 min. The deep red solution was stirred at rt for 
16 h, then diluted with CH2Cl2 (100 mL), washed .with sat aq NaHC03 solution (200 mL), sat 
brine solution (150 mL), dried with Na2S04, filtered and concentrated in vacuo. The crude 
material thus obtained was purified by repeated flash chromatography on DIOL, eluting with 
10-30% EtOAc/hexanes: to give the triaryl acetate as an orange solid (1.30 g, 98% pure, 50% 
yield). 
* Purification could also be carried out on silica, eluting with I: 1 EtOAc/hexanes, to give similar yields. 
Mp: 58-61°C. 
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IH NMR (500 MHz, CDCb): 0 2.30 (s, 3H, COCH3), 2.39 (s, 6H, SCH3), 7.26 (dd, J 4.9, 7.8 
Hz, IH, H-5), 7.30 (d, J = 4.9 Hz, 2H, H-5'), 7.89 (dd, J = 1.7, 8.1 Hz, IH, H-4), 8.39 (dd, J = 
2.0,4.9 Hz, IH, H-6), 8.51 (d, J = 4.8 Hz, 2H, H-6'). 
13e NMR (75 MHz, CDCb): 0 14.0 (SCH3), 21.3 (COCH3), 85.9 (C(Ar)30Ac), 114.7 (C-5'), 
121.1 (C-5), 134.0 (C-3), 141.3 (C-4), 149.2 (C-6), 150.3 (C-2), 157.4 (C-6'), 166.1 (C-4'), 168.6 
(COCH3), 172.6 (C-2'). 
IR (KBr): Umax 1757, 1549, 1400, 1348, 1207, 1086, 1061,903. 
HRMS (ESI): Calcd for CIgH1735CINsO/2S2 (MIt) mlz = 434.0512, found mh = 434.0512. 
9-(Methylsulf anyl)-5-[2-( m ethylsulf anyl)pyrim idin-4-yl] pyrido[3' ,2': 4,5] pyrrolo [1,2-
c]pyrimidine 2.6 
a) From friaryl acetate 2.5 (free ofbiaryl acetate 2.15 contamination):91 
Triaryl acetate 2.5 (745 mg, 1.72 mmol) was heated with TFA (264 ~, 3.43 mmol) and 
triethylsilane (2.19 mL, l3.7 mmol) in 1,2-dichloroethane (4 mL) at 100°C for 3 d. The orange 
solution was diluted with CH2Clz (350 mL), washed with sat aq NaHC03 solution (300 mL), sat 
brine solution (300 mL), dried with MgS04, filtered and concentrated in vacuo. The crude 
material thus obtained was purified by repeated flash chromatography on silica, eluting with 
37% EtOAc/hexanes, to give the variolin core as a yellow microcrystalline solid (424 mg, 95% 
pure, 69% yield). 
b) From triaryl acetate 2.5 (with the biaryl acetate 2.15 contamination): 
A 4: 1 mixture of triaryl acetate 2.5 and biaryl acetate 2.15 (1.42 2.6 mmol of the tri ary I 
acetate) was heated with TFA (503 ~, 6.53 mmol) and triethylsilane (3.04 mL, 26.1 mmol) in 
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1,2-dichloroethane (7 mL) at 100°C for 3 d. The orange solution was allowed to cool to rt then 
diluted with CH2Clz (100 mL), washed with sat ~q NaHC03 solution (100 mL), sat brine solution 
(100 mL), dried with Na2S04, filtered and concentrated in vacuo. The dark orangelbrown oil 
thus obtained was dissolved in THF (250 mL), 1M aq NaOH (250 mL) added, and the resulting 
brown solution stirred at rt for 1 h. Extraction with CHzClz (500 mL) gave a redlbrown organic 
solution that was washed with sat brine solution (500 mL), dried with Na2S04, filtered and 
concentrated in vacuo to give an orangelbrown oil. The crude material thus obtained was 
purified by flash chromatography on neutralised silica, eluting with 5% EtOAc/CH2Clz (0.1% 
TEA), to give the variolin core as an orange microcrystalline solid (642 mg, 72% yield). 
c) From acid iodide 2.1 and chloride 2.3 (without purification of the trimyi acetate intermediate 
2.5): 
o 
+ CI"Jo 
CI N 
A solution of iodide 2.1 (3.16 g, 12.6 mmol) in THF (10 mL) was transferred via cannula to a 
pre-cooled solution of acid chloride 2.3 (1.00 g, 5.7 mmol) in THF (40 mL) at -96°C. A solution 
of n-BuLi in hexanes (1.58 M, 7.94 mL, 12.6 mmol) was added dropwise over 20 min with 
vigorous stirring. The dark redlbrown solution was stirred at -96°C for a further 2h then acetyl 
chloride (2.04 mL, 28.5 mmol) was added over 5 min. The deep red solution was stirred at rt for 
1 h then diluted with CH2Clz (100 mL), washed with sat aq NaHC03 solution (100 mL), sat brine 
solution (100 mL), dried with NaZS04, filtered and concentrated in vacuo. The dark 
orangelbrown oil thus obtained was transferred to a Young's tube and left at reduced pressure 
(0.03 mm Hg) for 16 h. To this crude material was then added 1,2-dichloroethane (10 mL), TFA 
(879 j..tL, 11.4 mmol) and triethylsilane (7.27 mL, 45.6 mmol), and the resulting dark red/brown 
solution incubated at 100°C for 3 d. The solution was allowed to cool to rt then diluted with 
CH2Clz (400 mL), washed with sat aq NaHC03 (400 mL), sat brine solution (400 mL), dried 
with Na2S04, filtered and concentrated in vacuo. The crude material thus obtained was purified 
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by flash chromatography on silica, eluting with 10% EtOAcl CH2Ch, to give the variolin core as 
a yellow microcrystalline solid (985 mg, 98% pure, 50% yield over 2 steps). 
Mp: 209-211 °C [lit 210- 11°C (MeOHlI,2-dichloroethane)),87 
NMR (500 MHz, CDCh): 02.68 (s, 3H, 2'-SCH3), 2.74 (s, 3H, 9.SCH3), 7.35 (d, J == 5.4 Hz, 
IH, H-5'), 7.51 (dd, J 4.6, 8,1 Hz, tH, H-3), 7.82 (d, J;::= 6.3 Hz, IH, H-7), 8.06 (d, J 6.8 Hz, 
tH, H-6), 8.52 (d, J::: 5.4 Hz, IH, H-6'), 8.60 (dd, J = 1,7,4.6 Hz, IH, H-2), 8.64 (dd, J 1,7,8,1 
Hz, lH, H-4). 
13C NMR (75 MHz, CDCb): 0 14.3 (2'-SCH3), 14.9 (9-SCH3), 10L5 (C-5), 108.3 (C-6), 113.0 
(C-5'), 120.71 (C-4a), 120.84 (C-3), 128.0 (C-4), 137.5 (C-5a), 139,9 (C-7), 141.8 (C-2), 143.0 
(C-lOa), 155,1 (C-9), 156.7 (C-6'), 160.9 (C-4'), 172.5 (C-2'). 
(KBr): \)max 3140-2850 (series of weak bands), 1936. 1562, 1462, 1443, 1362, 1242, 1188, 
964,826. 
HRMS (ESI): Calcd for CltJf14Ns32S2 (MH+) m/z = 340,0691, found m/z == 340.0692. 
ICso (P388): >37 ~ 
2-Chloro-N-methoxy-N-methyl-nicotinamide 2.891 
o CI:O 
CI N 
o 
lVIeo"'N~ 
I ",J-.~,J CI N 
To a suspension of N,O-dimethylhydroxylamine hydrochloride (604 mg, 6.19 mmol) in THF 
(20 mL) was added TEA (1,71 mL, 12.4 mmol) and the white suspension stirred under N2 at It 
for 30 min, To this was added 2-chloronicotinoyl chloride (1.089 g, 6.19 mmol) and the 
suspension stirred at It for 18 h. At this time the suspension was diluted with sat aq NaHC03 
(40 mL) and the colourless solution extracted with CH2Ch (3 x 25 mL). The organic extractions 
were combined, dried with Na2S04, filtered and concentrated in vacuo to afford the Weinreb's 
amide as a light brown amorphous solid (1.16 g, 93% yield). 
lH NMR (500 MHz, CDCh): 03.41 (s, 3H, Me), 3.50 (s, 3H, Me), 7.29-7.34 (dd, J == 4.8,7.1 
Hz, tH, Ar), 7.70 (d, J = 7,1 Hz, tH, Ar), 8.46 (d, J 3.8 Hz, IH, Ar). 
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(2-Chloropyrid in-3-yl)-[2-( methyls ulfanyl)pyrim idin-4-yl] m ethanone 2.9 
a) From Weinreb's amide 2.8:91 
+ 
o 
Meo"N~ 
I ~I)t.) CI N 
140 
To a vigorously stirred solution of iodide 2.1 (1.81 g, 7.2 mmol) in toluene (10 mL) at -15°C 
was added a solution of i-PrMgCI in diethyl ether (1.46 M, 3.93 mL, 7.2 mmol) dropwise over 
10 min, and the resulting light brown solution stirred at -10°C for 45 min. Into this was 
transferred, via cannula, a similarly cooled solution of Weinreb's amide 2.8 (1.15 g, 5.7 mmol) 
in THF (3 mL) dropwise over 10 min, and the resulting brown solution stirred at °C for 1 h. 
The reaction was quenched with aq NlLICl (13 mL) and extracted with EtOAc (2 x 13 mL). The 
organic extractions were combined, dried with NaZS04, filtered and concentrated in vacuo. The 
brown residues thus obtained were triturated with 3: 1 diethyl ether/hexanes (2 x 5 mL, 5 x 2 mL) 
and dried in vacuo to afford the ketone as a light brown solid (1.14 g, 75% yield). 
b) From quaternary species 2.13: 
Quaternary species 2.13 (284 mg, 836 llmol) was dissolved in MeOH (100 mL), 1M aq NaOH 
solution (100 mL) added and the brown solution stirred at rt for 2 h. The brown solution was 
diluted with sat brine solution (100 mL) and extracted with CHzClz (3 x 50 mL). The organic 
extractions were combined, dried with NaZS04, filtered and concentrated in vacuo. The crude 
material thus obtained was purified by flash chromatography on silica, eluting with 1: 1 
EtOAc/hexanes, to afford the ketone as an orange foam (170 mg, 77% yield). 
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c) From methyl ester 2.12 (without purification of quaternary species 2.13): 
o Me0:O 
CI N 
+ 2.13 2.9 
To a vigorously stirred and cooled solution of methyl ester 2.12 (370 mg, 2,16 mmol) and iodide 
2.1 (1.087 g, 4.31 mmol) at -78°C was added a solution, of n-BuLi in hexanes (1.52 M, 2.84 mL) 
dropwise over 5 min. The dark brown mixture was stirred at this temperature for 30 min, then 
AcCI added dropwise over 1 min and the solution stirred at rt for 3 h. The solution was then 
poured slowly into 1 M aq NaOH (25 mL) at 0 °C with vigorous stirring, then stirred at rt for 
2 h. The solution was diluted with CH2Ch (30 mL) to give a redlbrown organic solution that 
was washed with sat brine solution (20 mL); dried with Na2S04, filtered and concentrated in 
vacuo. The crude material thus obtained was purified by repeated flash chromatography on 
silica, eluting with 40% EtOAc/hexanes, to give a 3: I mixture of the title compound 2.9 and 
contaminant 2.10, shown below, as an orange foam (334 mg, -70% yield of the ketone). 
Mp: 98-100 °C [lit. 107-9 °C (benzene/hexanes)].87 
IH NMR (500 MHz, CDCh): 02.38 (s, 3H, SCH3), 7.41 (dd, J 4.8, 7.5 Hz, IH, H-5), 7.65 (d, 
J == 4.8 Hz, IH, H-5'), 7.89 (dd, J 2.0, 7.5 Hz, 1H, H-4), 8.57 (dd, J = 2.0, 5.2 Hz, IH, H-6), 
8.83 (d, J 4.8 Hz, IH, H-6'). 
The pyrimidine side product, 2.10, had the following spectroscopic characteristics:87 
lH NMR (500 MHz, CDCb): 02.57 (s, 3H), 6.96 (t, J 4.8 Hz, IH), 8.52 (d, J 4.8 Hz, 2H). 
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Methyl 2-chloronicotinoate 2.12 
o CI:O 
CI N 
9~ Meo~~1.)5 
CI 2 N 6 
142 
To a stirred solution of acid chloride 2.3 (965 mg, 5.5 mmol) and TEA (1.14 mL, 8.2 mmol) in 
CH2Ch (10 mL) at 0 °C was added dry MeOH (2.22 mL, 55 mmol) dropwise over 3 min. A 
precipitate intitially formed during this addition but redissolved before the addition was 
complete. The solution was stirred for a further 30 min at rt then concentrated in vaclio. The 
light brown residues thus obtained were dissolved in CH2Ch (25 mL), washed with sat aq 
NaHC03 (25 mL), sat brine solution (25 mL), dried with Na2S04, filtered and concentrated in 
vacuo to afford the methyl ester as a light brown oil (798 mg, 85% yield). 
IH NMR (500 ]\.11Hz, CDCh): 83.97 (s, 3H, H~9), 7.36 (dd, J:;::: 4.8, 7.6 Hz, IH, H-5), 8.19 (dd, J 
l.9, 7.6 Hz, IH, H-4), 8.52 (dd, J:;::: 1.9,4.8 Hz, IH, H-6). 
13C NMR (75 MHz, CDCh): 8 52.7 (C-9), 122.0 (C-5), 126.5 (C-3), 140.1 (C-4), 149.7 (C-6), 
151.7 (C-2), 164.6 (C-7). 
IR (CH2CI2 soln): IJmax 1740, 1582, 1562, 1450, 1435, 1406, 1308, 1265, 1242, 1194, 1144, 
1067, 961, 835, 820, 762-683 (series of sharp bands), 646. 
HRMS (ESI): Calcd for C7H/5CIN02 (MH+) mlz:;::: 172.0165, found mlz = 172.0167. 
Unsuccessful Grignard arylation of 2.12 
o Meo:):) 
CI N 
+ Mixture: ester 2.12, ketone 2.9, dimer 2.11, triaryl acetate 2.5 
To a vigorously stirred solution of iodide 2.1 (441 mg, 1.75 mmol) in toluene (11 mL) at 0 °C 
was added a solution of i-PrMgCl in diethyl ether (1.50 M, 1.17 mL, 1.75 mmol) dropwise over 
5 min, and the resulting light brown solution stirred at 0 °C for 1.5 h. Into this was transferred, 
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via cannula, a similarly cooled solution of methyl ester 2.12 (100 mg, 0.58 mmol) in toluene 
(8 mL) dropwise over 5 min, and the resulting brown solution was stirred at 0 °C for 4 h. To this 
was added sat aq NaHC03 (20 mL) and the biphasic solution extracted with EtOAc (3 x 10 mL). 
The organic extractions were combined, dried with Na2S04, filtered and concentrated in vacuo. 
The crude material thus obtained was examined by IH NMR and shown to contain a mixture of 
compounds, including tri ary I acetate 2.5, ketone 2.9, pyrimidine 2.10 and bipyrimidine 2.11. 
Purification of the mixture was not carried out. 
Bipyrimidine side product 2.11 had the following spectroscopic characteristics:87 
lH NMR (500 MHz, CDCb): 82.65 (s, 6H), 8.04 (d, J 5.1 Hz, 2H), 8,71 (d, J == 5.1 Hz, 2H). 
Acetic acid (2-chloro-pyridin-3-yl)-methoxy-(2-methylsulfanyl-pyrimidin-4-yl)-methyl ester 
2.13 
o 
+ Meo:):) 
CI N 
To a vigorously stirred solution of iodide 2.1 (700 mg, 2.78 mmol) and methyl ester 2.12 
(159 mg, 0.93 mmol) in THF (9 mL) at -78°C was added a solution of n-BuLi in hexanes 
(1.52 M, 1.83 mL, 2,78 mmol) dropwise over 5 min, The dark brown solution was stirred at 
-78°C for 30 min, then AcCI (330 ilL, 4.63 mmol) was added dropwise over 5 min, The deep 
red solution was stirred at rt for 3 h, then diluted with CH2Ch (20 mL), washed with sat aq 
NaHC03 (20 mL), sat brine solution (20 mL), dried with Na2S04, filtered and concentrated in 
vacuo, The crude material thus obtained was purified by flash chromatography on silica, eluting 
with 1: 1 EtOAc/hexanes, to afford the quaternary product as an orange/brown amorphous solid 
(293 mg, 93% yield). 
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IH NMR (500 MHz, CDCh): 0 2.23 (s, 3H, COOCH3), 2.34 (s, 3H, SCH3), 3.32 (s, 3H, OCH3), 
7.37 (dd, J = 4.8, 7.9 Hz, 1H, H~5), 7.65 (d, J = 5.2 Hz, 1H, H-5'), 8.37 (dd, J = 2.0, 4.8 Hz, 1H, 
H-6), 8.46 (dd, J;::;: 2.0, 7.9 Hz, 1H, H-4), 8.60 (d, J = 5.2 Hz, 1H, H-6'). 
DC NMR (75 MHz, CDCh): 0 13.4 (SCH3), 20.7 (COOCH3), 50.6 (OCH3), 100.3 (C-3a), 114.7 
(C-5'), 121.9 (C-5), 132.7 (C-3), 139.0 (C-4), 146.9 (C-2), 149.2 (C-6), 156.8 (C-6'), 164.5 
(C-4'), 166.6 (COOCH3), 171.7 (C-2'). 
LRMS (ESI): Calcd for C14H1535CIN30332S (MH+) m/z = 340.05, found m/z = 340.08. 
9-(4-Methoxybenzylamino)-S-[2-(methylsulfanyl)pyrimidin-4-
yl]pyrido[3',2':4,S]pyrrolo[I,2-c]pyrimidine 2.17 
f' -?' 
===/i'l N-\ 
1q.NH 211 3" f' ~ 4" 
=-- 5" 
OMe 
Variolin core structure 2.6 (100 mg, 0.29 mmol) was heated with P.MB (190 ilL, 1.47 mmol) in 
toluene (2.0 mL) at 100°C for 3 d. The solution was allowed to cool to rt then concentrated in 
vacuo. The crude material thus obtained was subjected to flash chromatography on silica, eluting 
with 70% EtOAc/hexanes, to give the monosubstituted product as an orange foam (124 mg, 
99 % yield). 
Mp: 66-68 °C. 
IH NMR (500 MHz, CDCh): 02.67 (s, 3H, 2'-SCH3), 3.81 (s, 3H, OCH3), 4.88 (d, J = 5.4, 2H, 
H-1"), 6.92 (d, J = 8.8 Hz, 2H, H-4"), 7.26 (d, J = 5.4 Hz, 1H, H-5'), 7.40 (dd, J = 4.4, 7.8 Hz, 
1H, H-3), 7.41 (d, J = 8.7 2H, H-3"), 7.47 (d, J = 6.8 Hz, 1H, H-6), 7.72 (d, J;:::: 6.3 Hz, 1H, H-7), 
8.27 (dd, J = 1.0, 3.4 Hz, 1H, H-2), 8.44 (d, J = 5.4 Hz, 1H, H~6'), 8.65 (dd, J = 1.0, 6.8 Hz, 1H, 
H-4), 10.38 (t, J:;:: 5.4 Hz, lH, 9-NH). 
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l3C NMR (75 MHz, CDCh): 8 14.3 (2'-SCH3), 44.4 (C~IU), 55.3 (OCH3), 99.7 (C-5), 101.3 
(C-6), 112.4 (C-5'), 114.1 (PMB C-4"), 120.3 (C-3), 121.7 (C-4a), 128.3 (C-4), 128.9 (C-3"), 
130.1 (C-2"), 139.1 (C-5a), 139.8 (C-2), 143.5 (C-I0a), 144.0 (C-7), 149.1 (C-9), 156.3 (C-6'), 
159.0 (C-5 H), 161.3 (C-4'), 172.2 (C-2'). 
(KBr): Umax 3060-2850 (series of weak bands), 1614, 1558, 1475, 1364, 1248, 1182, 1032, 
806. 
HRMS (ESI): Calcd for C23H21N6032S (MH+) m/z = 429.1498, found mlz = 429.1492. 
1Cso (P388): >29 tlM 
9-Amino-5-[2-( methylsulfanyl)pyrim idin-4-yl] pyrido[3' ,2' :4,5] pyrrolo [1,2-c] pyrimidine 
~ 7' 
N\, N 
qNH ~ ~ :::--
OMe 
PMB-protected variolin 2.17 (124 mg, 0.29 mmol) was dissolved in triflic acid (3.0 mL), and the 
deep red/orange solution stirred for 2 h at rt. The solution was then cooled to 0 °C and aq NH3 
solution added dropwise until a yellow precipitate had formed and the solution was alkaline. Sat 
aq NaHC03 solution was slowly added with stirring, and the resulting yellow suspension 
extracted with CH2Cb (50 mL). The yellow organic solution was concentrated in vacuo, and the 
crude material thus obtained purified by flash chromatography on neutralised silica, eluting with 
2% MeOH/CH2Ch (0.1% TEA), to give the deprotected product as a yellow microcrystalline 
solid (84 mg, 94% yield). 
Mp: dec 237-242 °C. 
IH NMR (500 MHz, CDCh): 8 2.69 (s, 3H, SCH3), 5.8-6.4 (br s, IH, NHa), 7.33 (d, J 5.5 Hz, 
IH, H-5 t), 7.49 (dd, J = 4.8, 8.3 Hz, IH, H-3), 7.58 (d, J = 6.7 Hz, IH, H-7), 7.68 (d, J 6.3 Hz, 
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IH, H~6), 8.40 (dd, J"" 1.6,4.8 Hz, IH, H-2), 8.49 (d, J = 5.2 Hz, IH, H-6'), 8.74 (dd, J = 1.6,8.3 
Hz, IH, H-4), 9.4-10.2 (br s, IH, NHb). 
13C NMR (75 MHz, CDCh): 0 14 .3 (2'-SCH3), 100.2 (C-5), 102.2 (C-6), 112.6 (C-5'), l20.7 
(C-3), 122.0 (C-4a), 128.6 (C-4), 138.8 (C-5a), 140.3 (C-2), 143.4 (C-IOa), 143.7 (C-7), 149.8 
(C-9), 156.5 (C-6'), 161.4 (C-4'), 172.4 (C-2'). 
IR (KBr): Umax 3321,3117 (broad), 3016 (broad), 2341, 2341,1917,1647,1558,1516,1454, 
1404, 1323, 1269, 1196, 1010,980,818. 
HRMS (ESI): Calcd for ClsH13N/2S (MH+) mlz = 309.0922, found mlz 309.0921. 
ICso (P388): 3.9 ~ 
Glycine benzyl ester benzenesulfonate 138 
3" 
4"~" I 1" 0 ?' I ~ »5' ----l~... ,..-:; Sl 18 19 20 0 ~ , 
r!J .... OH . H2N~ l' z 3' 4 
o 
A solution of glycine (1.00 g, 13.3 mmol) and benzenesulfonic acid (2.32 g, 14.6 mmol) in 
benzyl alcohol (8.00 mL, 77.3 mmol) was heated to 130°C under reduced pressure (9 mm Hg) 
for 2 h, then kept at 100°C under reduced pressure (0.03 mm Hg) for 1 h. During this time a 
small amount of benzyl alcohol was collected by distillation (~1 mL). The thick oil was poured 
into a mortar and pestle, allowed to cool to rt, then ground with diethyl ether (20 mL) to give the 
ester salt as a white crystalline solid. This solid was collected by filtration, washed with diethyl 
ether, and dried in vacuo (3.71 g, 86% yield). 
IH NIVIR (500 MHz, CD30D): 0 3.87 (s, 2H, H-19), 5.25 (s, 2H, H-l'), 7.31-7.45 (m, 8H, H-3', 
H-3", H-4', H-4", H-5'), 7.82 (dd, J;: 1.7, 7.6 Hz, 2H, H-2'). 
13C NMR (75 MHz, CD30D): 041.4 (C-19), 69.2 (C-l'), 127,2 (C-3"), 129.6 (Ar), 129.92 (Ar), 
129.93 (Ar), 129.96 (Ar), 131.6 (C-2" or C-4"), 136.7 (C-2'), 168.7 (C-20). 
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N-(9-Fluorenylm ethoxycarbonyl)-L-leucine acid chloride 
H 0 01'N~ 
1(12 : 17 CI 
o 14~ 
15
1
._ 
16 
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This was prepared from Fmoc-L-leucine, via the slightly modified procedure of Carpino et al. 95 
A solution of Fmoc-L-leucine (500 mg, 1.41 mmol) in a mixture of CH2Cl2 (2.5 mL), thionyl 
chloride (2.0 mL) and DMF (10 ~) was heated to reflux for l.5 h. The solution was allowed to 
cool to rt then concentrated in vaCllO. The residues thus obtained were dissolved in benzene 
(5 mL) and concentrated in vacuo; this process of dissolution and concentration was repeated 
twice more. The residues thus obtained were left at reduced pressure (0.03 mm Hg) at 45°C for 
48 h to give the acid chloride as a white amorphous solid (523 mg, 99% yield). Examination of 
this material by IH NMR was hindered by hydrolysis of the acid chloride by traces of water in 
the CDCh NMR solvent, so that mixtures of the acid chloride and the acid were invariably 
observed. Therefore, in order to confirm the purity of the acid chloride sample, a small amount 
was converted to the methyl ester as follows. 
To a small amount of Fmoc-L-Ieucine acid chloride was added dry MeOH and the resulting 
solution stirred at rt for 10 min then concentrated in vacuo. The methyl ester thus obtained was 
shown by IH NMR spectroscopy to be free from contamination by the acid, and had the 
following spectroscopic properties: 
lH NNIR (500 MHz, CDCh): (5 0.947 (d, J = 3.4 Hz, 3H, H-l6a), 0.960 (d, J ;::: 3.4 Hz, 3H, 
H-16b), 1.50-1.75 (m, 3H, H-24 and H-15), 3.74 (s, 3H, OMe) , 4.23 (t, J = 7.0 Hz, lH, H-4'), 
4.42 (d, J = 7.3, 2H, H-3'), 5.20 (br, lH, H-l2), 7.32 (t, J 7.6 Hz, 2H, H-7'), 7.40 (t, J:;:; 7.6 Hz, 
2H, H-8'), 7.60 (t, J::::: 6.6 Hz, 2H, H-6'), 7.76 (d, J;:: 73 Hz, 2H, H-9'). 
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N-(9-Fluo renylmethoxycarbonyl)-L-phenylalanine acid chloride 
7' 
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This was prepared from Fmoc~L-phenylalanine via the slightly modified procedure of Carpino et 
al. 95 A solution of Fmoc-L-phenylalanine (2.00 g) in a mixture of CHzCIz (10 mL) and thionyl 
chloride (4 mL) was heated to reflux for 20 min. THF (2 mL) was added and the solution heated 
to reflux for a further 30 min. The solution was allowed to cool then concentrated in vacuo to 
give a colourless oiL The oily residues were dissolved in CH2Clz (10 mL), concentrated in 
vacuo, then again dissolved in CH2Clz (10 mL) and concentrated in vacuo, The residues thus 
obtained were dissolved in CH2Ch (10 mL) and diluted, with vigorous stirring, with hexanes 
(100 mL). The resulting precipitate was collected by filtration and dried in vacuo to afford the 
protected amino acid chloride as white needles (1.91 g, 91 % yield). 
Mp: 114-115 °C (lit. 120-1 OC).95 
IH NMR (500 MHz, CDCh): (3 3.22 (dd, J = 6.8, 14.2 Hz, lH, H-6a), 3.27 (dd, J = 5,4, 14.7 Hz, 
IH, H-6b), 4.20 (t, J = 6.8 Hz, lH, H-4'), 4,42 (d, J 6.8, 2H, H-3'), 4.88 (dt, J = 6.3, 8.3 IH, 
H-5), 5.14 (d, J 7.8 Hz, IH, H-4), 7.17 (d, J = 6.8 Hz, 2H, H-6'), 7.28-7.37 (m, 5H, H~8, H-9 
and H-lO), 7,41 (t, J = 7.3 Hz, 2H, H-7'), 7.52 (t, J 7.3 Hz, 2H, 8'), 7.77 (d, J = 7.3 Hz, 2H, 
H-9'). 
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N-(9-Fluorenylmethoxycarbonyl)glycine acid chloride 
This was prepared from Fmoc~glycine via the slightly modified procedure of Carpino et al. 95 A 
solution ofFmoc~glycine (500 mg, 1.68 mmol) in a mixture ofCH2Ch (2.0 mL), THF (0.5 mL) 
and thionyl chloride (1.0 mL) was heated to reflux for 30 min. The solution was allowed to cool 
then concentrated in vacuo. The residues were dissolved in CH2Cb (5 mL) and the solution 
concentrated in vacuo; this process of dissolution and concentrated was repeated. The residues 
thus obtained were dissolved in CH2Ch (5 mL) and diluted, with vigorous stirring, with hexanes 
(25 mL). The resulting precipitate was collected by filtration and dried in vacuo to afford the 
protected amino acid chloride as a white powder (465 mg, 88% yield). 
Mp: 107-108 °C (lit. I08_9°C).95 
lH NMR (500 MHz, CDCh): 04.24 (t, J 6.8 Hz, lH, H-4'), 4.38 (d, J = 6.3, 2H, H-3'), 4.47 (d, 
J 6,8 Hz, 2H, H-2), 5.32 (br, lH, H-l), 7.31 (t, J"'" 7.1 Hz, 2H, H-7'), 7.41 (t, J = 7.6 Hz, 2H, 
H-8'), 7.58 (d, J::::; 7.3 Hz, 2H, H-6'), 7.77 (d, J = 7.3 Hz, 2H, H-9'). 
Phosphate buffer, pH = 5.598 
NaH2P04.2H20 (94.2 g, 529 mmol) and Na2HP04 (30.4 g, 253 mmol) were dissolved in H20 
(1.5 L), and a small amount of dil aq H3P04 was added to lower the pH from 5.7 to 5.5. 
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N-(9~Fluorenylmethoxycarbonyl)-L-Ieucyl-glycine benzyl ester 
+ 
1 
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To a solution of Fmoc-L-Ieucine (1.95 g, 5.5 mmol), glycine benzyl ester benzene sulfonate 
(1.78 g, 5.5 mmol), HOBT (1.12 g, 8.3 mmol), and TEA (845 ~, 6.1 mmol) in THF (150 mL) 
was added DCC (1.48 g, 7.2 mmol) and the solution left at 4 °C for 18 h. The resulting fine 
suspension was concentrated in vacuo to leave a white solid, which was purified by flash 
chromatography on silica, eluting with 15% EtOAc/CH2Ch, to afford the dipeptide as a white 
amorphous solid (2.80 g, 90% yield). 
Mp: 106-108 ac. 
ID NMR (500 MHz, d6-DMSO): 8 0.84 (d, J 6.3 Hz, 3H, H-16a), 0.87 (d, J 0.: 6.3 Hz, 3H, 
H-16b), 1.41-1.54 (m, 2H, H-14), 1.60-1.69 (m, 1H, H-15), 3.86 (dd, J 5.4 17.6 Hz, IH, 
H-19a), 3.96 (dd, J = 5.9, 17.1 Hz, 1H, H-I9b), 4.10 (td, J = 4.9,9.0, IH, H-13), 4.22 (m, 2H, 
H-3"), 4.31 (m, IH, H-4"), 5.11 (s, 2H, H-I'), 7.29-7.37 (m, 7H, H-3', H-4', H-5', H-7"), 7.41 (t, J 
= 7.3 Hz, 2H, H-8"), 7.55 (d, J 8.8 Hz, 1H, H-12), 7.73 (t, J == 6.1 Hz, 2H, H-611), 7.88 (d, J = 
7.3 Hz, 2H, H-9"), 8.40 (t, J;::: 5.9 Hz, IH, H-18). 
llC NMR (75 MHz, d6-DMSO): 821.5 (C-16a), 23.2 (C-16b), 24.3 (C-15), 40.87 (C-14), 40.92 
(C-19), 46.9 (C-13), 65.7 (C-3"), 66.0 (C-l'), 120.2 (C-9"), 125.5 (C-6"), 127.2 (C-7"), 127.8 
(C-8"), 128.08 (Ar), 128.21 (Ar), 128.5 (Ar), 136.0 (C-2'), 140.9 (C-10"), 143.9 (C-5"), 156.1 
(C-1"), 169.8 (C-20), 173.2 (C-17). 
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IR (KBr): \)max 3288,3065,2941,1734,1695,1653, 1539, 1452, 1239, 1119, 1034,980,739, 
698. 
HRMS (ESI): Calcd for C30H33N205 (MHT) mlz = 501.2389, found mlz =:; 501.2396. 
N-(9-Fluorenylmethoxycarbonyl)-L-phenylalanyl-L-leucylglycine benzyl ester 
1 
4" 0 ,,,~J12 )--~J V 
3" 'IT : 11 N~~ 0 I ~ 
o - H 0 ~ 
'0 
A solution of FmocLGOBn (1.98g, 3.95 mmol) in 1:1 CHCb/AMP (90 mL) was stirred at rt for 
5 min. The solution was diluted with CHCb (350 mL) and washed with sat brine solution (2 x 
400 mL), then pR:;:5.5 phosphate buffer (2 x 400 mL). To the organic solution was immediately 
added Fmoc-L-phenylalanine acid chloride (1.96 g, 4.82 mmol) and 5% aq NazC03 (35 mL), and 
the biphasic solution stirred vigorously at rt for 45 min. The organic layer was isolated and 
washed with water (300 mL), sat brine solution (300 mL), dried with Na2S04, filtered and 
concentrated ;n vacuo to leave an off-white oily residue. To the crude material thus obtained 
was added CHzCh (250 mL) and silica (10 g), and the resulting slurry sonicated with swirling for 
5 min then loaded onto a column of silica (90 g) in CHzCh Flash chromatography, eluting with 
20% EtOAc/CH2Ch, afforded the tripeptide as a white amorphous solid (1.63 g, 64% yield). 
Mp: 160-162 °C. 
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IH NMR (500 MHz, d6-DMSO): 0 0.81 (d, J ::::; 6.2 Hz, 3H, H-9a), 0.84 (d, J = 6.7 Hz, 3H, 
H-9b), 1.46 (t, J:::: 7.2 Hz, 2H, H-14), 1.62 (p, J =:; 6.7 Hz, IH, H-15), 2.77 (dd, J = 10.9, 13.4 Hz, 
IH, H-6a), 3.02 (dd, J = 3.6, 13.4 Hz, 1H, H-6b), 3.86 (dd, J 5.7, 17.6 Hz, 1H, H-19a), 3.95 
(dd, J = 5.7, 17.6 Hz, 1H, H-19b), 4.11-4,17 (m, 3H, H-3" and H-4"), 4.30 (td, J = 3.6, 9,6 Hz, 
IH, H-5), 4.38 (q, J = 7.8 Hz, 1H, H-13), 5.11 (s, 2H, H-l'), 7.17 (t, J::::; 7.2 Hz, IH, H-lO), 
7.23-7.37 (m, I1H, H-3', H-4', H-5', H-7", H-8 and H-9), 7.40 (td, J = 2.6,7.5 Hz, 2H, H-8"), 
7.57-7.64 (m, 3H, H-6" and H-4), 7.87 (d, J 7,8 Hz, 2H, H-9"), 8.08 (d, J:::;: 8.3 Hz, IH, H-12), 
8.37 (t, J = 5.9 Hz, IH, H-18). 
Be NMR (75 MHz, doDMSO): 0 21.8 (C-16a), 23.1 (C-16b), 24,2 (C-15), 37.5 (C-6), 40.9 
(C-19), 41.3 (C-14), 46.7 (C-4"), 51.0 (C-13), 56.1 (C-5), 65.8 (C-3"), 66.1 (C-1'), 120.2 (C-9"), 
125.4 (C-6"), 126.6 (C-IO), 127.2 (C-7"), 127,8 (C-8"), 128.1 (C-9), 128.17 (OBn), 128.24 
(OBn), 128.6 (OBn), 129.4 (C-8), 136,0 (C-2'), 138.3 (C-7), 140.8 (C-lO"), 143.9 (C-5"), 155.9 
(C-1'), 169.8 (C-20), 171.5 (C-ll), 172.7 (C-17), 
IR (KBr): Umax 3279, 3065, 2948, 1690, 1647, 1545, 1452, 1261, 1196, 1143, 1086, 1040,993, 
741,698. 
HRMS (ESI): Calcd for C39H42N306 (MH+) mlz = 648.3074, found mlz = 648.3082. 
The deprotected dipeptide intermediate, LGOBn, had the following spectroscopic characteristics: 
IH NMR (500 MHz, d6-DMSO): 00.82 (d, J::::: 6,3, 3H, H-16a), 0.86 (d, J = 6.3 Hz, 3H, H-16b), 
1.21 (ddd, J 5.9, 8.8, 13.2 Hz, IH, H-14a), 1.39 (ddd, J 5.4,6,3, l3,2 Hz, IH, H-14b), 1.72 
(pd, J 2.4, 5.9 Hz, IH, H-l5), 3.18 (dd, J = 5.4, 9.3 Hz, lH, H-l3), 3.87 (dd, J = 5.4, 17.6 Hz, 
IH, H-19a), 3.92 (dd, J = 5.4, 17.6 Hz, IH, H-19b), 4.49 (s, 2H, H-12), 5.11 (s, 2H, H-l'), 
7.29-7.37 (m, 5H, H-3', H-4' and H-5'), 8.33 (t, J = 5.4 Hz, IH, H-18). 
Be NMR (75 MHz, d6-DMSO): 0 21.9 (C-16a), 23.3 (C-16a), 24.1 (C-15), 40.8 (C-19), 44.4 
(C-14), 53.0 (C-l3), 66.0 (C-1'), 128.10 (Ar), 128.23 (Ar), 128.57 (Ar), 136.0 (C-2'), 170,0 
(C-20), 176.5 (C-17). 
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N-(9-Fluorenylmethoxycarbonyl)glycyl-L-phenylalanyl-L-leucylglycine benzyl ester 
a) From FmocFLGOBn: 
A solution ofFmocFLGOBn (1.23 g, 1.9 mmol) in 6:1 CHCb/ANIP (70 mL) was stirred at rt for 
1.5 h. The solution was diluted with CHCh (100 mL), washed with sat brine solution (2 x 
100 mL) and pH "" 5.5 phosphate buffer (2 x 100 mL), dried with Na2S04, filtered and 
concentrated in vacuo. To the oily residues thus obtained were added EDCI (473 mg, 
2.47 mmol), HOBT (385 mg, 2.85 mmol), Fmoc-glycine (437 mg, 1.47 mmol), THF (120 mL) 
and TEA (342 ~, 2.47 mmol) and the resulting white suspension stirred at rt for 16 h. The 
suspension was washed with 1:3 1.0 M aq HCI/sat brine solutions (200 mL), diluted with THF 
(60 mL), washed with sat brine solution (200 mL), dried with Na2S04, filtered and concentrated 
in vacuo. The crude material thus obtained was purified by repeated flash chromatography on 
silica, eluting with 2: 1 CH2ChIEtOAc (2% MeOH), to give the tetrapeptide as a white 
amorphous solid (1.11 g, 83% yield). 
The deprotected tripeptide intermediate, FLGOBn, had the following spectroscopic 
characteristics: 
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1H NMR (500 MHz, d6-DMSO): 0 0.82 (d, J = 6.3 Hz, 3H, H-16a), 0.84 (d, J = 6.3 Hz, 3H, 
H-16b), 1.40-1.63 (m, 3H, H-14 and H-15), 2.64 (dd, J = 8.3, 13.7 Hz, IH, H-6a), 2.95 (dd, J = 
4.4, 13.2 Hz, IH, H-6b), 3.32 (br s, 2H, H-4), 3.46 (dd, J 4.4,8.3 Hz, tH, H-5), 3.84 (dd, J = 
5.9,17.6 Hz, IH, H-19a), 3.92 (dd, J 5.9,17.1 Hz, IH, H-I9b), 4.36 (p, J 6.8 Hz, 1H, H-13), 
5.11 (s, 2H, H-l'), 7.16-7.28 (m, 5H, H-8, H-9 and H-I0), 7.34-7.38 (m, 5H, H-3', H-4' and H-5'), 
8.00 (d, J = 8.3 Hz, IH, H-12), 8.41 (t, J 5.9 Hz, 1H, H-18). 
b) ContinilOtfS solution phase synthesis with Fmoc-amino acid chlorides: 
FmocGFLGOBn 
FmocGFLGOBn was synthesised via the slightly modified procedure of Carpino et al. 95,98 To a 
suspension of glycine benzyl ester hydrochloride salt (70 mg, 0.22 mmol) in CHCb (2 mL) was 
added a solution of Fmoc-L-Ieucine acid chloride (105 mg, 0.28 mmol) in CHCb (2 mL), 
followed immediately by 5% aq Na2C03 (2 mL). The biphasic solution was stirred vigorously 
for 10 min, transferred to a separating funnel, a small amount of sat brine solution added to assist 
phase separation, and the organic layer collected. AMP (2.5 mL) was added and the resulting 
solution stirred at rt for 30 min, diluted with CHCb (15 mL) and extracted with pH = 5.5 
phosphate buffer (5 x 10 mL). The organic solution was concentrated in vacuo to a volume of 
~4 mL, and the coupling reaction repeated as above, but with Fmoc-L-phenylalanine acid 
chloride (114 mg, 0.28 mmol) as the electrophile. The Fmoc deprotection manipulations were 
carried out exactly as before to give a solution of the deprotected tri peptide in CHCb (~4 mL), 
A final coupling round was carried out as above, but with Fmoc-glycine acid chloride (89 mg, 
0.28 mmol) as the electrophile. Following isolation of the organic layer as before, 
1,2-diaminoethane (50 ~, 0.75 mmol) was added, the solution stirred for 1 min, extracted with 
pH = 5.5 phosphate buffer (2 x 20 mL) and sat brine solution (20 mL), dried with Na2S04, 
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filtered and concentrated in vacuo. The oily residues thus obtained were dissolved in DMSO 
(5 mL) with sonicating to give a milky solution. CHzCIz (40 mL) was added (with a concomitant 
increase in the amount of the fine precipitate, which was isolated and shown by NMR 
spectroscopy to be non-peptidic) and the resulting milky solution extracted with H20 (3 x 
50 mL) and sat brine solution (50 mL) (the solution cleared with the sat brine solution wash), 
dried with Na2S04, filtered and concentrated in vacllo. The crude material thus obtained was 
purified by flash chromatography on neutralised silica, eluting with 2: I CH2ClzIEtOAc (2,5% 
MeOH), to give the title compound as a white amorphous solid (45 mg, 95% pure, 28% yield). 
Mp: 77-80 °C. 
I H NlVIR (500 MHz, d6-DMSO): (5 0.80 (d, J = 6.3 Hz, 3H, H-16a), 0.85 (d, J = 6.8 Hz, 3H, 
H-16b), 1,45 (t, J::::: 7.1 Hz, 2H, H-14), 1.59 (p, J = 6.8 Hz, IH, H-15), 2.76 (dd, J 9.3, 14.l Hz, 
1H, H-6a), 3.01 (dd, J = 4,4, 13.7 Hz, lH, H-6b), 3.50 (dd, J 5.9, 16.6 Hz, 1H, H-2a), 3.63 (dd, 
J 5.9,16.6 Hz, 1H, H-2b), 3.83 (dd,J == 5.9-,17.6 Hz, 1H, H-19a), 3.92 (dd, J = 5.9,17.1 Hz, 
lH, H-19b), 4,20 (t, J 6.8 Hz, 1H, H_4f1), 4.24 (d, J 6.3 Hz, 2H, H-3"), 4.32 (q, J = 7.8 Hz, 
IH, H-13), 4.54 (td, J = 4,4,8.8 Hz, 1H, H-5), 5.11 (s, 2H, H-1'), 7.13-7.17 (m, 1H, H-lO), 
7.19-7.22 (m, 4H, H-8 and H-9), 7.30-7.37 (m, 7H, H-3', H-4', H-5' and H-7"), 7,41 (t, J 7.3 
Hz, 2H, H-8"), 7.51 (t, J::::: 6.3 Hz, IH, H-1), 7.69 (d, J = 7.8 Hz, 2H, H-6"), 7.88 (d, J = 7.3 Hz, 
2H, H-9"), 8.00 (d, J = 8.3 Hz, 1H, H-4), 8.11 (d, J = 8.3 Hz, IH, H-12), 8.27 (t, J 5.9 Hz, IH, 
H-18). 
13C NMR (75 MHz, d6-DMSO): (5 21.8 (C-16a), 23.1 (C-16b), 24,2 (C-15), 37.7 (C-6), 40.9 
(C-19), 41.1 (C-14), 43.5 (C-2), 46.8 (C-4"), 51.1 (C-13), 53.9 (C-5), 65.99 (C-3"), 66,07 (C-l'), 
120.3 (C-9"), 125,4 (C-6"), 126.4 (C-10), 127.3 (C-7"), 127.82 (C-8"), 128.13 (C-9), 128.18 (Ar), 
128.25 (Ar), 128.58 (Ar), 129,4 (C-8), 136.0 (C-2'), 137.8 (C-7), 140.9 (C-10fl), 144.0 (C-5"), 
156.7 (C-l"), 169.2 (C-3), 169.7 (C-20), 171.0 (C-ll), 172.7 (C-17). 
IR (KBr): Umax 3275, 3055, 2955, 1653, 1522, 1452, 1399, 1356, 1257, 1192, 1107, 1043, 995, 
743,698. 
HRMS (ESI): Calcd for C41H45N407 (Mff) mlz 705.3288, found mlz = 705.3284. 
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N-(9-Fluorenylmethoxycarbonyl)glycyl-L-phenylalanyl-L-leucylglycine 
a) From FmocGFLGOBn: 
To a solution of FmocGFLGOBn (700 mg, 0.99 mmol) in THF (60 mL) was added 10% 
palladium on charcoal (700 mg). The black suspension was subjected to 3 vacuumIH2 cycles, 
then stirred under H2 for 16 h at rt. The suspension was passed through a celite plug and the 
colourless filtrate concentrated in vacuo to a volume of around 25 mL. To this was added 
hexanes (200 mL) with vigorous stirring, and the resulting gel-like precipitate collected by 
filtration to afford the deprotected tetrapeptide as a white amorphous solid (496 mg, 98% pure, 
80% yield). 
b) Solid phase synthesis:94 
1-0 f\lHFmoc r 
1) Resin loading 2) Peptide synthesis 
I-°GLFGFmOC 
3) Cleavage ~ 
FmocGFLG 
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1) Loading: Wang resin (1.00 g, 0.95 mmol available benzyl alcohol positions) was gently 
agitated with Fmoc-glycine (311 mg, 1.05 mmol) in dry DMF (8.0 mL) for approximately 
15 min prior to the addition of pyridine (461 !iL, 5.70 mmol) and 2,6-dichlorobenzoyl chloride 
(400 !iL, 2.85 mmol). The reaction flask was then sealed and gently agitated overnight, after 
which the resin was filtered under vacuum and washed with DMF (3 x 5 mL) and CH2Ch 
(3 x 5 mL). The resin was then dried thoroughly in vacuo prior to determination of the loading. 
To ascertain the degree of resin loading, 2 small amounts of resin (0.91 and 1.12 mg) were 
accurately weighed into 2 quartz cuvettes. Freshly made 20% piperidinefDMF (3.0 mL) was 
then dispensed into the cuvettes along with a third empty cuvette which was used a solvent 
blank. Each sample was mixed for approximately 5 min and allowed to settle, and the UV 
absorbance measured to give A(29o tun) 0.924 and 1.189, respectively. The loading of the resin 
was then calculated on the basis of a linear relationship between absorbance at 290 nm and the 
quantity of Fmoc-amino acid present (with 1 mmol of Fmoc-amino acid giving an absorbance of 
1.650), to give loadings of 0.62 and 0,64 meq/g, or an average of 0.63 meq/g. 
The remaining benzyl groups of the resin were capped by stirring the resin (1.08 g, 0.32 mmol 
available benzyl alcohol positions) with pyridine (466 !iL, 5.8 mmol) and benzoyl chloride 
(441 !iL, 3.8 mmol) in 1,2-dichloroethane (8 mL) for two hours. The resin was isolated by 
filtration, washed with 1,2-dichloroethane (3 x 5 mL) and CH2Ch (3 x 5 mL) and dried in vacuo. 
2) Peptide synthesis: The synthesis of FmocGFLG-Wang resin was carried out by standard solid 
phase technique in a glass reaction vessel equipped with a frit (porosity 3) to allow both filtration 
and agitation of the resin by application of vacuum or positive pressure of nitrogen, respectively. 
Fmoc-glycine-Wang resin (l.00 g, 0.61 mmol glycine) was allowed to swell in DMF (8 mL) for 
15 min, drained, and the Fmoc protecting group removed by reacting the resin with freshly made 
20% piperidinefDMF (12 mL) for 10 min. After draining and washing with DMF (3 x 15 mL) 
and i-Pr alcohol (3 x 15 mL) the Kaiser test (for free amines) was carried out as follows: 
Kaiser Test: Several beads of the resin were removed and washed with EtOH (3 x 1 mL) in a 
small glass vial. The following 3 stock solutions were made and 3 drops from each were 
added to cover the beads: 
ninhydrin (2.5 g) in EtOH (50 mL) 
phenol (40 g) in EtOH (10 mL) 
1 mM aq KeN (2 mL) in pyridine (98 mL). 
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The vial was capped and placed in an oven (120 0c) for 3 min. A positive result (indicating 
the presence of free amines) was shown by the beads turning blue, while a negative result 
(indicating the absence of free amines) was shown by no change in colour (beads remained 
yellow). 
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With a positive Kaiser test, indicating the presence of free amines and hence the success of the 
deprotection reaction, the coupling reaction was carried out. The bulk resin sample was again 
washed with DMF (3 x 15 mL) and the collection flask changed to remove all traces of 
piperidine. A solution of Fmoc-L-leucine (431 mg, 1.22 mmol) in DMF (8 mL) was activated 
for 2 min with HBTU (463 mg, 1.22 mmol) and DIPEA (426 J,tL, 2.44 mmol), then the resulting 
solution added to the resin. The coupling reaction was gently agitated for 1 h before draining 
and washing with DMF (3 x 15 mL). The Kaiser test was again performed to give a negative 
result, indicating the absence of free amines and thereby the success of the coupling reaction. 
This process of deprotection and coupling was repeated for Fmoc-L-phenylalanine (473 mg, 
1.22 mmol) and Fmoc-glycine (363 mg, 1.22 mmol) with all other reagents used in the same 
quantities as those described above. Following the final coupling reaction, the resin was washed 
with DMF (3 x 15 mL), MeOH (3 x 15 mL) and CH2CIz (3 x 15 mL) before drying in vacuo. 
3) Cleavage: The N-protected tetrapeptide was cleaved from the resin by agitation with a 
cleavage brew consisting of 95% TFAl2.5% H20/2.5% TES (5 mL) for 30 min. The mixture 
was filtered, then the resin subjected to a second cleavage reaction (5 mL, 10 min) and again 
filtered. The combined acidic filtrates were pooled, diluted with H20 (100 mL), to give a white 
precipitate, and extracted with CH2CIz (1 x 200 and 2 x 100 mL). The organic fractions were 
combined, washed with sat brine solution (200 mL), dried with Na2S04, filtered and 
concentrated in vacuo. The yellow oily residues thus obtained were dissolved in THF (20 mL), 
and the resulting solution diluted with hexanes (200 mL) with vigorous stirring. The precipitate, 
which formed immediately, was collected by filtration, washed with hexanes and dried in vacuo 
to give the tetrapeptide as an off-white amorphous solid (141 mg, 38% yield). 
Mp: 197-199 °C. 
IB NMR (500 MHz, d6-DMSO): 8 0.83 (d, J = 6.3 Hz, 3H, H-16a), 0.87 (d, J == 6.3 Hz, 3H, 
H-16b) 1.48 (t, J 73 Hz, 2H, H-14), 1.60 (m, 1H, H-15), 2.77 (dd, 9.3, 14.2 Hz, IH, H-6a), 
3.02 (dd, J == 4.4,13.7 Hz, IH, H-6b), 3.51 (dd, J:= 6.3, 17.1 Hz, tH, H-1a), 3.63 (dd, J == 5.9, 
16.6 Hz, IH, H-1b), 3.70 (dd, J = 6.3, 17.6 Hz, IH, H-19a), 3.76 (dd, J = 5.9, 17.1 Hz, lH, 
H-I9b), 4.18-4.27 (m, 3H, H-3' and H-4'), 4.33 (dd, J == 7,8, 15.6 Hz, IH, H-13), 4.55 (td, J = 4.4, 
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8.6 Hz, IH, H~5), 7.13-7.18 (m, IH, H-lO), 7.19-7.24 (m, 4H, H-8 and H-9), 7.32 (t, J = 7.3 Hz, 
2H, H-7'), 7.41 (t, J = 7.3 Hz, 2H, H-8'), 7.52 (t, J =: 5.9 Hz, IH, H-l), 7.70 (d, J 7.3 Hz, 2H, 
H-6'), 7.89 (d, J = 7.3 Hz, 2H, H-9'), 8.00 (d, J = 8.3 Hz, IH, H-4), 8.09 (t, J = 5.9 Hz, IH, H-18), 
8.12 (d, J = 8.3 Hz, IH, H-12). 
13C NMR (75 MHz, d6-DMSO): (5 21.6 (C-16a), 23.1 (C-16b), 24.1 (C-15), 37.7 (C-6), 40.4 
(CI4), 40.9 (C-19), 43.3 (C-2), 46.6 (C-4'), 51.1 (C-13), 53.9 (C-5), 65.8 (C-3 1), 120.1 (C-9'), 
125.3 (C-6'), 126.3 (C-lO), 127.1 (C-7'), 127.7 (C-8'), 128.0 (C-9), 129.3 (C-8), 137.8 (C-7), 
140.7 (C-lO'), 143.9 (C-5'), 156.5 (C-l'), 169.0 (C-3), 170.9 (C-l1), 171.2 (C-20), 171.6 (C-17). 
IR (KBr): Umax 3275,3055,2938, 1712, 1647, 1545, 1452, 1404, 1348, 1250, 1169, 1088, 1061, 
935,741,702. 
HRMS (ESI): Calcd for C3Ji39N407 (MH+) m/z = 615.2819, found m/z =: 615.2816. 
9-[N-(9-Fl uorenylmethoxycarbo nyl)glycyl phenylalanyUeucylglycylam ido ]-5-[2-
(methylsulfanyl)pyrimidin-4-yl] pyrido[3' ,2': 4,5] pyrrolo [1,2-c] pyrimidine 2.18 
+ 
1 
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A solution of va rio lin 2.16 (10.0 mg, 32Ilmol), FmocGFLG (19.9 mg, 32 Ilmol), DCC (11.7 mg, 
57 Ilmol) and HOBT (8.8 mg, 65 Ilmol) in THF (2.0 mL) was left at 4 °C for 4 d, during which 
time a yellow gel-like precipitate formed. The precipitate was collected by filtration, washed 
with CHzCh (1 mL), MeOH (1 mL) and dried in vacuo to afford the conjugate, with 10 mol% 
contamination by DCU, as a yellow amorphous solid (8.6 mg, 95% pure, 28% yield). (All 
attempts at further purification of the conjugate material, including the significant amount that 
remained in solution when the reaction was complete, were hindered by decomposition of the 
conjugate.) 
1H NMR (500 MHz, d6-DMSO): 0 0.86 (d, J = 6.8 Hz, 3H, H-16*a), 0.87 (d, J = 6,3 Hz, 3H, 
H-16*b), 1.52-1.67 (m, 3H, H-14* and H-15*), 2.59 (s, 3H, SCH3), 2.78 (dd, J= 8.9, 14.2 Hz, 
IH, H-6*a), 3.02 (dd, J = 4.7, 14.2 Hz, IH, H-6*b), 3.52 (dd, J == 5.8, 16.8 Hz, IH, H-2*a), 3.66 
(dd, J 6.3, 16.8 Hz, IH, H-2*b), 4.15-4.25 (m, 3H, H-3*' and H-4*'), 4.40-4.53 (m, 3H, H-13*, 
H-19*a and H-19*b), 4.57.(td, J 4.2,8.4 Hz, 1H, H-5*), 7.13-7.18 (m, IH, H-10*), 7.19-7.24 
(m, 4H, H-8* and H-9*), 7.28 (t, J 7.4 Hz, 2H, H-7*'), 7.36 (t, J =: 7.4 Hz, 2H, H-8*'), 
7.49-7.55 (m, 2H, H-5' and H-l *), 7.62 (dd, J ::::: 4.2, 7.9 Hz, IH, H-3), 7.67 (d, J 7.4 Hz, 2H, 
H-6*'), 7.75 (d, J::::: 6.8 Hz, IH, H-7), 7.82 (d, J = 7.9 Hz, 2H, H-9*'), 7.91 (d, J = 6.8 Hz, IH, 
H-6), 8.06 (d, J::::: 7.9 Hz, IH, H-4*), 8.20 (d, J = 8.4 Hz, IH, H-12*), 8.37 (t, J = 5.3 Hz, IH, 
H-18*), 8.51-8.54 (m, 2H, H-2 and H-6'), 8.75 (d, J = 7.9, IH, H-4), 12.87 (s, IH, 9-NH). 
13C NMR (75 MHz, d6-DMSO): 0 13.9 (SCH3), 21.8 (C-16*a), 23.2 (C-16*b), 24.2 (C-15*), 
35.7 (C-6*), 41.0 (C-14*), 43.4 (C-2*), 45.4 (C-19*), 46.7 (C-4*'), 51.2 (C-13*), 54.0 (C-5*), 
65.9 (C-3*'), 100.4 (C-5), 107.8 (C-6), 113.3 (C-5'), 120.2 (C-9*'), 120.9 (C-4a), 121.6 (C-3), 
125.4 (C-6*'), 126.4 (C-I0*'), 127.2 (C-7*'), 127.8 (C-8*'), 128.2 (C-9*), 129.4 (C-IO*), 129.9 
(C-4), 137.75 (C-5a or C-7*), 137.77 (C-5a or C-7*), 140.8 (C-I0*'), 141.39 (C-2 or C-7), 
141.47 (C-2 or C-7), 142.1 (C-lOa), 143.0 (C-9), 143.9 (C-5*'), 156.7 (C-l *'), 157.5 (C-6'), 
160.3 (C-4'), 169.2 (C-3*), 169.6 (C-20*), 171.0 (C-ll *), 171.4 (C-2'), 172.8 (C-17*). 
IR (KEr): t)max 3348, 2965, 1735, 1669, 1587, 1554, 1510,1475, 1366, 1243, 1205, 1046. 
HRMS (ESI): Calcd for C49H49NIQ0632S (MH+) mlz 905.3557, found mlz = 905.3556. 
ICso (P388): >13.8 !lM 
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9-(N-Acetam ido )-5-[2-(methylsulfanyl)pyrimidin-4-yl]pyrido[3' ,2': 4,5] pyrrolo [1 ,2-
c]pyrimidine 2.19 
and 
9-(N,N-Diacetimido )-5-[2-( methylsulfanyl)pyrimid in-4-yl] pyrido[3' ,2': 4,5] pyrro)o [1,2-
c]pyrimidine 2.20 
2.19:R=H 
2.20: R = COCH3 
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a) To a stirred solution of va rio lin amine 2.16 (14.0 mg, 45 !J.mol) and TEA (35 IlL, 250 !J.mol) in 
THF (5.0 mL) was slowly added AcCI (16 !J.L, 227 !J.mol), and the solution stirred at rt. The 
solution darkened significantly from yellow to orange during the first 15 min. After 44 h the 
reaction solution was concentrated in vacuo, and the yellow/brown residues thus obtained 
purified by repeated flash chromatography on neutralised silica, eluting with 1~2.5% IP A/CH2Ch 
(0,05% TEA), to afford the monoacetylated derivative 2.19 (5.7 mg, 36% yield) and diacetylated 
derivative 2.20 (4.5 mg, 25% yield) as yellow microcrystalline solids. 
b) To a stirred solution of va rio lin amine 2.16 (20.0 mg, 65 !J.mol) and TEA (50 IlL, 359 !J.mol) in 
THF (3,0 mL) was slowly added AcCI (23 IlL, 323 !J.mol), and the solution stirred at rt. The 
solution darkened significantly from yellow to orange during the first 15 min. Aliquots (30 IlL) 
were periodically taken, dried in vacuo, and examined by IH NMR spectroscopy. 
c) To a stirred solution of va rio lin amine 2.16 (20.0 mg, 65 !J.mol) and TEA (50 IlL, 359 !J.mol) in 
THF (3.0 mL) was slowly added AcCI (23 IlL, 323 !J.mol), and the solution stirred at rt for 19 h, 
during which time the solution had darkened significantly from yellow to orange. At this time an 
aliquot (25 ttl) was removed, dried in vacuo, and examined by IH NMR spectroscopy, 
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d) To a stirred solution" of variolin amine 2.16 (20,0 mg, 65 Ilmol) and TEA (14 IlL, 97 Ilmol) in 
THF (3,0 mL) was slowly added AcCl (4,6 IlL, 65 Ilmol), and the solution stirred at Ii for 19 h, 
during which time the solution darkened significantly from yellow to orange. An aliquot (25 IlL) 
was removed, dried in vacuo, and examined by IHNMR spectroscopy. 
e) To a stirred solution of va rio lin amine 2.16 (22,0 mg, 71 Ilmol) and TEA (25 IlL, 178 Ilmol) in 
THF (5.0 mL) was slowly added AcCl (10 Ill, 143 Ilmol), and the solution stirred at Ii, The 
solution darkened significantly from yellow to orange during the first 15 min, Aliquots (10 IlL) 
were periodically taken, diluted with THF (100 IlL), and examined by HPLC at 256 nm, eluting 
with 85% MeOH!H;zO (0.05% TF A), 
t) To a stirred solution of va rio lin amine 2.16 (20,0 mg, 65 Ilmol) and TEA (14 IlL, 97 Ilmol) in 
THF (6,0 mL) was slowly added AcCI (4.6 IlL, 65 Ilmol), and the solution stirred at rt for 48 h, 
during which time the solution darkened significantly from yellow to orange, The solution was 
then concentrated in vacuo and the yellowlbrown residues dissolved in CH2Clz (15 mL), washed 
with sat aq NaHC03 (15 mL), sat brine solution (15 mL), dried with Na2S04, filtered and 
concentrated in vacuo, The crude material thus obtained was purified by flash chromatography 
on silica, eluting with 0,5·5% MeOHJCH2CIz, to give the monoacetylated derivative 2.19 
(0,9 mg, 4% yield), diacetylated derivative 2.20 (7,2 mg, 28% yield) and variolin staliing 
material 2.16 (6.5 mg, 33% recovery) as yellow microcrystalline solids, 
~ 
N~ N 
\(NH 
o 
Mp: 203-205 0c, 
IH NMR (500 MHz, CDCh): is 2.676 (s, 3H, COCH3), 2,684 (s, 3H, SCH3), 7.35 (d, J;:: 5,4 Hz, 
IH, H-5'), 7,58 (dd, J = 4,4,8.3 Hz, IH, H-3), 7.83 (d, J = 6,8 Hz, lH, H-7), 7,93 (d, J = 6,8 Hz, 
lH, H-6), 8.52 (dd, J 1.5,4,4 Hz, lH, H-2), 8.54 (d, J = 5,4 Hz, lH, H-6'), 8,77 (dd, J = 1.5,8,3 
Hz, lH, H-4) , 
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13C NMR (75 MHz, CDCh): 0 14.3 (SCH3), 26.5 (COCH3), 101.4 (C-5), 107.4 (C-6), 112.9 
(C-5'), 121.1 (C-3), 121.6 (C-4a), 129.5 (C-4), 137.7 (C-5a), 141.0 (C-2), 141.2 (C-7), 142.5 
(C-10a), 143.3 (C-9), 156.9 (C-6'), 160.7 (C-4'), 170.2 (CO), 172.7 (C-2'). 
IR (KBr): Umax 1867, 1682, 1568, 1456, 1273, 1202, 1132, 1030,800,768,721,552. 
HRMS (ESI): Cal cd for C17HlSN6032S (lVlH+) mlz = 351.1028, found mlz = 351.1027. 
ICso: (P388) 12.6 ~. 
Mp: 166-169 °C. 
IH NMR (500 MHz, CDCb): 02.41 (s, 6H, CO(CH3)2), 2.68 (s, 3H, SCH3), 7.34 (d, J = 5.4 Hz, 
1H, H-5'), 7.53 (dd, J = 4.9, 8.3 Hz, IH, H-3), 7.90 (d, J = 6.8 Hz, !H, H-7), 8.36 (d, J 6.3 Hz, 
IH, H-6), 8.53 (dd, J = 1.5,4.4 Hz, IH, H-2), 8.56 (d, J = 5.4 Hz, 1H, H-6'), 8.62 (dd, J 1.5,8.3 
Hz, 1H, H-4). 
13C NMR (75 MHz, CDCb): 0 14.3 (SCH3), 25.8 (COCH3), 103.4 (C-5), 113.4 (C-5'), 114.2 
(C-6), 121.0 (C-4a), 121.8 (C-3), 128.9 (C-4), 137.2 (C-5a), 139.2 (C-7), 141.5 (C-9), 141.8 
(C-10a), 144.2 (C-2), 157.1 (C-6'), 160.3 (C-4'), 171.4 (C-2'), 172.9 (CO). 
IR (KBr): Umax 1684, 1567, 1456, 1273, 1203, 1132, 1030,800. 
HRMS (ESI): Calcd for CJ9H17N60l2s (MH+) mlz = 393.1134, found mlz = 393.1147. 
ICso: (P388) 16.1 ~. 
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Attempted acetylation of monoacetylated variolin 2.19 
a) To a stirred solution of monoacetylated variolin 2.19 (15.0 mg, 43 jlmol) and TEA (33 jlL, 
237 jlmol) in 1:1 THF/CH2Cb (5.0 mL) was slowly added AcCI (15 jlL, 211 jlffiol) and the 
solution stirred at rt for 22 h. During this time the solution darkened significantly from yellow to 
orange. The solution was then concentrated in vacuo, examined by IH NMR spectroscopy, and 
purified by flash chromatography on neutralised silica, eluting with 1% MeOHlCH2Cb (0.1 % 
TEA), to give the monoacetylated starting material 2.19 as a yellow microcrystalline solid 
(13.7 mg, 81% recovery). 
b) To a stirred solution ofmonoacetylated variolin 2.19 (15 mg, 43 jlmol), bis-SMe analogue 2.6 
(14.0 mg, 41 )lmol) and TEA (33 jlL, 237 jlmol) in THF (10 mL) was slowly added AcCI 
(15 jlL, 211 jlmol) and the solution stirred at rt for 48 h. During this time the solution darkened 
significantly from yellow to orange. An aliquot (50 jlL) was removed, concentrated in vacuo 
and examined by IH NMR spectroscopy. 
Buffers 
Acetate buffer, pH = 5.0 (0.02 M); 
Acetic acid (50 ~) and NaCOCH3 (82 mg) were dissolved in H20 (100 mL), and NaCOCH3 
(-100 mg) added to adjust the pH to 5.0. 
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Phosphate buffer, pH = 7.4 (0.04 M): 
KH2P04 (118 mg) and Na2HP04.12H20 (1.09 g) were dissolved in H20 (100 mL), and a small 
amount of KH2P04 was added adjust the pH to 7.4. 
Borax buffer, pH = 9.3 (0.01 M): 
Decomposition of monoacetylated variolin 2.19 
a) To a solution of monoacetylated variolin 2.19 (5.0 mg, 14 !lmol) in 1: 1 MeOH/CH2Cb 
(2.0 mL) was added piperidine (2 IlL, 20 !lmol), and the reaction analysed by tic, eluting with 
5% MeOHlCH2CI2, after 30 min and 2h. Piperidine (20 IlL, 201 !lIDol) was again added, and the 
reaction analysed by tic as before. Finally, piperidine (200 IlL, 2.0 mmol) was again added, and 
the reaction analysed by tIc as before. 
b) To a solution of monoacetylated variolin 2.19 (5.0 mg, 14 !lmol) in 1:1 MeOHlCH2Ch 
(2.0 mL) was added TFA (2 IlL, 26 !lmol), and the reaction analysed by tic, eluting with 5% 
MeOHlCH2Cb, after 30 min and 2h. TF A (20 IlL, 260 !lmol) was again added, and the reaction 
analysed by tIc after 30 min. 
c) Monoacetylated variolin 2.19 (7.0 mg, 20 !lmo1) was dissolved in triflic acid (500 IlL) and the 
deep orange/yellow solution stirred at rt for 22 h. The solution was cooled to 0 °C and, with 
stirring, neutralised with aq NH3 (4 mL). Sat aq NaHC03 solution (10 mL) was added, and the 
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resulting yellow suspension extracted with CH2Clz (IO mL). The yellow organic solution was 
washed with sat brine solution (10 mL), dried with Na2S04, filtered and concentrated in VclCUO to 
afford free amine 2.16 as a yellowlbrown amorphous solid (4.4 mg, 95% pure, 76% yield). 
d) The following manipulations were carried out separately with pH = 5.0 acetate, pH ::::: 7.4 
phosphate and pH = 9.3 borax buffers. A solution of monoacetylated variolin 2.19 in DMSO 
(29 I-lM, 1.2 mL) was diluted with aqueous buffer solution (0.3 mL) and left at 30 0c. Aliquots 
(100 ~) were periodically removed and analysed by HPLC (5 ~ injections) at 256 nm, eluting 
with 85% MeOHlH20. 
e) The protocols described in part d) were replicated, with the exceptions that a 2% DMSO/THF 
organic solution was used (in the place of DMSO) and reactions were only analysed once after 
43 h. 
Decomposition of diacetylated variolin 2.20 
a) To a solution of diacetylated variolin 2.20 (5.0 mg, 13 I-lmol) in 1: 1 MeOHlCH2Clz (2.0 mL) 
was added piperidine (2 !-tL, 20 I-lmol), and the reaction analysed by tic, eluting with 5% 
MeOH/CH2Clz, after 30 min and 2h. Piperidine (20 !-tL, 201 I-lmol) was again added, and the 
reaction analysed by tic after 30 min. 
b) To a solution of diacetylated variolin 2.20 (5.0 mg, 14 I-lmol) in 1: 1 MeOHlCH2Cl2 (2.0 mL) 
was added TF A (2 !-tL, 26 I-lmol), and the reaction analysed by tic, eluting with 5% 
MeOH/CH2Clz, after 30 min and 2h. TFA (20 ~, 260 I-lmol) was again added, and the reaction 
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analysed by tIc as before. Finally, TFA (200 ~, 2.6 mmol) was again added, and the reaction 
analysed by tic after 30 min. 
Pivaloyl chloride 
This was prepared from pivalic acid,139 following the procedure of Brown. 140 A solution of 
pivalic acid (74.2 mL, 431 mmol) in benzoyl chloride (100 mL, 861 mmol) was fractionally 
distilled, with the fraction boiling at 60-80 °C being collected. This material was again 
fractionally distilled, and the fraction boiling at 92 °C collected to give the title compound 
(50.3 g, 64% yield). 
Bp: 92 °C (Ii t. 93 oC).139 
N-Hydroxysuccinimidyl pivalate 2.23 
+ 
To a stirred solution of NHS (1.00 g, 8.7 mmol) and TEA (1.39 mL, 10.0 mmol) in CH2Ch 
(50 mL) at rt was added pivaloyl chloride (1.18 mL, 9.6 mmol) dropwise over 10 min, and the 
solution left stirring at rt for 1 h. The resulting white suspension was washed with 0.2 M aq HCI 
(50 mL), sat aq NaHC03 (50 mL), sat brine solution (50 mL), dried with Na2S04, filtered and 
concentrated in vacuo. The crude material thus obtained was recrystallised from 
benzene/hexanes to afford the title compound as white needles (1.45 g, 83% yield). 
Mp: 77·78 °C (benzene) (lit. 77_8°C).108 
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NMR (500 MHz, CDCh): 8 1.39 (s, 9H, CH3), 2.83 (d, J == 5.4 Hz, 4H, CH2). 
9-(N-pivalamido)-5-[2-(methylsulfanyl)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-
c]pyrimidine 2.24 
+ 
~ 
N~N 
NH 
°::\1" 
.. ~ 3" 
168 
a) A solution of va rio lin analogue 2.16 (10.0 mg, 32 I-tmol) and ester 2.23 (13.0 mg, 64 I-tmol) in 
DMSO (0.7 mL) was heated at 100°C for 19 h. The yellow solution was allowed to cool to rt, 
diluted with CH2Ch (10 mL), washed with sat brine solution (15 mL), dried with Na2S04, 
filtered and concentrated in vacuo. The crude material thus obtained was purified by repeated 
flash chromatography on neutralised silica, eluting with 1% MeOH/CH2Ch (0.1% TEA), to 
afford both the variolin starting material 2.16 as a yellow microcrystalline solid (5.1 mg, 51% 
yield) and the acylated conjugate 2.24 in low purity. This conjugate material was then purified 
by flash chromatography on silica, eluting with 10-50% EtOAc/CH2Ch, to afford the acylated 
variolin product as a yellow powder (3.0 mg, 24% yield). 
b) A solution of va rio lin 2.16 (7.6 mg, 25 !Jffiol) and ester 2.23 (49.1 mg, 246 I-tmol) in DMSO 
(0.7 mL) was heated at 110°C for 72 h. The yellow solution was allowed to cool to rt, diluted 
with CH2Ch (10 mL), washed with sat brine solution (15 mL), dried with Na2S04, filtered and 
concentrated in vacuo. The crude material thus obtained was purified by flash chromatography 
on neutralised silica, eluting with 1% MeOH/CH2Clz (0.1 % TEA), to afford the acylated variolin 
product as a yellow powder (3.0 mg, 31 % yield). 
Mp: >230°C. 
In NMR (500 MHz, CDCh): 8 1.50 (s, 9H, H-3"), 2.69 (s, 3H, SCH3), 7.36 (d, J = 5.4 Hz, 1H, 
H-5 1), 7.59 (dd, J = 4.4,8.3 Hz, 1H, H-3), 7.93 (d, J;;::: 6.8 Hz, IH, H-7), 7.95 (d, J 6.8 Hz, 1H, 
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H-6), 8.50 (dd, J = 1.5,4,4 Hz, IH, H-2), 8.54 (d, J ::::; 5,4 Hz, 1H, H-6'), 8.81 (dd, J::::: 1.5, 8.3 Hz, 
lH, H-4), l3 .37 (s, lH, 9-NH). 
13C NMR (75 MHz, CDCh): 0 14.3 (SCH3), 27.3 (C-3"), 41.4 (C-2"), 101.3 (C-5), 107.5 (C-6), 
112.9 (C-5'), 121.1 (C-3), 121.6 (C-4a), 129.8 (C-4), 138.0 (C-5a), 140,4 (C-2), 142.0 (C-7), 
142.5 (C-lOa), 143.7 (C-9), 156.8 (C-6'), 160.8 (C-4'), 172.7 (C-2'), 176,4 (C-l"). 
IR (KBr): Omax 1722, 1630, 1558, 1520, 1497, 1477, l396, l362, 1335, 1246, 1165, 1070, 1007, 
910,831,806,770,741,687. 
HRMS (ESI): Calcd for C2oH21N6032S (MHl m/z::::; 393.1498, found m/z::::; 393.1494. 
ICso (P388): >8.0 jlM. 
Ester 2.23 from acylated variolin 2.24 
+ 
A solution of va rio lin 2.24 (2.0 mg, 5 /-tmol) and NHS (0.6 mg, 5 /-tmol) in DMSO (0.5 mL) was 
heated to 100 °C for 48 h. The yellow solution was allowed to cool to rt, diluted with CH2Ch 
(10 mL), washed with H20 (2 x 15 mL), sat brine solution (15 mL), dried with Na2S04, filtered, 
concentrated in vacuo and examined by IH NMR spectroscopy. The crude material thus 
obtained was purified by flash chromatography on neutralised silica, eluting with 1% 
MeOH/CH2Ch (0.1 % TEA), to afford the NHS ester product 2.23 (50% pure, yield not taken) 
and both the variolin starting material 2.24 and product 2.16 in high purity (yields not taken). 
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9-(Methylsulfinyl)-5-[2-( methylsulfinyl )pyrimidin-4-yl] pyrido[3' ,2': 4,5] pyrrolo [1,2-
c]pyrimidine 2.2587 
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Under atmospheric conditions, a solution of m-CPBA (102 mg, 591 I-lmol) in chlorofonn 
(10 mL) was cooled to -55 DC (MeOWN2), and added dropwise, over 15 min, to a similarly 
cooled stirred solution of core structure 2.6 ClOO mg, 295 I-lmol) in chloroform (10 mL). The 
solution was left to warm to ~O DC over 1 h then washed with sat aq NaHC03 solution (25 mL), 
sat brine solution (25 mL), dried with Na2S04, filtered and concentrated in vacuo to leave a 
yellow solid. This crude material, which was used without further purification, was 
predominantly a mixture of diastereomeric bis-sulfoxides with the following spectroscopic 
characteristics. 
In NMR (500 MHz, CDCh): (As most signals for the diastereoisomers coincide, some are 
quoted as multiplets.) 03.04 (d, 3H, 2'-SCH3), 3.24 (d, 3H, 9-SCH3), 7,65 (dd, IH), 7.79 (d, IH), 
8.24 (m, IH), 8.64 (m, IH), 8.69 (m, IH), 8.80 (m, IH), 8,86 (d, IH). 
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9-( 4-Methoxybenzylamino )-5-[2-( 4-methoxybenzylamino )pyrimidin-4-
yl] pyrido [3',2': 4,5] pyrrolo [1 ,2-c] pyrim idine 2.2687 
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Oxidised core structure 2.25 (109 mg, 0.29 mmoi, if oxidation reaction gave a quantitative yield) 
was heated with p-methoxybenzylamine (192 !-iL, 1.46 mmol) in toluene (2 mL) at 100°C for 
3 d. The solution was allowed to cool to rt then diluted with CH2Cb (20 mL), washed with sat 
aq NallCO) solution (20 mL), sat brine solution (20 mL), dried with Na2S04, filtered and 
concentrated in vaCliO. The crude material thus obtained was purified by repeated flash 
chromatography on neutralised silica, eluting with 0.5% MeOHIDCM (0.1 % TEA), to give the 
title compound as an orange foam (109 mg, 72% yield over 2 steps). 
Mp: 58-62°C (lit. 54-60 °C).87 
lH NMR (500 MHz, CDCb): a 3.801 (s, 3H, OCH3), 3.805 (s, 3H, OCH3), 4.68 (d, J ::=: 5.9 Hz, 
2H, H-l111), 4.88 (d, J::=: 5.4 Hz, 2H, H-l"), 5.58 (br, lH, 2'-NH), 6.9 (m, 4H, H-4" and H-4"1), 6.97 
(d, J 5.4 Hz, IH, H-5'), 7.33-7.42 (m, 6H, H-3, H-6, H-3" and H-3'"), 7.62 (d, J::=: 6.3 Hz, IH, 
H-7), 8.26 (dd, J = 1.5,4.9 Hz, lH, H-2), 8.29 (d, J = 5.4 Hz, lH, H-6'), 8.55 (br d, J = 7.8 Hz, 
IH, H-4), 10.35 (t, J = 5.9 Hz, lH, 9-NH). 
ICso (P388): >34 ~ 
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9~( 4~ Methoxybenzylamino )-5-[2-( amino )pyrimidin~4-yl] pyrido[3',2' :4,5] pyrrolo[1,2~ 
c]pyrimidine 2.2787 
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Bis-PMB-protected variolin 2.26 (20.0 mg, 39 J!mol) was dissolved in TFA (0.5 mL) and stirred 
at 45°C for 24 h. The deep red solution was cooled to 0 °C then neutralised by the dropwise 
addition of aq NH3. Sat aq NaHC03 solution was added until effervescing ceased. The yellow 
suspension was then extracted with CHzCIz (10 mL). The yellow organic solution was washed 
with sat brine solution (15 mL), dried with NaZS04, filtered and concentrated in vacuo. The 
crude material thus obtained was purified by flash chromatography on neutralised silica, eluting 
with 2% MeOH/CHzCIz (0.1% TEA), to give the monoprotected product as a yellow 
microcrystalline solid (12.8 mg, 83% yield). 
Mp: 192-194 °C. 
NMR (500 MHz, CDCh): 0 3.80 (s, 3H, OCH3), 4.88 (d, J 5.4 Hz, 2H, H-llt), 5.14 (br s, 
2H, 2'·NHz), 6.91 (dt, J = 2.0, 8.8 Hz, 2H, H-4"), 6.99 (d, J = 5.4 Hz, 2H, H-5'), 7.38 (dd, J = 4.4, 
7.8 Hz, IH, H-3), 7.41 (dt, J = 8.8, 2.9 Hz, 2H, H-3/1), 7.45 (d, J = 6.8 Hz, lH, H-6), 7.68 (d, J = 
6.8 Hz, IH, H-7), 8.26 (dd, J = 1.5,4.4 Hz, lH, H-2), 8.28 (d, J 5.4 Hz, IH, H-6'), 8.64 (dd, J = 
1.5,8.3 Hz, IH, H-4), 10.34 (t, J = 5.4 Hz, IH,9-NH). 
13C NMR (75 MHz, CDC h): 044.4 (C-l"), 55.3 (OCH3), 100.2 (C-5), 101.4 (C-6), 108.8 (C-5 1), 
114.1 (C-4"), 120.1 (C-3), 121.9 (C-4a), 128.3 (C-4), 128.8 (C-3"), 130.3 (C-21t), 138.5 (C-5a), 
139.6 (C-2), 143.22 (C-7), 143.39 (C-lOa), 149.1 (C-9), 157.6 (C-6'), 159.0 (C-5"), 162.5 (C-4'), 
162.9 (C-2'). 
Chapter 6: Experimental ~ Experiments Described in Chapter 2 
IR (KBr): Umax 1565,1508,1459,1420,1250,1175,1038,1008,806,768,705. 
HRMS (ESI): Calcd for CZZH20N70 (MH+) mlz 398.1729, found mlz == 398.1726. 
ICso (P388): 5.4 ~ 
9-(4-Methoxybenzylam ino )-5-[2-{N-(9-fluorenylm ethoxycarbonyl)glycyl} pyrim id in-4-
yJ]pyrido[3' ,2' :4,5] pyrrolo[1,2-c]pyrimidine 2.28 
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a) PMB-protected variolin 2.27 (19.9 mg, 50 ~mol), Fmoc-glycine acid chloride (15.8 mg, 
50 ~ol) and DMAP (0.2 mg, 1.6 J.lmol) were disolved in THF (4.0 mL) and TEA (35 ~, 
252 ~ol) immediately added to give an orange solution with a fine colourless precipitate. After 
stirring at rt for 20 h the reaction was concentrated in vacuo, The crude material thus obtained 
was purified by flash chromatography on neutralised silica, eluting with 1% MeOHIDCM (0.1 % 
TEA), to give the monoacylated variolin analogue as a thick yellow gum (4.8 mg, 14% yield). 
b) PMB-protected variolin 2.27 (29.8 mg, 75 ~mol), Fmoc-glycine acid chloride (95.4 mg, 
302 ~mol) and DMAP (0.4 mg, 3 ~mol) were disolved in THF (5.0 mL) and TEA (52 ~, 
377 ~ol) immediately added to give an orange solution with a fine colourless precipitate, After 
stirring at rt for 16 h the reaction was examined by tic, and shown to contain a mixture of 
variolin compounds in similar proportions to the previous experiment. Concentration of the 
reaction mixture in vacuo gave an orange oil, which was purified by flash chromatography on 
neutralised silica, eluting with 1% MeOHIDCM (0.1 % TEA), to give the monoacylated variolin 
analogue as a thick yellow gum (yield not taken), 
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IH NMR (500 MHz, CDCh): 63,81 (s, 3H, OCH3), 4,25 (t, J = 6,7 Hz, 1H, H-4'"), 4.43 (d, J = 
6,7 Hz, 2H, H-3"'), 4,57 (br s, 2H, H-29), 4,89 (d, J = 4,8 Hz, 2H, H-1"), 5,86 (br, 1H, H-14), 
6,92 (d t, J = 2,6,6.3 Hz, 2H, H-4"), 7,28-7.32 (m, 3H, H-5' and H-7"'), 7.36-7.43 (m, 5H, H-3, 
H-3" and H-8"'), 7.54 (d, J = 6,3 Hz, 1H, H-6), 7,62 (d, J = 7,1 Hz, 2H, H-6"'), 7,74 (d, J::;: 7,5 
Hz, 2H, H-9'"), 7,77 (d, J::;: 6,7 Hz, 1H, H-7), 8,27 (d, J::;: 4.4 Hz, IH, H-2), 8.48 (d, J = 5,2 Hz, 
1H, H-6'), 8,74 (d, J;::: 7,9 Hz, 1H, H-4), 8,81 (br s, 1H, 2'-NH), 10.40 (br, 1H, 9-NH) , 
13C NMR (75 MHz, CDCh): 644. (C-1"), 45,8 (C-29), 47,1 (C-4'"), 55,3 (OCH3), 67.3 (C-3'''), 
99,5 (C-5), 101.3 (C-6), 112,7 (C-5'), 114.1 (C-4"), 119.9 (C-9'''), 120,6 (C-3), 121.8 (C-4a), 
125,1 (C-6"'), 127.0 (C-7"'), 127.6 (C-8"'), 128.4 (C-4), 128,9 (C-3"), 130,1 (C-2"), 139,6 (C-5a), 
139,9 (C-2), 141.2 (C-10'"), 143,60 (C-10a), 143.84 (C-5"'), 144,6 (C-7), 149,2 (C-9), 156,77 
(C-l "' and C·2'), 157.2 (C-6'), 159,0 (C-5"), 162,7 (C-4'), 170,1 (C-30), 
HRMS (ESI): Cal cd for C39H33Ns04 (MIt) nllZ = 677,2625, found m/z = 677,2626. 
Testing stability of va rio lin analogue 2.28 towards TFA 
An orange solution of va rio lin analogue 2.28 (~1 mg) in 10% TFAlDMSO (0,5 mL) was stirred 
at rt for 5 h, then examined by HPLC, 
Testing stability of variolin analogue 2.28 towards TEA 
An orange solution of variolin analogue 2.28 (~1 mg) in 10% TEAlDMSO (0,5 mL) was stirred 
at rt for 5 h, then examined by HPLC, 
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9~(4-Methoxybenzylamino)-5-[2-(glycyl)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-
c]pyrimidine 2.29 
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Variolin analogue 2.28 (~1 mg) was dissolved in 20% piperidine/THF (0.5 mL) and the yellow 
solution stirred at rt for 15 min. The solution was diluted with H20 (l0 mL) and loaded onto a 
CIS cartridge. The cartridge was washed with H20, then the variolin material washed off with 
MeOHlDCM. To the yellow solution thus obtained was added a small amount of TF A, and the 
orange solution examined by HPLC, 
Depreotection of variolin analogue 2.28 
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Variolin analogue 2.28 (-1 mg) was dissolved in triflic acid (200 ~L) and the deep red solution 
stirred at rt for 2 h. The solution was diluted with H20 (5.0 mL) and loaded onto a CI8 cartridge. 
The cartridge was washed with H20, and the variolin material washed off with MeOHIDCM. 
The yellow solution thus obtained was examined by HPLC. 
Deoxyvariolin B (DVB) 
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DVB was synthesised via the slightly modified procedure of Anderson and Morris. 87 2.26 
(180 mg, 0,35 mmol) was dissolved in triflic acid (2 mL) and the deep orange/red solution stirred 
at rt for 2.5 h. The solution was cooled to 0 °C and aq NH3 was added dropwise until a yellow 
precipitate had formed and the solution was alkaline. Sat aq NaHC03 solution was added 
carefully until effervescing ceased, the suspension filtered and the yellow/green solid washed 
with H20. This crude material was dissolved in THF (40 mL), DIOL (1.5 g) added and the 
suspension slowly diluted with hexanes (60 mL) with vigorous swirling. The resulting yellow 
slurry was loaded onto a DIOL column (8.5g diol) and flash chromatography, eluting with 2% 
MeOHlCH2Ch, afforded DVB as a yellow microcrystalline solid (84 mg, 88% yield). 
Mp: dec at ~200-230 °C (lit. dec at ~220-240). 87 
IH NMR (500 MHz, (CD3)SO): (5 6.55 (br s, 2H, 2'-NH2), 7.06 (d, J == 5.4 Hz, lH, H-5'), 7.08 
(dd, J = 4.4,7.8 Hz, IH, H-3), 7.63 (d, J = 6.4 Hz, IH, H-7), 7,68 (d, J 6.8 Hz, IH, H-6), 8.22 
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(d, J:= 5.4 Hz, IH, H-6'), 8.35~8.80 (br s, IH, 9-NH), 8.45 (dd, J 1.5,4.9 Hz, IH, H-2), 8.92 
(dd, J:= 1.5, 8.3 Hz, IH, H~4), 9.20-9.55 (br s, 1H, 9-NH). 
HRMS (ESI): Cal cd for C1Ji12N7 (MH+) mlz = 278,1154, found mlz 278.1153. 
IC50 (P388): 0.47 JlM 
L-Leucine benzyl ester benzenesulfonate138 
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A solution of L-leucine (1.00 7.62mmol)' and benzenesulfonic acid (1.33 g, 8.39 mmol) in 
benzyl alcohol (5.0 mL) was heated at 115°C for 1 h at atmospheric pressure, then for a further 
1.5 h under reduced pressure (10 mm Hg), with only a small amount of benzyl alcohol «1 mL) 
being removed by distillation during this time. The solution was transferred to a mortar and 
pestle, allowed to cool to rt, then ground with diethyl ether (30 mL). The resulting precipitate 
was collected by filtration, washed with diethyl ether and dried in vacuo to afford the benzyl 
ester salt as a white crystalline solid (2.34 g, 81 % yield), 
Mp: 169-170 0c. [lit. 167-8 °c (ethanolldiethyl ether)]. 141 
NMR (500 MHz, do-DMSO): 00.86 (d, J = 4.9 Hz, 6H, H-16), 1.57-1.72 (m, 3H, H-14 and 
H-15), 4.05 (t, J = 7.1 Hz, IH, H-13), 5.23 (s, 2H, H-I'), 7.31-7.42 (m, 8H, Ar), 7.61 (d, J 7.7 
Hz, 2H, H-2"), 8.36 (br s, 3H, H-12). 
13C NMR (75 MHz, d6-DMSO): 0 22.2 (C-16), 23.9 (C-15), 39.1 (C-14), 50.8 (C-13), 67.4 (C. 
I'), 125.7 (C-2"), 127.9 (Ar), 128.47 CAr), 128,67 (Ar), 128,74 (Ar), 128,81 (Ar), 123.3 (C-21), 
148.1 (C-1"), 170,0 (C-17). 
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N-(9-Fluorenylmethoxycarbonyl)-L-phenylalanyl-L-leucine benzyl ester 
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To a solution/suspension of L-Ieucine benzyl ester benzenesulfonate salt (100 mg, 264 fimol), 
Fmoc-L-phenylalanine (107 mg, 276 jlmol), DCC (71 mg, 344 fimol) and HOBT (53 mg, 
392 fimol) in THF (10 mL) was added TEA (55 fiL, 397 jlmol), and the white suspension stirred 
at rt for 18 h. This was then diluted with CH2Cb (10 mL), washed with sat brine solution 
(10 mL), filtered and concentrated in vacuo. To the crude material thus obtained was added 
CH2Clz (10 mL) and silica (1 g), and the resulting suspension stirred at rt for 5 min. Hexanes 
(10 mL) were next added with vigorous stirring, and the suspension loaded onto a column of 
silica (9 g) in hexanes. Flash chromatography, eluting with 10-15% EtOAc/hexanes, afforded 
the dipeptide as a white amorphous solid (140 mg, 95% pure, 85% yield) .. 
Mp: 108-110 °C (lit. 154-5 0C)?5 
IH NMR (500 l\I1Hz, d6-DMSO): 0 0.82 (d, J = 6.4 Hz, 3H, H-16a), 0.88 (d, J = 6.4 Hz, 3H, 
H-16b), 1.51-1.68 (m, 3H, H-14 and H-15), 2.73 (dd, J= 11.2, 14.2 Hz, 1H, H-6a), 2.94 (dd, J = 
3.4, 13.7 Hz, 1H, H-6b), 4.08-4.13 (m, 3H, H-3" and H-4"), 4.29 (m, 1H, H-5), 4.36 (m, 1H, 
H-13), 5.12 (8, 2H, H-1'), 7.17 (t, J = 7.3 Hz, IH, H-I0), 7.23-7.36 (m, 6H, H-3', H-4', H-8, H-5', 
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H-9, and H-7"), 7.49 (td, J;: 3.2, 8.S Hz, 2H, H-8"), 7.59-7.64 (m, 3H, HA and H-6"), 7.86 (d, J 
7.3 Hz, 2H, H-9"), 8.46 (d, J:::: 7.8 Hz, IH, H-12). 
BC NMR (75 MHz, d6-DMSO): 8 21.5 (C-16a), 22.9 (C-16b), 24.4 (C-15), 37.5 (C-6), 39.4 
(C-14), 46.7 (C-4"), 50.7 (C-13), 56.0 (C-5), 65.8 (C-3"), 66.2 (C-l'), 120.3 (C-9"), 125.5 (C-6"), 
126.5 (C-lO), 127.3 (C-7"), 127.84 (C-8"), 128.03 (Ar), 128.22 (Ar), 128.27 (Ar), 128.6 (Ar), 
129.4 (C-S), 136.1 (C-2'), 13S.3 (C-7), 140.8 (C-lO"), 143.9 (C-SU), 156.0 (C-l"), 172.19 (C-ll), 
172.41 (C-17). 
IR (KBr): Umax 3314,3071,2959, 1740, 1693, 1659, 1535, 1450, 1261, 1146, 1034,741,698. 
HRMS (ESI): Calcd for C37H39N20S (MIr) m/z = 591.2859, found m/z = 591.2863. 
L~Phenylalanine benzyl ester hydrochloride 
This was prepared from L-phenylalanine via the slightly modified procedure of Miller and 
Waelsch. 138 A solution ofL-phenylalanine (1.00 g, 6.1 mmol) and benzenesulfonic acid (1.05 g, 
6.7 mmol) in benzyl alcohol (12.0 mL) was heated to 120°C under reduced pressure 
(10 mm Hg). When about half of the benzyl alcohol (-5 mL) had been removed by distillation 
the solution was transferred to a mortar and pestle, allowed to cool to rt, then ground with diethyl 
ether (50 mL). The resulting precipitate was collected by filtration, washed with diethyl ether 
and dried in vacuo to give white crystals (2.14 g). Examination of this material by IH NMR 
revealed that only -50% esterification had occurred, so the material was again dissolved in 
benzyl alcohol (10 mL), benzenesulfonic acid (1.00 g, 6.32 mmol) added, and about half of the 
benzyl alcohol (~5 mL) removed by distillation under reduced pressure (10 mm Hg) at 120°C 
over 3 h. The solution was then transferred to a mortar and pestle, allowed to cool to rt, and 
ground with diethyl ether (l00 mL). The resulting precipitate was collected by filtration, washed 
with diethyl ether and dried in vacuo to afford the benzyl ester salt as white crystals (1.96 g). 
Examination of this material by IH NMR showed it to be of insufficient purity, and so it was 
decided to convert the benzyl ester to the hydrochloride salt for purification purposes. 
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Thus, to a suspension of the benzenesulfonate salt in CHCb (10 mL) was added TEA (1.30 mL, 
9.4 mmol) and the white suspension stirred at rt for 10 min. Diethyl ether (40 mL) was added, 
and after 1 h at -20°C the suspension was filtered and the filtrate collected and concentrated in 
vacuo. The crude material thus obtained was dissolved in THF (30 mL) and diluted with 
1M aq HCI (20 mL). The resulting solution with cloudy precipitate was concentrated in vacuo to 
a volume of -S mL, diluted with MeOH (30 mL) and concentrated in vacuo to close to dryness, 
dissolved in MeOH (30 mL), concentrated in vacuo and left at reduced pressure (0.03 mm Hg) 
overnight. The crude material thus obtained was dissolved in warm benzyl alcohol (20 mL), 
diluted with diethyl ether (60 mL) and left at -20°C for Ih. The resulting crystals were collected 
by filtration to afford the benzyl ester hydrochloride salt as white needles (342 mg, 19% yield). 
Addition of ether (100 mL) to the mother liquor, followed by cooling to -20°C for Ih, afforded a 
further 120 mg (26% total yield) of the title compound in high purity. 
Mp: 201.;204 °C (lit. 207-9 OC).142 
1M NMR (SOO MHz, d6-DMSO): <5 3.09 (dd, J = 7.8, 14.2 Hz, IH, H-6a), 3.22 (dd, J = 5.4, 13.7 
Hz, IH, H-6b), 4.32 (t, J = 6.6 Hz, IH, H-S), 5.l1 (d, J"" 12.2 Hz, IH, H.l'a), S.15 (d, J 12.2 
Hz, IH, H-l 'b), 7.18-7.36 (m, 10H, Ar), 8.71 (br s, 3H, H-4). 
13e NMR (75 MHz, d6-DMSO): <536.0 (C-6), S3.2 (C-5), 67.1 (C-l'), 127.3 (Ar), 128.37 (Ar), 
128.42 (Ar), 128.45 (Ar), 128.65 (Ar), 125.S (Ar), 134.6 (C-7), 134.8 (C-2'), 168.9 (C-ll). 
N-(9-Fluorenylrnethoxycarbonyl)glycyl-L-phenylaJanine benzyl ester 
+ 
1 
~I o ~ -;7 4" 01"~~4 O~ 3" 1(1 2 3 N o H 0 
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To a solution ofFmoc~glycine (288 mg, 0.97 mmol), L~phenylalanine benzyl ester hydrochloride 
(283 mg, 0.97 mmol), EDeI (242 mg, 1.26 mmol) and HOBT (197 mg, 146 mmol) in THF 
(30mL) was added TEA (336 !-tL, 2.42 mmol), and the resulting white suspension stirred at rt for 
18 h. This was then diluted with eH2eb (30 mL), washed with 1.0 M aq Hel (50 mL), sat brine 
solution (50 mL), dried with Na2S04, filtered and concentrated in vacuo. The crude residues 
thus obtained were purified by flash chror:natography on silica, eluting with 1: 1 EtOAc/hexanes, 
to afford the dipeptide as a white foam (454 mg, 95% pure, 83% yield). 
Mp: 142-144 0c. 
1H NMR (500 MHz, d6-DMSO): <3 2.94 (dd, J = 8.3, 13.7 Hz, IH, H-6a), 3.03 (dd, J =: 6.4, 13.7 
Hz, 1H, H-6b), 3.59 (dd, J 6.4, 17.1 Hz, IH, H-2a), 3.64 (dd, J = 6.4, 17.1 Hz, IH, H-2b), 4.21 
(t, J =: 6.8 Hz, lH, H-4"), 4.27 (d, J = 6.8 Hz, 2H, H-3"), 4.53 (dd, J 7.8, 14.2 Hz, 1H, H-5), 
5.05 (d, J = 12.7 Hz, lH, H-l'a), 5.09 (d, J 12.7 Hz, 1H, H-l'b), 7.17-7.27 (m, 7H, H-7", H-8, 
H-9 and H-I0), 7.31-7.36 (m, 5H, H-3', H-4', H-5'), 7.41 (t, J = 7.6 Hz, 2H, H-8"), 7.51 (t, J = 6.4 
Hz, IH, H-l), 7.71(d, J 7.3 Hz, 2H, H-6"), 7.89 (d, J = 7.3 Hz, 2H, H-9"), 8.37 (d, J = 7.8 Hz, 
IH, H-4). 
13C NMR (75 MHz, d6-DMSO): <3 36.8 (e-6), 42.2 (e-2), 46.7 (e-4"), 53.8 (e-5), 65.9 (e-3"), 
66.2 (e-l'), 120.2 (e-9"), 125.4 (e-6"), 126.7 (e-l0), 127.2 (e-7"), 127.78 (e·8"), 127.96 (Ar), 
128.16 (Ar), 128.43 (Ar), 128.52 (Ar), 129.2 (e-8), 135.8 (e-2'), 137.0 (e-7), 140.8 (e-IO"), 
144.0 (e-5"), 156.5 (e-l"), 169.4 (e-3), 171.4 (e-ll). 
IR (KBr): U max 3329,3071,2959, 1732, 1659, 1535, 1450, 1234, 1161, 1049, 741, 702. 
HRMS (ESI): ealcd for e33H30N20S (MH"") mlz 535.2233, found mlz = 535.2215. 
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N-(9-Fluorenylmethoxycarbonyl)glycyl-L-phenylalanine 
I 
~I o ~ 4' 0 l' ~J OH 3' n N o H 0 
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10% Pd/C (450 mg) was added to a solution ofFmocGFOBn (448 mg, 95% pure, 0.80 mmol) in 
THF (50 mL), and the black suspension subjected to 3 succesive vacuum/H2 cycles. This was 
stirred under H2 for 18 h at rt, then filtered through a celite plug and concentrated in vacuo to 
give the dipeptide acid as a white foam (353 mg, 95% pure, 95% yield). 
Mp: 187-189 °C (lit. 204-6 oC).143 
lH NMR (500 NIHz, d6-DMSO): 0 2.88 (dd, J = 8.8, 14.2 Hz, lH, H-6a), 3.04 (dd, J = 5.4, 14.2 
Hz, 1H, H-6b), 3.56 (dd, J = 6.4,17.1 Hz, 1H, H-2a), 3.63 (dd, J = 6.4,17.1 Hz, 1H, H-2b), 4.21 
(t, J = 6.8 Hz, IH, H-4'), 4.26 (d, J = 6.4 Hz, 2H, H-3'), 4.43 (td, J = 5.4, 8.3 Hz, 1H, H-5), 
7.17-7.27 (m, 5H, H-8, H-9, H-lO), 7.32 (t, J::::: 7.3 Hz, 2H, H-7'), 7.41 (t, J 7.3 Hz, 2H, H-8'), 
7.49 (t, J 6.1 Hz, IH, H-l), 7.70 (d, J = 7.3 Hz, 2H, H-6'), 7.89 (d, J = 7.8 Hz, 2H, H-9'), 8.12 
(d, J ::= 7.8 Hz, IH, H_4).13C NMR (75 NIHz, d6-DMSO): 0 36.9 (C-6), 43.2 (C-2), 46.7 (C-4'), 
53.6 (C-5), 65.9 (C-3'), 120.2 (C-9'), 125.4 (C-6'), 126.6 (C-I0), 127.2 (C-7'), 127.8 (C-8'), 128.3 
(C-9), 129.3 (C-8), 137.5 (C-7), 140.8 (C-10'), 144.0 (C-5'), 156.6 (C-l'), 169.1 (C-3), 172.9 (C-
11 ). 
IR (KBr): \)max 3329, 1732, 1597, 1535, 1450, 1412, 1234, 1161, 1088, 1045, 995, 918, 760, 
741, 702. 
HRMS (ESI): Calcd for C2Jf2SN20S (MIt) mlz 445.1763, found mlz = 445.174. 
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N-(9-Fluorenylmethoxycarbouyl)glycyl-L-phenylalanyl-L-leucine benzyl ester 
+ 
1 
o 
H ,~ II l' 3' N~U'~4' 12 .: 170 I 
o 14Y'" 0 5' 
~~I 16 
To a solution of FmocGF (350 mg, 95% pure, 0.75 mmol), L-leucine benzyl ester 
benzenesulfonate (329 mg, 0.87 mmol), EDCI (196 mg, 1.02 mmol) and HOBT (160 mg, 
1.18 mmol) in THF (50 mL) was added TEA (273 ~, 1.97 mmol), and the resulting white 
suspension stirred at rt for 18 h. This was then diluted with CH2Cb (30 mL), washed with 
1.0 M aq Hel (30 mL), sat brine solution (40 mL), dried with Na2S04, filtered and concentrated 
in vaclio. The crude residues thus obtained were purified by flash chromatography on silica, 
eluting with 30% EtOAc/CH2Clz, to afford the tripeptide as a clear colourless glass (354 mg, 
73% yield). 
Mp: 125-128 °C [lit. 130-2 °C (3:1 n-hexanelEtOAc)].144 
lH NMR (500 MHz, d6-DMSO): 0 0.82 (d, J:=,; 5.9 Hz, 3H, H-16a), 0.88 (d, J 6.4 Hz, 3H, 
H-16b), 1.49-1.66 (m, 3H, H-14 and H-15), 3.49 (dd, J 5.9,16.6 Hz, 1H, H-2a), 3.61 (d, J:=,; 
6.4,17.1 Hz, 1H, H-2b), 4.20 (t, J 6.8 Hz, 1H, H-4"), 4.24 (d, J::::: 5.9 Hz, 2H, H-3"), 4.33 (m, 
1H, H-13), 4.55 (td, J == 3.9,9.3 Hz, 1H, H-5), 5.11 (s, 2H, H-1'), 7.19-7.21 (m, 5H, H-8, H-9, 
H-10), 7.31 (t, J == 7.8 Hz, 2H, H-7"), 7.34-7.36 (m, 5H, H-3', H-4', H-5'), 7.50 (t, J 7.3 Hz, 2H, 
H-8'), 7.48 (t, J 6.1 Hz, 1H, H-l), 7.69 (d, J 7.8 Hz, 2H, H-6"), 7.88 (d, J;;::: 7.8 Hz, 2H, H-9"), 
8.04 (d, J 8.3 Hz, 1H, HA), 8.46 (d, J::::: 7.3 Hz, 1H, H-12). 
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13C NMR (75 MHz, d6-DMSO): 0 21,5 (C-16a), 22.8 (C-16b), 24.3 (C-15), 38.1 (C-6), 39.9 
(C-13), 43.2 (C-2), 46.7 (CA"), 50.6 (C-14), 53.6 (C-5), 65.9 (C-3"), 66.1 (C-l'), 120.2 (C-9"), 
125.4 (C-6"), 126.4 (C-lO), 127.2 (C-7"), 127.77 (C-8"), 127.97 (Ar), 128.14 (Ar), 128.20 (C-9), 
128.55 (C-3'), 129.3 (C-8), 136.0 (C-2'), 137.8 (C-7), 140.8 (C-I0"), 143.9 (C-5"), 156.6 (C-l"), 
168.9 (C-3), 171,5 (C-ll), 172.2 (C-17). 
IR (KBr): Umax 3306,3071,2959, 1728, 1659, 1528, 1450, 1250, 1153, 1049,741,698. 
HRMS (ESI): Calcd for C39aUN306 (MH+) m/z = 648.3074, found m/z :::;: 648.3048. 
N-(9-Fluorenylmethoxycarbonyl)gJycyl-L-phenylalanyl-L-leucine 
1 
7' y 
10% Pd/C (350 mg) was added to a solution of FmocGFLOBn (350 mg, 0.54 mmol) in THF 
(60 mL), and the black suspension was subjected to 3 successive vacuumIH2 cycles. This was 
stirred, under H2, at rt for 18 h, then filtered through a celite plug and concentrated in vacuo. 
The crude residues thus obtained were purified by flash chromatography, eluting with 
1:1 EtOAc/CHzCh (2-20% MeOH), to give the tripeptide acid as a white foam (253 mg, 95% 
pure, 80% yield). 
Mp: 94-97 °C. 
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III NMR (500 MHz, d6-DMSO): 0 0.83 (d, J = 6.8 Hz, 3H, H-16a), 0.88 (d, J = 6.4 Hz, 3H, 
16b), 1.52 (t,J=7.1 HZ,2H,H-14), 1.62(m, IH,H-15),2.75 (dd,J=9.8, 13.7 Hz, 1H,H-6a), 
3.03 (dd, J = 3.9, 13.7 Hz, 1H, H-6b), 3.49 (dd, J 16.6,6.4 Hz, 1H, H-2a), 3.62 (dd, J = 5.9, 
16.6 Hz, IH, H-2b), 4.16-4.21 (m, 2H, H-4' and H-13), 4.24 (d, J = 6.8 Hz, 2H, H-3'), 4.55 (td, J . 
3.9,9.3 Hz, 1H, H-5), 7.14-7.17 (m, IH, H-IO), 7.19-7.24 (m, 4H, H-8 and H-9), 7.32 (t, J = 
7.6 Hz, 2H, H-7'), 7.41 (t, J ::; 7.3 Hz, 2H, H-8'), 7.50 (t, J = 6.1 Hz, IH, H-l), 7.69 (d, J;:: 7.3 
Hz, 2H, H-6'), 7.88 (d, J = 7.8 Hz, 2H, H-9'), 8.00 (d, J 8.3 Hz, IH, H-4), 8.18 (d, J 6.4 Hz, 
IH, H-12). 
13C NMR (75 MHz, d~DMSO): 0 21.5 (C-16a), 23.0 (C-16b), 24.4 (C-15), 37.6 (C-6), 39.9 
(C-14), 43.3 (C-2), 46.7 (C-4'), 50.5 (C-13), 53.6 (C-5), 65.9 (C-3'), 120.2 (C-9'), 125.4 (C-6'), 
126.4 (C-lO), 127.3 (C-7'), 127.8 (C-8'), 128.2 (C-9), 129.4 (C-8), 137.8 (C-7), 140.9 (C-IO'), 
144.0 (C-5'), 156.6 (C-l'), 168.9 (C-3), 171.3 (C-11), 174.1 (C-17). 
(KBr): U max 3306,3071,2959, 1729, 1659, 1450, 1254, 1157, 1049,995, 741,702. 
HRMS (ESI): Calcd for CnH36N306(MH+) m/z = 558.2604, found m/z 558.2624. 
9-am in 0-5-[2- {N-(9-fl uorenylmeth oxycarbonyl)glycyl} pyrim id in-4-
yl] pyrido[3' ,2' :4,5]pyrrolo[1,2-c]pyrimidine 2.30 
R ::: H or Fmocglycyl 
R'::: H or Fmocglycyl 
2.30: R = Fmocglycyl, R' = H 
a) To a mixture of DVB (10.0 mg, 36 \lmol) and Fmoc-glycine acid chloride (11.4 mg, 36 1J11l01) 
was simultaneously added THF (5 mL) and TEA (5.5 !1L, 40 \lmol) with stirring, and the 
resulting yellow solution was stirred at rt for 18 h. At this time the reaction solution was 
examined by HPLC using the standard gradient elution protocol. 
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b) A solution of DVB (10.0 mg, 36 Ilmol), Fmoc-glycine (12.5 mg, 40 Ilmol), EDCI (9.0 mg, 
47 Ilmol) and HOBT (7.3 mg, 54 !lmol) in pyridine (1 mL) was stirred at rt for 19 h. At this time 
the solution was analysed by HPLC using the standard gradient elution protocol. After a further 
24 h stirring at rt the solution was again analysed by HPLC. 
c) A solution of DVB (10.0 mg, 36 !lmol), Fmoc-glycine (10.7 mg, 36 Ilmol) and HBTU 
(15.0 mg, 40 Ilmol) in DMF (0.5 mL) was stirred at rt for 20 h. At this time the solution was 
analysed by HPLC using the standard gradient elution protocol. 
d) To a solution ofDVB (10.0 mg, 36 !lmol) and TEA (25 ~, 180 !lmol) in pyridine (1 mL) at 
-10 °C was added a solution of Fmoc-glycine acid chloride (34 mg, 108 Ilmol) in THF (1.0 mL) 
dropwise over 1 min, and the yellow solution was allowed to warm slowly to rt over 16 h. The 
solutions was analysed by HPLC. Dry MeOH (100 ~) was added and the solution stirred at rt 
for 24 h, then the solution again analysed by HPLC using the standard gradient elution protocol. 
To the solution was added a slurry of neutralised silica (-1 g) in CH2Cb (3 mL), and, with 
vigorous swirling, the resulting slurry was slowly diluted with hexanes (20 mL). The resulting 
yellow/brown slurry was loaded onto a column of neutralised silica (9 g) in CH2Ch, and the 
variolin material eluted with 2-5% MeOHlCH2Clz (0.1 % TEA). The yellow variolin-containing 
fractions (as determined by tic) were combined, concentrated in vacuo, and examined by HPLC. 
e) A solution of DVB (16.0 mg, 58 Ilmol), Fmoc-glycine acid chloride (54.7 mg, 173 Ilmol) and 
DMAP (1.0 mg, 8 Ilmol) in pyridine (1 mL) was stirred at rt for 17 h. At this time the solution 
was diluted with CH2Ch (3 mL), DIOL (-1 g) added, and the slurry slowly diluted with hexanes 
(10 mL) with vigorous swirling to coat the diol. The resulting yellow slurry was loaded onto a 
column ofDIOL (9 g) in CH2Cb, and the variolin material eluted with 0.5-10% MeOHlCH2Cb. 
Further purification of the yellow amorphous material thus obtained by repeated flash 
chromatography on neutralised silica, eluting with 2% MeOHI CH2Cb (0.1 % TEA), afforded the 
monoacetylated analogue 2.30 as a yellow amorphous solid (1.1 mg, 80% pure, 3% yield). 
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o 
N ~ 30 29 28)l 3" Y TN 1"0 I ~N 0 H 
7" 
1H NMR (500 MHz, d6-DMSO): 0 4.03 (d, J::; 5.9 Hz, 2H, H-29), 4.28 (t, J::; 6.8 Hz, IH, H-4"), 
4.33 (d, J ::; 6.8 Hz, 2H, H-3"), 7.35 (t, J ::; 7.3 Hz, 2H, H-7"), 7.43 (t, J = 7.3 Hz, 2H, H-8"), 7.58 
(dd, J::; 4.4,7.8 Hz, IH, H-3), 7.61 (d, J = 5.4 Hz, IH, H-5'), 7.66-7.68 (m, 2H, H-7 and H-28), 
7.76 (d, J = 7.3 Hz, 2H, H-6"), 7.90 (d, J ::; 7.8 Hz, 2H, H-9"), 8.05 (d, J = 6.4 Hz, IH, H-6), 
8.4-8.8 (br, IH, 9-NHa), 8.45 (dd, J = 1.2, 4.4 Hz, IH, H-2), 8.55 (d, J = 5.9 Hz, IH, H-6'), 9.19 
(dd, J = 1.1, 7.8 Hz, IH, H-4), 9.2-9.6 (br, IH, 9-NHb), 10.63 (s, IH, 2'-NH). 
13C NMR (75 MHz, d6-DMSO): 0 45.8 (C-29), 46.8 (C-4"), 66.1 (C-3"), 98.8 (C-5), 102.0 (C-6), 
112.8 (C-5'), 120.3 (C-9"), 121.0 (C-3), 121.5 (C-4a), 125.4 (C-6"), 127.2 (C-7"), 127.8 (C-8"), 
129.9 (C-4), 139.5 (C-5a), 140.3 (C-2), 140.9 (C-lO"), 143.1 (C-I0a), 144.0 (C-5"), 145.7 (C-7), 
149.8 (C-9), 157.5 (C-2'), 156.8 (C-l"), 157.7 (C-6'), 161.8 (C-4'), 168.9 (C-30). 
HRMS (ESI): Calcd for C31H25N803 (MH+) m/z = 557.2050, found m/z 557.2060. 
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6.3 Experiments described in Chapter 3 
9-[3-(Dimethylam ino )propylamin 0] -5-[2-( methyls ulfanyl)pyrimidin-4-
yl]pyrido[3' ,2':4,S]pyrrolo[1,2-c]pyrimidine 3.12 
188 
A solution of core structure 2.6 (12.0 mg, 35 liM) and N,N-dimethylaminopropaneamine (55 ~, 
443 liM) in toluene (0.5 mL) was heated at 100°C for 24 h. The yellow solution was allowed to 
cool to rt then concentrated in vacuo to leave an oily yellow residue. The crude material thus 
obtained was purified by flash chromatography on CI8, eluting with 50~70% MeOHlH20 (0.1% 
TFA). The orange material thus obtained was dissolved in MeOH (0.7 mL), diluted with CH2Cb 
(10 mL), stirred with solid K2C03 (during which time the solution lightened from an orange to a 
yellow colour), filtered and concentrated ;n vacuo to give the title compound as a dark 
yellow/green gum (11.6 mg, 98% pure, 98% yield). 
IH NMR (500 MHz, CDCI3): 0 1.98 (p, J = 6.8 Hz, 2H, H-2"), 2.30 (s, 6H, N(CH3)2), 2.49 (t, J ::; 
7.1 Hz, 2H, H-3"), 2.68 (s, 3H, SCH3), 3.81 (m, 2H, H-1"), 7.31 (d, J = 5.4 Hz, 1H, H-51), 7.46 
(dd, J 4.9,8.3 Hz, lH, H-3), 7.48 (d, J = 6.8 Hz, IH, H-6), 7.73 (d, J = 6.3 Hz, lH, H-7), 8.36 
(dd, J 1.5,4.9 Hz, IH, H-2), 8.64 (d, J::::: 5.4 Hz, IH, H-6'), 8.71 (dd, J =.: 1.5, 8.3 Hz, 1H, H-4), 
10.22 (t, J;::: 5.4 Hz, IH, 9-NH). 
Be NMR (75 MHz, CDCh): 0 14.3 (2'-SCH3), 27.14 (C-2!1), 39.4 (C-l"), 45.6 (C-5"), 57,2 
(C-3!1), 99,5 (C-5), 100,8 (C-6), 112.4 (C-5'), 120.3 (C-3), 121.8 (C-4a), 128.2 (C-4), 139.3 
(C-5a), 139.6 (C-2), 143.6 (C·10a), 144.1 (C-7), 149.2 (C-9), 156.2 (C-61), 161.4 (CAl), 172.2 
(C-2'). 
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IR (KBr): U max 2950"2750 (series of weak bands), 1686, 1558, 1473, 1458, 1404, 1285, 1207, 
1184, 1130. 
HRMS (ESI): Calcd for C2oH24Nl2s (MH+) mlz = 394.1814, found mlz = 394.1810. 
ICso (P388): 11 ~ 
9-[3-(Dimethylam ino) propylam ino] -5-[2-(3-( dim ethyl am ino ) pro pylam ino )pyrim id in-4-
yl] pyrido[3',2':4,5] pyrrolo[1,2-c]pyrimidine 3.13 
Oxidised core structure 2.25 (10.9 mg, 29 llIDol, assuming quantitative yield in prior oxidation 
reaction) was heated with N,N-dimethylaminopropaneamine (56 liL, 443 limol) in toluene 
(0.2 mL) at 105°C for 19 h. The solution was allowed to cool to rt then concentrated in vacuo. 
The crude material thus obtained was purified by repeated flash chromatography on C18, eluting 
with 30-60% MeOHlH20 (0.1% TF A). The orange material thus obtained was dissolved in 
MeOH (0.5 mL), diluted with CH2Ch (10 mL), stirred with solid K2C03 (during which time the 
solution lightened from an orange to a yellow colour), filtered and concentrated in vacuo to give 
the title compound as a thick yellow oil (8.3 mg, 63% yield over 2 steps, ie, from core structure 
2.6). 
1H NMR (500 MHz, CDCh): 8 1.87 (p, J = 6.8 Hz, 2H, H-2"'), 1.99 (p, J 6.8 Hz, 2H, H-2"), 
2.28 (s, 6H, H-S'''), 2.30 (s, 6H, H-S"), 2.46 (t, J 7.3 Hz, 2H, H-3"'), 2.49 (t, J = 7.3 Hz, 2H, 
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H-3"), 3.61 (m, 2H, H-1'11), 3.80 (m, 2H, H-1"), 5.75 (br, 1H, 2'_NH), 6.93 (d, J 5,4 Hz, lH, 
H~5'), 7,42 (dd, J;;::; 4.9,8.3 Hz, 1H, H-3), 7,48 (d, J = 6.3 Hz, IH, H-6), 7.65 (d, J = 6.3 Hz, 1H, 
H-7), 8.28 (d, J = 5,4 Hz, 1H, H-6'), 8.33 (dd, J:::; 1.5,4.9 Hz, IH, H-2), 8.70 (dd, J = 1.5, 7.8 Hz, 
1H, H-4), 10.17 (t, J::= 5,4, IH Hz, 9-NH). 
BC NMR (75 .MHz, CDCb): 8 27.17 (C-2"), 27.19 (C-211!), 39.3 (C-1"), 40.6 (C_11!1), 45.52 
(C-5"), 45.54 (C-5 '11), 57.2 (C-3"), 57.9 (C-3"'), 100.6 (C-5), 101.1 (C-6), 107.5 (C.5'), 120.0 
(C-3), 122.0 (C-4a), 128.3 (CA), 138.5 (C-5a), 139,4 (C-2), 143.0 (C-7), 143.5 (C-lOa), 149.2 
(C-9), 157.5 (C-4'), 162.1 (C-2' or C-6'), 162.5 (C-2' or C-6'). 
IR (CDCb): Umax 3449, 3252, 2950-2770 (series of weak bands), 1620-1470 (series of bands), 
1261, 1188. 
HRMS (ESI): Caled for C24H34N9 (MH+) m/z = 448.2937, found m/z 448.2945. 
ICso (P388): 6.0 j1M 
9-( 4-Methoxy benzylamino )-5- [2-( methylsulfinyl)pyrim idin-4-
yl] pyrido [3' ,2' :4,5] pyrrolo[1 ,2-c]pyrim idine 3.18 
P 
N~N 
1q' NH 2" 3" P ~ 4" 
'- 5" 
OMe 
To a solution of oxidised core structure 2.25 (20 mg, 54 !lmol, assuming quantitative yield in 
prior oxidation reaction) in CH2Clz (5.0 mL) was added p-methoxybenzylamine (8.0 !1L, 
61 Ilffiol), and the solution stirred at rt for 10 min. The solvent was removed in vacuo and the 
yellow oil left under reduced pressure (0.03 mm Hg) for 48 h. The crude material thus obtained 
was purified by repeated flash chromatography on neutralised silica, eluting with 0.3-1% 
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MeOHIDCM (1% TEA), to give the monosubstituted sulfoxide as a thick yellow oil (16.6 mg, 
63% yield over two steps, ie, from core structure 2.6). 
IH NMR (500 MHz, CDCb): (5 3.02 (s, 3H, 2'-SOCH3), 3.82 (s, 3H, PMB OCH3), 4.91 (d, J = 
5.9 Hz, 2H, H-l"), 6.93 (d, J = 8.3 Hz, 2H, PMB H-4"), 7.42 (d, J = 8.8 Hz, 2H, PMB H-3"), 7.47 
(dd, J = 4.6, 8.1 Hz, 1H, H-3), 7.61 (d, J = 6.9 Hz, IH, H-6), 7.62 (d, J = 5.3 Hz, 2H, H-5'), 7.85 
(d, J = 6.3 Hz, 1H, H-7), 8.32 (dd, J = 1.0, 3.9 Hz, 1H, H-2), 8.71 (d, J 5.9 Hz, 1H, H-6'), 8.82 
(dd, J 1.5,7.8 Hz, 1H, H-4), 10.47 (t, J = 5.4 Hz, IH, 9-NH). 
lJC NMR (75 MHz, CDCh): (5 40.2 (2'·SOCH3), 44.4 (C-1"), 55.3 (OCH3), 98.8 (C-5), 101.3 
(C-6), 114.0 (PMB C-4"), 116.3 (C-5'), 120.8 (C-3), 121.6 (C-4a), 128.8 (C-4), 128.9 (C-3"), 
129.9 (C-2"), 140.1 (C-2), 140.4 (C-5a), 143.7 (C-lOa), 145.6 (C-7), 149.1 (C-9), 157.0 (C-6'), 
159.0 (C-5"), 162.5 (C-4'), 173.3 (C-2'). 
IR (KBr): \)max 3060-2800 (series of weak bands), 1558, 1474, 1354, 1250, 1184, 1069, 1033, 
980. 
HRMS (ESI): Calcd for C23H21N60l2s (MH+) mlz 445.1447, found mlz 445.1445. 
ICso (P388): >28 ~ (may have decomposed in situ). 
NB - In subsequent reactions, described below, this intennediate was not purified; that is, it was genemted and 
used in situ. 
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9-( 4-Methoxybenzylamino )-5- [2-(3-( dimethyl amino )propylamino )pyrimidin-4-
yl] pyrido [3' ,2':4,5] pyrrolo[I,2-c]pyrimidine 3.19 
~ 
N~ N 
qNH ~ ~ ~ 
OMe 
OMe 
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Monosulfoxide variolin 3.18 (26 mg, 59 !-tmol, assuming quantitative yield in prior oxidation 
reaction) was heated with N,N~dimethylaminopropaneamine (200 ~, 1.59 mmol) in toluene 
(0.8 mL) at 100 °C for24 h. The solution was allowed to cool to rt then concentrated in vacuo to 
leave a yellow oil, which was purified by repeated flash chromatography on C 18, eluting with 
60% MeOHJH20 (0.1 % TF A). The orange oil thus obtained was dissolved in MeOH (0.5 mL), 
diluted with CH2Ch (10 mL), stirred with solid K2C03 (during which time the solution lightened 
from an orange to a yellow colour), filtered and concentrated in vacuo to give the title 
compound as a yellow oil (19.7 mg, 98% pure, 68% yield over three steps, ie, from core 
structure 2.6). 
lH NMR (500 MHz, CDCb): 0 2.04 (p, J 6.8 Hz, 2H, H-2"'), 2.56 (s, 6H, H_5 '1t), 2.86 (t, J 
7.3 Hz, 2H, H-3'"), 3.62 (br, 2H, H-l"'), 3.81 (s, 3H, OCH3), 4.89 (d, J 5.4 Hz, 2H, H-l"), 5.93 
(br, 1H, 2'-NH), 6.91 (d, J::::: 8.8 Hz, 2H, H-4"), 6.94 (d, J::::: 5.4 Hz, IH, H-5'), 7.38-7.43 (m, 3H, 
H-3 and H-3"), 7.47 (d, J 6.8 Hz, IH, H-6), 7.68 (d, J:=: 6.3 Hz, IH, H .. 7), 8.25 (d, J = 5,4 Hz, 
IH, H-6'), 8.27 (dd, J = 1.5, 4.9 Hz, IH, H-2), 8.66 (dd, J = 1.5, 8.3 Hz, IH, H-4), 10.37 (t, J = 
5.6, lH, 9-NH). 
Be NMR (75 MHz, CDCb): 025.8 (C-2t1!), 39.3 (C-l'11), 44.0 (C-5'"), 44.4 (C-l"), 55.3 (OCH3), 
56.6 (C-3"'), 100.5 (C-5), 101.5 (C-6), 107.7 (C-5'), 114.1 (C-411), 120.1 (C-3), 121.9 (C-4a), 
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128.4 (C-4), 128.8 (C-3") 130.2 (C-2"), 138.6 (C-Sa), 139.6 (C-2), 143.3 (C-7), 143,4 (C-I0a), 
149.1 (C-9), IS6.9 (C-6t), IS8.9 (C-5"), 162.07 (C-2t), 162.25 (C-4t), 
IR (KBr): U rna" 2950-2830 (series of weak bands), 1686, 1616, 1570, 1514, 1477, 1421, 1360, 
124~ 1180, 1132, 1034,808,768, 
HRMS (ESI): Calcd for CZ7H31N80 (MH+) m/z = 483.2621, found m/z = 483.2623. 
ICso (P388): 2, 1 ~ 
9-Am ino-S-[2-(3-( dim ethyla m ino)p ropyJamino )pyrim idin-4-yl] pyrid 0 [31,2': 4,5] pyrrolo [1,2-
c]pyrimidine 3.15 
.f/ 
N~ N 
qNH .f/ ~ 
=---
OMe 
PMB-protected variolin analogue 3.19 (13.0 mg, 27 Jlmol) was dissolved in triflic acid (OJ mL) 
and the deep red/orange solution stirred at rt for Ih. The solution was cooled to 0 °C and aq NH3 
added dropwise to give a yellow precipitate and an alkaline solution, This suspension was 
loaded onto a CI8 cartridge, and the product eluted with 40-80% MeOHlH20 (0.1% TFA). The 
orange oil thus obtained was dissolved in MeOH (O.S mL), diluted with CH2Ch (10 mL), stirred 
with solid KZC03 (during which time the solution lightened from an orange to a yellow colour), 
filtered and concentrated in vacuo to give the title compound as a yellow oil (3.2 mg, 33% 
yield). 
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IH NlVIR (500 MHz, CDCh): is 1.93 (p, J:::= 6.8 Hz, 2H, H-2111), 2.37 (s, 6H, H-5'1t), 2.59 (t, J = 
6.8 Hz, 2H, H-3'"), 3.62 (m, 2H, H-11t1), 5.83 (br, 1H, 2'·NH), 5.0-7,6 (br, 1H, 9-NH) 6.95 (d, J = 
5.4 Hz, 1H, H-5'), 7.46 (dd, J ;:::: 4.9,8.3 Hz, 1H, H-3), 7.56 (d, J = 6,3 Hz, 1H, H-6), 7.62 (d, J = 
6.8 Hz, 1H, H-7), 8.30 (d, J 4.9 Hz, 1H, H-6'), 8.37 (dd, J = 1.2,4.6 Hz, 1B, H-2), 8.72 (dd, J = 
1.2, 8.1 Hz, 1H, H-4), 9.2-10.3 (br, 1H, 9-NH). 
13C NNIR (75 MHz, CDCb): is 26.8 (C-2!1!), 40.3 (C-1111), 45.1 (C-5"'), 57,6 (C-3"'), 101, 1 (C-5), 
102,5 (C-6), 107,7 (C-5'), 120.5 (C-3), 122.2 (C-4a), 128.7 (C-4), 138.0 (C-5a), 140.0 (C-2), 
142,7 (C-7), 143.3 (C-lOa), 149.6 (C-9), 157.6 (C-6'), 162.0 (C-4'), 162.5 (C-2'). 
IR (KBr): U max 3256-2750 (series of weak bands), 1560, 1508, 1491, 1271, 1205, 1124, 1011. 
HRMS (ESI): Calcd for Cl9H23N8 (MH+) m/z;:::: 363.2046, found mlz 363.2042. 
ICso (P388): 2.5 ~. 
9-[3-(Dimethylamino )propylamino ].;.5-[2-( methyls ulfinyi)pyrimidin-4-
yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine 3.16 
A solution ofbis-sulfoxide variolin 2.25 (5.5 mg, 15 Ilmol, assuming quantitative yield in prior 
oxidation reaction) and N,N-dimethylpropylenediamine (4.0 1iL, 31 Ilmol) in CDCb was stirred 
at rt for 10 min. The solvent was removed in vacuo to leave a yellow oil, which was purified by 
repeated flash chromatography on CI 8, eluting with 60-80% MeOH!H20 (1% TFA), to give the 
TF A salt of the monosubstituted sulfoxide as an orange gum (yield not taken). 
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la NMR (500 MHz, CD30D): (5 2.25-2.31 (m, 2H, H-2"), 2.97 (s, 6H, H-5"), 2.99 (s, 3H, 
2'·SOCH3), 3.35 (t, J = 7.8 Hz, 2H, H-3"), 3.84 (td, J = 1.5,6.3 Hz, 2H, H-l"), 7.45 (d, J = 5.4 
Hz, IH, H-5'), 7.55 (dd, J = 4.6,8.1 Hz, IH, H-3), 7.61 (d, J 6.3 Hz, IH, H-7), 7.70 (d, J 6.8 
Hz, IH, H-6), 8.44 (dd, J = 1.2,4.6 Hz, IH, H-2), 8.54-8.60 (br, IH, H-6'), 8.67 (dd, J 8.1 
Hz, lH, H-4). 
ICso (P388): >28 ~ (may have decomposed in situ). 
NB - In the subsequent reaction, described below, this intermediate was not purified; that is, it was generated and 
used 111 situ. 
9~ [3-(Dirnethylamino )propylamino ]-5-[2-( 4-rnethoxybenzylarnino )pyrirnidin-4-
yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrirnidine 3.17 
---~-:liI>" f' 
N~ N 
1;' NH 
2" 
3" 
N_ 
5"/ 
Monosulfoxide variolin 3.16 (24.0 mg, 59 /lmol, assuming quantitative yields in prior oxidation 
and substitution reactions) was heated with p-methoxybenzylamine (100 /lL, 765 /lmol) in 
toluene (0.8 mL) at 105°C for 22 h. The mixture was allowed to cool to rt then concentrated in 
vacuo. The crude material thus obtained was subjected to flash chromatography on C18, eluting 
with 55-100% MeOHlH20 (0.1% TFA). The orange material thus obtained was dissolved in 
MeOH (1.0 mL), diluted with CH2Ch (20 mL), stirred with solid K2C03 (during which time the 
solution lightened from an orange to a yellow colour), filtered and concentrated in vacuo. This 
material was then purified by flash chromatography on C18, eluting with 30-100% 
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CH2ClzlMeOH, to give the title compound as a thick yellow oil (17.8 mg, 63% yield over three 
steps, ie, from core structure 2.6), 
In NMR (SOO MHz, CDCb): 02.00 (p, J = 6.8 Hz, 2H, H-2!!), 2.33 (s, 6H, H-S"), 2.53 (t, J = 7.3 
Hz, 2H, H-3"), 3.78-3.81 (m, SH, H-l" and OCH3), 4.69 (d, J::::: S.4 Hz, 2H, H-l"'), S.50 (br, 1H, 
2'-NH) , 6.90 (d, J 8.8 Hz, 2H, H-4"'), 6.98 (d, J 4.9 Hz, IH, H-5'), 7.35-7.38 (m, 4H, H-3, 
H-6 and H-3"'), 7.61 (d, J = 6.3 Hz, 1H, H-7), 8.30-8.32 (m, 2H, H-2 and H-6'), 8.S6 (br d, J 
6.3 Hz, IH, H-4), 10.16 (t, J 5.1 Hz, IH, 9-NH). 
BC NMR (75 MHz, CDCb): 0 27.0 (C-2"), 39.2 (C-1"), 45.1 (C-1"'), 4S.3 (C-5"), 55.3 (OCH3), 
57.1(C-3"), 100.5 (C-S), 101.1 (C-6), 107.9 (C-5'), 113.9 (C-4'"), 120.0 (C-3), 12l.9 (C-4a), 
128.3 (C-4), 128.9 (C-3'!!) 13l.5 (C-2"'), 138.5 (C-5a), 139.4 (C-2), 143.1 (C-7), 143.4 (C-I0a), 
149.1 (C-9), 157.4 (C-6'), 158.7 (C-5'''), 162.10 (C-2' or C-4'), 162.19 (C-2' or C-4'). 
(KBr): U max 2961,2916,2851, 1562, 1514, 1504, 1410, 1263, 1049,1020,802. 
HRMS (ESI): Calcd for C27H31NgO (MH+) m/z = 483.2621, found m/z = 483.2625. 
ICso (P388): 8.3 f1M 
9- [3-(Dimethylam ino )propylam ino ]-5-[2-( amino )pyrimidin-4-
yl] pyrido [3' ,2' :4,S]pyrrolo[1,2-c]pyrimidine 3.14 
~I P OMe 
NvNH I '/ 
..-:::N 
PMB-protected variolin 3.17 (13.0 mg, 27 Jlmol) was dissolved in triflic acid (300 ~) and the 
deep orange/red solution stirred at rt for 1 h. The solution was cooled to 0 °C and aq NH3 added 
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dropwise until a yellow precipitate formed and the solution was alkaline. This suspension was 
loaded onto a C I8 cartridge and washed with 60-80% MeOHlH20 (0.1% TF A). The orange 
material thus obtained was dissolved in MeOH (0.5 mL), diluted with CH2Ch (10 mL), stirred 
with solid K2C03 (during which time the solution lightened from an orange to a yellow colour), 
filtered and concentrated in vacuo to give the title compound as a thick yellow oil (S.9 mg, 60%). 
IH NMR (500 MHz, CDCb): 0 1.99 (p, J = 6.8 Hz, 2H, H-2"), 2.31 (s, 6H, H-S"), 2.51 (t, J:= 7.3 
Hz, 2H, H_3!t), 3.80 (q, J = 5.4 Hz, 2H, H-l"), 5.09 (br s, 2H, 2'-NH2), 7.02 (d, J 5.4 Hz, IH, 
H-5'), 7.41-7.4S (m, 2H, H-3 and H-6), 7.67 (d, J = 6.3 Hz, IH, H-7), 8.30 (d, J:= 5.4 Hz, IH, 
H-6'), 8.33 (dd, J = 1.5, 4.9 Hz, IH, H-2), 8.68 (dd, J 1.5, 8.3 Hz, IH, H-4), 10.16 (t, J = 5.4 
Hz, IH, 9-NH). 
l3C NMR (75 MHz, CDCb): 0 27.1 (C-2"), 39.3 (C-l"), 45.5 (C-5"), 57.2(C-3"), 100,1 (C-5), 
100.9 (C-6), 108.8 (C-S'), 120.1 (C-3), 121.9 (C-4a), 128.3 (C-4), 138.6 (C-Sa), 139.5 (C-2), 
143.4 (C-7), 143.5 (C-lOa), 149.2 (C-9), 157 .. 6 (C-6'), 162.6 (C- C-4'), 162.9 (C-2'). 
IR (KBr): U max 2943-2766 (series of weak bands), 1558, 1506, 1456, 1261, 1190, 1007, 810, 
766. 
HRMS (ESI): Calcd for C19H23Ng (MH+) mlz 363.2046, found mlz = 363.2043. 
ICso (P388): 17 11M. 
9-(4-Metboxybenzylamino)-5-[2-(methoxy)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-
c]pyrimidine 3.21 
o 
II 
N~S, 
I "I 
...-.;N 
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Monosulfoxide variolin 3.18 (6.6 mg, 15 !-lmol, assuming quantitative yields in prior oxidation 
and substitution reactions) was heated in a NaOMelMeOH solution (1.37 M, 0.5 mL, 0.69 mmol 
of methoxide) at 105°C for 20 h. The reaction mixture was sonicated periodically during the 
first 2 h to create a fine suspension. The mixture was allowed to cool to rt then concentrated in 
vacuo. The crude material thus obtained was purified by flash chromatography on silica, eluting 
with 40% EtOAclhexanes, to give the title compound as a yellow amorphous solid (3.8 mg, 61% 
yield over 3 steps, ie, from core structure 2.6). 
Mp: 145-150 0c. 
IH NMR (500 MHz, CDCh): 0 3.82 (s, 3H, PMB OCH3), 4.14 (s, 3H, 2'-OCH3), 4.91 (d, J:: 5.9 
Hz, 2H, 9-NHCH2Ar), 6.92 (d, J 8,8 Hz, 2H, PMB H-3"), 7.32 (d, J:::: 5.4 Hz, 1H, H-5'), 7.42 
(d, J 8,8 Hz, 2H, PMB H-2"), 7.45 (dd, J = 4.9, 8.3 Hz, IH, H-3), 7.57 (d, J:;::: 6.8 Hz, 1H, H-6), 
7.76 (d, J :::: 6.3 Hz, IH, H-7), 8.32 (dd, J :::: 1.5, 4.4 Hz, 1H, H-2), 8.49 (d, J:::: 5.4 Hz, 1H, H-6'), 
8.75 (dd, J:::: 1.5,8.3 Hz, IH, H-4), 10.43 (t, J:::: 5.4 Hz, IH, 9-NH) , 
13C NMR (75 MHz, CDCb): 044.4 (9-NHCH2Ar), 54.7 (2'·OCH3), 55.3 (PMB O(113), 100.0 
(C-5), 101.5 (C-6), 111 (C-5'), 114.1 (PMB C-3"), 120.4 (C-3), 122.0 (C-4a), 128.5 (C-4), 
128.9 (PMB C-2"), 130.2 (PMB C-l"), 139.3 (C-5a), 139.9 (C-2), 143.7 (C-I0a), 144.1 (C-7), 
149.3 (C-9), 158.6 (C-6'), 159.0 (PMB C-4I1), 163.6 (C-4'), 165.6 (C-2'), 
IR (KBr): U max 3240-2710 (series of weak bands), 1701, 1581, 1358, 1249, 1134,818,521. 
HRMS (ESI): Calcd for C23H21N602 (MH+) mlz = 417.1726, found mlz :::: 413.1721, 
ICso (P388): >30 !-1M 
9-Amino-5-[2-(methoxy)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine 3.20 
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PMB-protected variolin 3.21 (3.8 mg, 9.2 Jlmol) was dissolved in triflic acid (100 JlL) and the 
deep red/orange solution stirred at rt for 1 h. The solution was cooled to 0 QC and aq NH3 added 
dropwise until a yellow precipitate formed and the solution was alkaline. This suspension was 
loaded onto a CIS cartridge and washed first with 1:1 MeOHlH20, then with MeOH to give the 
product as a thick yellow oil (0.9 mg, 90% pure, 30% yield). 
iH NMR (500 MHz, CDCh): i5 4.14 (s, 3H, 2'-OCH3), 7.34 (d, J = 5.4 Hz, 1H, H-5'), 7.52 (dd, J 
= 4.6, 8.1 Hz, H-3), 7.63 (m, 2H, H-6 and H-7), 8.43 (dd, J = 1.4,4.9 Hz, IH, H-2), 8.54 (d, J = 
4.9 Hz, 1H, H-6'), 8,77 (dd, J 1.5,8.3 Hz, 1H, H-4), 
HRMS (ESI): Calcd for C1sHI3N60 (MH+) miz 293,1151, found m/z 293,1148. 
ICso (P388): 3,6 ~ 
9-[3 .. ( Amino )propylamino ]-5-[2-( methylsulfanyl)pyrimidin-4-
yl]pyrido[3',2':4,S]pyrrolo[1,2-c]pyrimidine 3.23 
Deoxyvariolin core structure 2.6 (300 mg, 0.88 mmol) was heated with a 7.5 mol% 
1,3-diaminopropane/toluene solution (4.91 mL, 4.42 mmol of the amine) at 100 QC for 16 h. 
(Water was rigorously excluded from the reaction, and the amine/toluene solution had been 
previously dried using a Dean-Stark apparatus.) The reaction solution was allowed to cool to rt 
then diluted with CH2Ch (50 mL), washed with 10% sat aq NaHC03 /sat brine solutions 
(50 mL), sat brine solution (50 mL), dried with Na2S04, filtered and concentrated in vacuo to 
give the title compound as thick orange gum (332 mg, 95% pure, 94% yield). 
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III NMR (500 MHz, CDCh): 0 1.97 (p, J 6.8 Hz, 2H, Hq 2"), 2.68 (s, 3H, SCH3), 2.92 (t, J :;::: 
7.1 Hz, 2H, H-3"), 3.85 (q, J:::; 6.7 Hz, 2H, H-1"), 7.31 (d, J 5.2 Hz, lH, H-5'), 7,46 (dd, J = 
4.8,7.9 Hz, 1H, H-3), 7,48 (d, J 6.7 Hz, lH, H-6), 7.72 (d, J"" 6.3 Hz, 1H, B-7), 8.35 (dd, J 
1.6,4.8 Hz, lH, H-2), 8,46 (d, J:;;:: 5.2 Hz, IH, H-6'), 8.71 (dd, J == 1.2, 7.9 Hz, lH, B-4), 10.15 (t, 
J 5.2 Hz, IH, 9.NH). 
13C NMR (75 MHz, CDCh): 0 14,3 (2'-SCH3), 32.6 (C-2"), 38.3 (C-l "),39.2 (C-3"), 99.8 (C-5), 
101.2 (C-6), 112.5 (C-5'), 120.4 (C-3), 121.8 (C-4a), 128.5 (C-4), 138.9 (C-5a), 139.8 (C-2), 
143.49 (C-lOa), 143.58 (C-7), 149.5 (C-9), 156.3 (C-6'), 161.3 (C-4'), 172.2 (C-2'). 
IR (CDCh): UlIla;.; 1686, 1558,1489, 1258, 1184, 1134, 802, 725. 
llRMS (ESI): Calcd for CI!J-hoN732S (MH+) mlz 366.1501, found mlz:;::: 366.1494. 
ICso (P388): 5.7 !JM 
9-[3-( Amino )bu tylamino J-5-[2-( methylsulf anyl)pyrimidin-4-yIJ pyrid 0[3' ,2': 4,5] pyrrolo [1 ,2-
c]pyrimidine 3.24 
NVSMe 
I "I 
~N 
9' 
________ ~. N~N 
1~' NH 
2" 
3" 
4" 
H2N 
Deoxyvariolin core structure 2.6 (30 mg, 88 Ilmol) was heated with a 32% 
1,4-diaminobutane/toluene solution (420 ~, 1.32 mmol of the amine) at 90°C for 20 h. (Water 
was rigorously excluded from the reaction, and the amine/toluene solution had been previously 
dried using a Dean-Stark apparatus.) The reaction solution was allowed to cool to rt, 
concentrated in vacuo, and the amine impurities removed by Kugelrohr distillation (120 °C, 0.03 
mm Hg) to give the title compound as an orange gum (34 mg, 98% pure, 99% yield). 
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IH NMR (500 MHz, CDCb): 6 1.67 (p, J 7.4 Hz, 2H, H-3"), 1.88 (p, J :::;: 7.3 Hz, 2H, H-2"), 
2.68 (s, 3H, SCH3), 2.82 (br, 2H,H-4"), 3.75 (q, J:::;: 6.7 Hz, 2H, H-l"), 7.29 (d, J = 5.3 Hz, 1H, 
H-5'), 7.46 (dd, J:::;: 4.8, 8.2 Hz, IH, H-3), 7.46 (d, J:::;: 6.5 Hz, IH, H-6), 7.71 (d, J = 6.4 Hz, IH, 
H-7), 8.34 (dd, J:::;: 1.4,4.8 Hz, 1H, H-2), 8.45 (d, J:::;: 5.6 Hz, 1H, H-6'), 8.69 (dd, J:::;: 1.7, 8.2 Hz, 
IH, H-4), 10.12 (t, J:::;: 5.6 Hz, 1H, 9-NH). 
13C NMR (75 MHz, CDCb): 6 14.3 (2'-SCH3), 26.7 (C-2"), 31.2 (C-3"), 41.1 (C-l"), 41.8 (C-4"), 
99.7 (C-5), 100.9 (C-6), 112.5 (C-5'), 120.4 (C-3), 121.9 (C-4a), 128.4 (C-4), 139.3 (C-5a), 139.7 
(C-2), 143.6 (C-10a), 144.1 (C-7), 149.3 (C-9), 156.3 (C-6'), 161.5 (C-4'), 172.3 (C-2'). 
IR (KBr): t)max 1682, 1558, 1489, 1256, 1184, 1138,806, 772, 721. 
HRMS (ESI): Calcd for C19H22Nl2S (MH+) mlz 380.1657, found m/z =:; 380.1660. 
ICso (P388): 21 ~ 
2-Methyl-3-(2-m ethylsulfanyl-pyrim id in-4-yl)-l H -pyrrolo [2,3-b] pyridine 3.25 
If water was allowed to contaminate either of the above two reactions (synthesis of variolin 
analogues 3.24 and 3.25), the degradation product shown above was isolated from the reaction 
mixture. 
Mp: 175-185 °C. 
t ' 
H NMR (500 MHz, CDCb): 6 2.66 (s, 3H, 8CH3), 2.90 (s, 3H,H-2a), 7.20-7.23 (m, 2H, 
H-5'and H-6), 8.32 (dd, J 1.5,5.0 Hz, 1H, H-7), 8.47-8.50 (m, 2H, H-6'and H-5), 11.59 (br s, 
IH, NH). 
13C NMR (75 MHz, CDCh): 6 14.2 (8CH3), 15.0(C-2a), 110.9 (C-3), 113.5 (C-5'), 116.5 (C-6), 
124.0 (C-4), 132.1 (C-7), 136.6 (C-5), 142.0 (C-9), 142.8 (C-2), 157.3 (C-6'), 160.2 (C-4'), 173.1 
(C-2'). 
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IR (KBr): Utnax 1686, 1558, 1339, 1281, 1138,802,672. 
HRMS (EI): Calcd for CI3H12N4S (M+) mlz;=: 256.0783, found mlz =: 256.0785. 
ICso (P388): 35 ~. 
202 
9-[3-{N-(9-Fluorenylmethoxycarbonyl)glycylphenylalanylleucylglycylamido}propylamino]-
5-[2-(methylsulfanyl)pyrimidin-4-yl]pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine 3.27 
+ 
H 0 
01"N.h 
3"' '1(1* 2" 3* N 
o H 
1 
To a stirred solution of variolin analogue 3.23 (332 mg, 0.91 mmol), FmocGFLG (614 mg, 
1.00 mmol), EDCI (226 mg, 1.18 mmot) and HOBT (184 mg, 1.36 mmol) in THF (60 mL) was 
added TEA (164~, 1.18 mmol), and the resulting yellow solution with colourless precipitate 
stirred at rt for 24 h. The suspension was washed with sat brine solution (2 x 100 mL), dried 
with Na2S04, filtered and concentrated in vacuo. The crude material thus obtained was purified 
by flash chromatography on diol, eluting with 2% MeOH/CH2Ch, to give the Frrioc-protected 
conjugate as an orange foam. Yield and melting point data were not able to be taken for this 
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conjugate due to the relatively large amount of solvent still present in the sample. * However, the 
yield was estimated to be -65% based on IHNMR data. 
* In an attempt to remove solvent residues from the sample, the conjugate material was heated to 70 DC under 
reduced pressure (0.03 mm Hg). This, however, led to the formation of a compound possessing very low 
solubility in all solvents investigated, thus disallowing the possibility for NMR characterisation. 
IH NMR (500 MHz, CDC b): 6 0.82 (d, J = 6.3 Hz, 3H, H-16*a), 0.86 (d, J 6.6 Hz, 3H, 
H-16*b), 1.50 (t, J 7.2 Hz, 2H, H-14*), 1.58 (p, J 6.3 Hz, lH, H-15*), 1.87 (p, J 7.0 Hz, 
2H, H-2"), 2.59 (s, 3H, SCH3), 2.77 (dd, J 9.5, 13.7 Hz, lH, H-6*a), 3.02 (dd, J =: 4.2, 13.7 Hz, 
IH, H-6*b), 3.25 (q, J;::= 6.3 Hz, 2H, H-3"), 3.51 (dd, J:;::: 6.3, 17.0 Hz, lH, H-2*a), 3.60-3.69 (m, 
4H, H-l", H-2*b and H-19a), 3.73 (dd, J 6.0, 16.7 Hz, IH, H-19*b), 4.15-4.28 (m, 4H, H-3*', 
H-4*' and H-13*), 4.54 (td, J 4.2,8.9 Hz, IH, H-5*), 7.10 (m, lH, H-I0), 7.13-7.18 (m, 4H, 
H-8* and H-9*), 7.29 (t, J:;::: 7.5 Hz, 2H, H-7*'), 7.38 (t, J:;::: 7.4 Hz, 2H, H-8*'), 7.48 (d, J:;::: 5.7 
Hz, IH, H-5'), 7.50-7.54 (m, 3H, H-l, H-3 and H-6), 7.66 Cd, J;::: 7.5 Hz, 2H, H-6*'), 7.70 (d, J:;::: 
6.6 Hz, IH, H-7), 7.84 (d, J = 7.5 Hz, 2H, H-9*'), 7.87 (t, J:;::: 5.7 Hz, H-4"), 8.03 (d, J :;::: 8.0 Hz, 
1H, H-4*), 8.07 (t, J 5.7 Hz, 1H, H-18*), 8.18 (d, J 7.5 Hz, IH, H-12*), 8.38 (dd, J 1.2,4.8 
Hz, 1H, H-2), 8.48 (d, J 5.7 Hz, IH, H-6'), 8.71 (dd, J 1.5,8.3 Hz, IH, H-4), 10.00 (t, J = 5.7 
Hz, IH, 9-NH). 
13C NMR (75 MHz, CDCb): 6 13.8 (SCH3), 21.8 (C-16*a), 23.1 (C-16*b), 24.2 (C-15*), 29.1 
(C-2"), 36.4 (C-3"), 37.5 (C-6*), 38.5 (C-l"), 40.9 (C-14*), 42.3 (C-19*), 43.4 (C-2*), 46,7 
(C-4*'), 51.6 (C-13*), 53.9 (C-5*), 98.6 (C-5), 101.0 (C-6), 112.7 (C-5'), 120.2 (C-9*'), 120.82 
(C-3), 121.05 (C-4a), 125.3 (C-6*'), 126.3 (C-IO'), 127.2 (C-7*'), 127.7 (C-8*'), 128.0 (C-9*), 
128.6 (C-4), 129.3 (C-8*), 137.7 (C-7*), 139.1 (C-5a), 140.l (C-2), 140.8 (C-IO*'), 143.0 
(C-I0a), 143.9 (C·5*'), 144.5 (C-7), 148.7 (C-9), 156.6 (C-l *'), 156.9 (C-6'), 160.8 (C-4'), 168.8 
(C-20*), 169.2 (C-3*), 171.08 (C-2'), 171.32 (C-ll*), 172.2 (C-17). 
JR (KBr): Dmax .3277, 3067, 2953, 1630, 1558, 1474, 1456, 1406, 1364, 1267, 1184, 1045, 1007, 
978,808, 743, 698. 
HRMS (ESI): Calcd for (MH+) m/z 962.4136, found m/z:;::: 962.3864. 
ICso (P388): 9.0 ~. 
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9~[3~(Glycylphenylalanylleucylglycylamido)propylamino]-5-[2-(methylsulfanyl)pyrimidin-
4-yl]pyrido[3' ,2':4,5]pyrrolo[1,2~c]pyrimidine 3.26 
1 
The mixture of polymer 3.28 and deprotected conjugate 3.27 obtained in the previous reaction 
(530 mg, 0.58 mmol of conjugate) was dissolved in 2.5% piperidine/THF (40 mL) and stirred at 
rt for 40 min. Analysis of the reaction mixture by tlc showed the deprotection reaction to be 
complete. Hexanes (500 mL) were added with vigorous stirring to give a yellow gel-like 
precipitate in a very light yellow solution. This suspension was left at -20°C for 3 h, then the 
precipitate collected by filtration. This material was dissolved in THF (50 mL) to give a light 
orange solution with a fine colourless precipitate, which was filtered, concentrated in vacuo and 
heated to 70°C under reduced pressure (0.03 mm Hg) for 48 h to afford the deprotected 
conjugate as an orange foam (412 mg, 95% pure, 62% yield over 2 steps, ie, from variolin 
analogue 3.23). 
Mp: 109-111 °C. 
IH NMR (500 MHz, CDCh): 0 0.83 (d, J = 6.4 Hz, 3H, H-16*a), 0.87 (d, J :: 6.4 Hz, 3R, 
H-16*b), 1.49 (t, J:=: 7.3 Hz, 2H, H-14*), 1.57 (p, J = 6.7 Hz, IH, H-15*), 1.87 (p, J = 7.8 Hz, 
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H-2"), 2.61 (s, 3H, SCH3), 2.80 (dd, J 8.8, 13.7 Hz, lH, H-6*a), 3.01 (m, 3H, H-6*b and 
H-2*), 3.24 (m, 2H, H-3 11), 3.60-3.76 (m, 4H, H-l" and H-19*), 4.25 (q, J 7.7 Hz, IH, H-13*), 
4.57 (m, IH, H-5*), 7.09-7.18 (m, 5H, H-8*, H-9* and H-I0*), 7.57-7.62 (m, 3H, H-3, H-5' and 
H-6), 7.76 (d, J 6.4 Hz, IH, H-7), 7.90 (t, J = 5.4 Hz, IH, H-4"), 8.01 (br, IH, H-4*), 8.13 (t, J 
= 5.9 Hz, IH, H-18*), 8.25 (d, J 7.3 Hz, IH, H-I2*), 8.45 (dd, J l.5, 4.9 Hz, IH, H-2), 8.52 
(d, J"" 5.4 Hz, IH, H-6'), 8.80 (dd, J:::; 1.0, 7.8 Hz, IH, HA), 10.06 (t, J = 5.9 Hz, IH, 9-NH). 
13C NMR (75 MHz, CDCI3): 8 14.0 (SCH3), 21.8 (C-16*a), 23.2 (C-I6*b), 24.3 (C-15*), 29.1 
(C-2"), 36.4 (C-3"), 37.8 (C-6*), 38.6 (C·I"), 40.7 (C-I4*), 42.3 (C-I9*), 44.5 (C-2*), 51.7 
(C-13*), 53.5 (C-5*), 101.1 (C-6), 112.8 (C-5'), 121.01 (C-3 or C-4a), 121.15 (C-3 or C-4a), 
126.4 (C-I0*), 128.2 (C-9*), 128.6 (CA), 129.4 (C-8*), 137.5 (C-7*), 139.2 (C-5a), 140.3 (C-2), 
144.7 (C-7), 148.9 (C-9), 157.l (C-6'), 160.9 (C-4'), 169.0 (C-20*), 171.2 (C-2'), 171.5 (C-11*), 
172.4 (C-17*), 172.9 (C-3*). 
IR (KBr): umax.3281, 3067, 2957,2870, 1653, 1558, 1472, 1406, 1364, 1265, 1207, 1184, 1057, 
1007,976,910,808,768,700. 
S(4IOnm): 20000 Lmor1cm-1 
HRMS (ESI): Calcd for (MH+) mlz ~ 740.3455, found mlz 740.3476. 
ICso (P388): 9.9 ~ 
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6.4 Experiments described in Chapter 4 
Methacryloxysuccinimide (MAOS) 
This was synthesised via the slightly modified protocols of Chang. 145 To a solution of 
methacrylic acid (1.00 mL, 11.8 mmol) and NHS (1.36 g, 11.8 mmol) in THF (15 mL) at 0 °C 
was added DCC (2.676 g, 13.0 mmol), and the solution/suspension stirred at 0 °C for 1 h. The 
white suspension was then allowed to warm to room temperature and stirred for a further 1 h, 
before being filtered, the residues washed with EtOAc (30 mL), and the pooled filtrates 
concentrated in vacllo. The resulting crude material was dissolved in boiling EtOAc (50 mL) 
and filtered while hot. The filtrate was concentrated in vacuo, and the residues dissolved in 
boiling EtOAc (30 mL), filtered while hot, and concentrated in vacuo. The resulting residues 
were again dissolved in boiling EtOAc (10 mL), filtered while hot, and concentrated in vacuo. 
The resulting material was recrystallised from EtOAc/hexanes to afford MAOS in high purity as 
fine white crystals (1.1295 g, 52% yield). 
Mp: 73-75 °C. 
lH NMR (500 MHz, CDCb): 82.06 (t, J == 1.5 Hz, 3H, H-3), 2.86 (s, 4H, H-8), 5.89 (d, J = 1.0 
Hz, IH, H-la), 6.42 (t, J 1.3 Hz, IH, H-lb). 
Copper(I) chloride146 
To a solution of CuS04.5H20 (3.480 g) and NaBr (1.506 g) in H20 (20 mL) was added, over 
2 min, a solution of Na2S03 (1.791 g) in H20 (15 mL). The resulting pale blue/green solution 
with white precipitate was poured into a solution of conc. HCI (0.7 mL) and Na2S03 (0.35 g) in 
H20 (350 mL). The suspension was stirred thoroughly, filtered, the precipitate washed with 
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glacial acetic acid (5 x 10 mL), EtOH (3 x 10 mL) and diethyl ether (3 x 10 mL), then dried in 
vacuo to give the title compound as an off-white solid (1.190 g, 60% yield). 
Bis( thiobenzyl)disulfide 147 
To a yellow suspension of elemental sulfur (1.01 g, 31.5 mmol) in sodium methoxide/methanol 
(2.0 M, 15 mL, 30.0 mmol of NaOMe) was added benzyl chloride (1.82 mL, 15.8 mmol) over 
1 h with stirring. The resulting brown solution/suspension was heated to reflux for 20 h, allowed 
to cool to rt, filtered, and the filtrate concentrated in vacuo. The red oil thus obtained was 
dissolved in H20 (16 mL), washed with diethyl ether (3 x 8 mL), acidified with 32% aq HCI 
(5 mL) and extracted with diethyl ether (8 mL). The deep purple organic solution was extracted 
with 0.67 M aq NaOH (3 x 55 mL). The resulting purple.coloured aqueous solutions of sodium 
dithiobenzoate were combined, and 0.2 M aq potassium ferricyanide (250 mL, 50 mmol) added 
by dripping funnel over 45 min with vigorous stirring at rt. The resulting red precipitate was 
collected by filtration, washed with H20, and dried under reduced pressure (0.03 mm Hg). 
Recrystallisation from EtOAc gave bis(thiobenzyl)disulfide as red crystals (740 mg, 31 % yield). 
Mp: 90-91 °C (lit. 91-2 OC).148 
IH NMR (500 MHz, CDCI3): 8 7.46 (tt, J 1.8, 7.9 Hz, 4H, H-6), 7.61 (tt, J = 1.2, 7.5 Hz, 2H, 
H-7), 8.09 (dd, J = 1.2,8.3 Hz, 4H, H-5). 
2-(2-Cyanopropyl)dithiobenzoate (CPDB) 4.1 147 
+ 
\,,-N..:- \/CN 
NC,\ N'\ 
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Bis(thiobenzyl)disulfide (740 mg, 2.41 mmol) and AIBN (595 mg, 3.62 mmol) were dissolved in 
EtOAc (15 mL) and heated to reflux for 24 h. The red solution was allowed to cool to rt, 
concentrated in vacuo and the crude material purified by flash chromatography on silica, eluting 
with 2% EtOAc/hexanes, to give the title compound as a red oil (699 mg, 87% yield). 
III NMR (500 MHz, CDCh): 8 1.93 (s, 6H, H-4), 7.39 (tt, J 1.8, 7.9 Hz, 2H, H-9), 7.55 (tt, J = 
1.3,7.3 Hz, 1H, H-I0), 7.91 (dd, J = 0.7,8.7, 2H, H-8). 
Poly~methyacryloxysuccinimide (pMAOS) 
a) Atom-transfer radical polymerisation (ATRP): 
This was synthesised via the slightly modified protocols of Godwin et al.60 To MAOS (1.00 
5.46 mmol), CuBr (7.0 mg, 49 Ilmol) and 2,2' -bipyridine (15.3 mg, 98 Ilmol) in a Young's tube 
was added DMSO (700 !1L) and the resulting solution degassed with three successive freeze-
pump-thaw cycles and left under argon. Ethyl-2-bromoisobutyrate (7.2 !1L, 49 Ilmol) was added 
under a flow of argon, and the solution left in an oven at at 90°C for 4 h, during which time it 
changed from a pale greenlblue to a darker green colour. DMF (2 mL) was added to the viscous 
solution, which was allowed to cool to rt before being poured into acetone (10 mL) with 
vigorous stirring. The white precipitate which formed immediately was collected by filtration, 
washed with acetone, and redissolved in DMF (10 mL). To the resulting solution was slowly 
added acetone (40 mL), and the resulting precipitate collected, washed with acetone, and left 
under reduced pressure (0.03 mm Hg, 3 d) to afford pMAOS as a white powder (661 mg,66% 
yield). 
1ll NMR (500 MHz, d6-DMSO): 8 1.0-1.8 (br, 3H, H-l), 1.9-1 (br, 2H, H-3), 2.6-3.1 (br, 4H, 
H-8). 
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IR (KBr): Umax 2997,2947, 1778, 1740, 1429, 1364, 1205, 1065,814,650. 
Mtarget: 13.4 kDa 
Mn: 25 kDa 
MnfMw: 1.87 
b) Reversible addition-!ragmentatiol1 chain transfer (RAFT) polymerisatton: 
209 
This was synthesised via the slightly modified protocols of Schilli et al. 120 To MAOS (1.331 g, 
7.27 mmol) and CPDB (91 mg, 414 f.1mol) in a Young's tube was added DMF (7.3 mL) and the 
resulting solution degassed with three successive freeze-pump~thaw cycles and left under argon. 
AIBN (6,8 mg, 41 f.1mol) was added under a flow of argon, and the solution stirred at 60°C for 
16 h. The red solution was allowed to cool to rt and the polymer precipitated with MeOH 
(25 mL). The precipitate was collected by filtration, redissolved in hot DMF (5 mL), and MeOH 
(25 mL) added, The resulting precipitate. was collected by filtration and traces of solvent 
removed in vacuo to give pMAOS as a light pink powder (1.20 g, 90 % yield). 
Mtarget: 2.6 kDa 
Mn: 30 kDa 
MnlMw: 1.36 
Measuring extinction coefficient of va rio lin conjugate 3.26 
a) Using UV spectroscopy: 
Three solutions of variolin conjugate 3.26 in DMSO (1.0 mglmL) were generated. An aliquot 
(80 f.1L) of each solution was diluted into DMSO (1.92 mL); these dilutions were performed in 
triplicate to give a total of 9 solutions of conjugate 3.26 in DMSO (2 mL, 54 JlM). The 
absorbancy of each of these solutions was measured at 410 nm, with the average of the 
9 readings (which were all within 2% of the average) being ~410) ;: 1.08 cmol . This figure gives 
8(410) = 20 x 103 L.mor1cm-1• 
b) Using the HPLC: 
Three solutions of variolin conjugate 3.26 in DMSO (0.25 mglmL) were generated. Two 
aliquots (10 and 50 f.1L) of each solution were injected onto the HPLC and analysed using the 
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standard gradient elution protocol at 248 nm. The average of the six values (which were in close 
agreement) gave an 'extinction coefficient' at 248 nm of 1.03 x 1012 AU.min.morl . Also, the 
'extinction coefficient' at 410 nm was 1.47 x 1011 AU.min.mor1. 
Attempted syntheses of polymer therapeutics incorporating analogue 3.23 
a) From pMAOS: 
A solution of variolin conjugate 3.26 (7.9 mg, 11 ~mol) and pMAOS (20 mg, 109 ~mol) in 
DMSO (500 ~) was stirred under argon at 60°C for 2 h. 1A2P (17 ~, 215 J.Ul101) was added 
and the yellow solution stirred for a further 3 hat 60°C. The solution was allowed to cool to rt, 
diluted with MeOH (500 ~) and subjected to LH20 chromatography, eluting with MeOH The 
fast-eluting, high Mr fraction was collected and concentrated in vacuo to give the polymer as a 
light yellow solid (11 mg, -70% yield). The slower eluting, low Mr material was collected as 
six separate fractions, which were concentrated in vacuo to give amorphous solids, some of 
which were yellow in colour. 
b) From ring-opened copolymer 4.3 (formed in situ from pMAOS) at high temperature: 
A solution ofpMAOS (27 mg, 149!-lmol) and lA2P (13 ~L, 164 ~mol) in dry DMSO (500~) 
was stirred under argon at 70°C for 4 h. To this solution was added, via cannula, a solution of 
variolin conjugate 3.26 (11 mg, 15 ~mol) in DMSO (600 ~), and the resulting yellow solution 
stirred at 70°C for 22 h. 1A2P (24 ~, 297 !-lmol) was added and the yellow solution stirred at 
70°C for an additional 17 h. The solution was allowed to cool to rt, diluted with MeOH (1 mL), 
and subjected to LH20 chromatography, eluting with MeOH The fast-eluting, high Mr fraction 
was collected and concentrated in vacuo to give the polymer as a light yellow solid (19 mg, 
-85% yield). The slower eluting, low Mr material was collected and concentrated in vacuo. A 
solution of the polymeric material in DMSO (0.25 mglmL) was generated to allow UV 
quantification of the variolin material on the polymer backbone. The solution was generated in 
tri plicate, and the readings were taken in tri pJi cate at 410 nm to give an average absorbancy of 
1.024 cm"I. The low Mr material was dissolved in DMSO (3 mL), an aliquot removed and 
diluted 1: 100 into DMSO, and an aliquot (1 00 ~) of the resulting solution injected onto the 
HPLC and analysed using the standard gradient elution protocol. 
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c) From ring-opened copolymer 4.3 at low temperature: 
A solution of ring-opened copolymer 4.3 (x 0.55, y 0.45, 47 mg, 270 jlmol), variolin 
conjugate 3.26 (20 mg, 27 !lmol) and TEA (19 jlL, 137 jlL) in DMSO (500 jlL) was stirred under 
argon at 45 0c.* Aliquots (10 jlL) were removed after 1,2 and 7 h, diluted into DMSO (1 mL), 
and an aliquot (10 jlL) of the resulting yellow solution injected onto the HPLC and analysed 
using the standard gradient elution protocol. From the solution that had been created by removal 
of an aliquot after 7 h was removed an aliquot (100 jlL) which was further diluted into DMSO 
(0.9 mL). The UV absorbancy of this solution was measured in triplicate to give an average 
A(410 nm) = 1.012 cm'l. After 7 h at 45°C, the resulting yellow solution was allowed to cool to rt, 
diluted with MeOH (1 mL) and subjected to LH20 chromatography, eluting with MeOH. The 
fast-eluting deep yellow high Mr fraction was collected and concentrated in vacuo to give the 
copolymer as a light yellow powder (46 mg, -90% yield). Analysis of this material by IH NMR 
spectroscopy indicated a >5% molar loading of variolin analogue 3.23, with 40 mol% 
hydroxamate material. A solution of the copolymer in DMSO (0.1 mg/mL) was generated, and 
the absorbancy measured in triplicate to give an average ~410) 0.585 cm-I, The faint yellow 
low Mr material was collected, concentrated in vacuo and shown by HPLC and LCMS to contain 
a small amount of conjugate 3.26 and other compounds bearing a variolin-like chromophore. 
A solution of the newly-formed copolymer (40 mg, -215 jlmol), IA2P (36 jlL, 455 jlL) and TEA 
(80 jlL, 577 jlL) in DMSO (500 jlL) was stirred under argon at 45°C for 19 h. The resulting 
yellow solution was allowed to cool to rt, diluted with MeOH (I mL) and subjected to LH20 
chromatography, eluting with MeOH. The fast-eluting yellow high Mr fraction was collected 
and concentrated in vacuo to give the polymer as a light yellow water soluble powder (yield not 
taken). Analysis by IH NMR spectroscopy confirmed the presence of variolin material, aswell 
as 5-10% polymer-bound hydroxamate material. A solution of the polymer in DMSO 
(0.1 mglmL) was generated and the UV absorbancy measured to give ~410) 0.700 cm'I. HPLC 
analysis showed the sample to be free of low Mr material. The pale yellow low Mr material was 
At t "" 0 an aliquot (10 ~) was removed, diluted l: lOOO into DMSO, and the UV absorbance of the resulting 
solution measured to give AC410nm) == 1.091 cm'l. 
Chapter 6: Experimental- Experiments Described in Chapter 4 212 
collected, concentrated in vacuo, and shown by HPLC to contain small amounts of three 
conjugate-like compounds. 
ICso (P388) of the copolymer: > 125 llg/mL. 
d) From ring-opened copolymer 4.3 at low temperatll1~e: 
A solution of ring-opened copolymer 4.3 (9.4 mg, 45 llmol), variolin conjugate 3.26 (5.0 mg, 
6.8 !Jmol) and TEA (1.2 !JL, 8.7 !lffiol) in DMSO (500 !JL) was stirred under argon at 45°C for 
5 h. 1A2P (36 !JL, 455 Ilmol) was added and the yellow solution stirred at 45°C for 48 h. The 
solution was allowed to cool to rt, diluted with MeOH (0,5 mL) and subjected to LH20 
chromatography, eluting with MeOH. The high Mr material was collected and concentrated ;n 
vacuo to give a non-water soluble powder (yield not taken). Analysis by IH NMR spectroscopy 
showed the polymer to be -50% comprised of glutarimide material. 
ICso (P388) of the copolymer: > 125 llg/mL. 
Ring-opened copolymer 4.3 
11NH 12'~OH 
13' 14' 
15' 
This reaction was performed many times, with the following conditions being a typical example. 
pMAOS (100 mg, 546 Ilmol) was stirred with 1A2P (52 !JL, 658 Ilmol) in dry DMSO (500 !JL) 
for 3,5 h at 45°C. Chromatography on LH20, eluting with MeOH, afforded the copolymer as a 
clear colourless glass (x 0,6, y = 0.4, 116 mg, 82% yield). 
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In NMR (500 MHz, d6'"DMSO): (all peaks are broad) 0 0.7-1.4 (H-l and I'), 1.1-1. 2 (H-15 and 
H-lS'), 1.4-2.4 (H-3 and H-3'), 2.3-2,S (H-8 and H-9), 2.7-3.1 (H-12'), 2.9-3.1 (H-12), 3.6-3.7 
(H-13), 3,6-3.8 (H-13'), 4.6-4.7 (H-14), 4.6-4.8 (H-14'), 7.1-7.S (H-ll'), 7.8-7.9 (H-ll), 
l1.S-1l.8 (H-6). Integrals: H-l, H-1', H-3, H-3', H-15 and H-1S' "" 7.67; H-8 and H-9 = 2.20; 
H=12 and H-12' == 2.10; H-13 and H-13' 1.05; H-14 and H-14'::::; 0.86; H-ll'::::; 0.34; H-ll ::::; 
0.52; H-6 0.54. 
IR (KBr): Umax (all signals are weak) 2930, 1767, 1695, IS39, 1373, 1261, 1080. 
Glutarimide copolymer 4.6 
a) In the absence of lA2P: 
N 0 
6~9 
OH 
8 
A solution of ring-opened copolymer 4.3 (x ::::; 0.35, y 0.6S; 35mg, 191 ~mol) in d6-DMSO 
(200 ~) was heated at 70°C for 24 h, and examined periodically by IH NMR. Over 24 h the 
broad polymeric hydroxamate peaks of copolymer 4.3 were replaced by the sharper, more well-
defined peaks of hydroxamic acids 4.4 and 4.5. The reaction mixture was subjected to LH20 
chromatography, eluting with MeOH, and the high-molecular weight fractions collected and 
concentrated in vacuo to afford copolymer 4.6 as a clear colourless glass (w = O.4S, Z ::::; 0.S5; 
19 mg, 85 % yield). 
b) In the presence of lA2P: 
Ring-opened copolymer 4.3 (x = 0.5S, y ::::; 0.45; 10.0 mg, 48 !-tmo!) was stirred with IA2P 
(2S0~, 3.2 mmol) in dry DMSO (2S0~) for 24 h at 45°C. Chromatography on LH20, eluting 
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with MeOH, afforded copolymer 4.6 as a clear colourless glass (w = 0.55, z 0.45; 5.2 mg, 88% 
yield). 
NMR (500 MHz, drmethanol): (all signals are broad) 0 0.9-l.5 (H-I, H.I', H-9 and H-9'), 
1.5-2.5 (H-3 and H-3'), 2.9-3.3 (H-6'), 3.4-3.9 (H-6), 3.8-4.0 (H-7 and H-7'), 7.5-7.7 (H-5'). 
Integrals: H-I, H-1', H-9 and H-9' 5.50; H-3 and H-3' 2.00; H-6' 0.60; H-6, H-7 and H-7' 
l.05; H-5' = 0.33. 
IR (KBr): U max (all signals are weak) 2968, 2934, 1719, 1533, 1380, 1194, 1090, 101,889. 
N-(9-Fl uorenylm ethoxycarbonyl )-glycyl-P-na phthylamide 
1 
H 0 
8 9 10 1 2 N 12 13 14)l co:~ ~ 11r~ l' 0 S' 7 ~ ~ 3 0 -.;;; 10' S ~ 
6 4 ~ ,,99' 
p-Naphthylamine hydrochloride salt (60 mg, 0.33 mmol), Fmoc-glycine (104 mg, 0.35 mmol), 
DeC (90 mg, 0.43 mmol), HOBT (68 mg, 0.50 mmol) and TEA (51 Ill, 0.37 mmol) were 
dissolved in THF (5 rnL) and the solution/suspension stirred at rt for 19 h. The resulting fine 
white suspension was concentrated in vacuo and the crude material thus obtained purified by 
flash chromatography on silica, eluting with 10% EtOAc/hexanes, to afford the title compound 
as a white solid (125 mg, 88% yield). 
Mp: 176-177 0c. 
tH NMR (500 MHz, d6-DMSO): 0 3.86 (d, J = 6.4 Hz, 2H, H-13), 4.26 (t, J == 6.8 Hz, 1H, H-4'), 
4.32 (d, J = 7.3 Hz, 2H, H-3'), 7.35 (t, J == 7.6 Hz, 2H, H-7'), 7.38-7.48 (m, 4H, H-7, H-8 and 
H-8'), 7.58 (dd, J == 2.0,8.8 Hz, lH, H-3), 7.68 (t, J 6.1 Hz, 1H, H-14), 7.74 (d, J == 7.3 Hz, 2H, 
Chapter 6: Experimental- Experiments Described in Chapter 4 215 
H~6'), 7.80 (d, J = 8.3 Hz, IH, H-9), 7.83 (d, J 8.3 Hz, lH, H-6), 7.86 (d, J;::: 8.8 Hz, lH, H-4), 
7.91 (d, J = 7.3 Hz, lH, H-91), 8.27 (s, IH, H-l), 10.18 (s, IH, H-II). 
13C NMR (75 MHz, d6-DMSO): 0 44.2 (C-13). 46.8 (C-4'), 65.9 (C-3'), 115.3 (C-l), 120.0 
(C-3), 120.3 (C-9'), 124.8 (C-8), 125.4 (C-6'), 126.6 (C-7), 127.2 (C-7'), 127.4 (C-9), 127.6 
(C-6), 127.8 (C-8'), 128.6 (C-4), 129.9 (C-lO), 133.6 (C-S), 136.6 (C-2), 140.9 (C-10'), 144.0 
(C-S'), 156.8 (C-l'), 168.4 (C-12). 
IR (KBr): U max 3335, 3042, 1684, 1591, 1539, 1450, 1398, 1352, 1285, 1236, 1150, 1042, 856, 
816, 739. 
llRMS (ESI): Calcd for C27H23N203 (MH+) m/z = 423.1709, found mlz = 423.1723. 
Glycyl-p-naphthylam ide 
1 
Fmoc-Glycyl-~-naphthylamide (305 mg, 0.72 mmol) was dissolved in 10% piperidine/THF 
(10 mL) and stirred at rt for 30 min. Hexanes (200 mL) were added with vigorous stirring, and 
the resulting white suspension left at -20°C overnight. The precipitate was collected by filtration 
and washed with hexanes to give the title compound as a white solid (120 mg, 83% yield). 
Mp: 118-120 DC. 
III NMR (500 MHz, d~DMSO): 0 3.33 (s, 2H, H-13), 7.39 (t, J 7.6 Hz, IH, H-8), 7.46 (t, J = 
7.6 H, IH, H-7), 7.65 (dd, J 2.0,8.8 Hz, IH, R-3), 7.80-7.87 (m, 3H, H-4, H-6 and H-9), 8.33 
(s, IH, H-l), 9-11 (br s, 1H, H-I1). 
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lJc NMR (75 MHz, d6-DMSO): (5 45.7 (C~13), 115.0 (C-l), 120.0 (C-3), 124.6 (C-8), 126.5 
(C-7), 127.4 (C-6), 127.6 (C-9), 128.5 (C-4), 129.8 (C-I0), 133.6 (C-5), 136.6 (C-2), 170.0 
(C-12). 
IR (KBr): U max 3059, 1663, 1591, 1570, 1506, 1472, 1367, 1265, 1244,966, 941, 891,856,810, 
746. 
HRMS (ESI): Caled for C12H13N20 (MH+) m/z 201.1028, found mlz:;:: 201.1030. 
N-{9-Fluorenylmethoxycarbonyl)-glycylglycyl-~-naphthylamide 
1 
Glycyl-~-naphthylamide (112 mg, 0.56 mmo!), Fmoc-glycine (166 mg, 0.56 mmol), DCC 
(150 mg, 0.73 mmol) and HOBT (113 mg, 0.84 mmol) were dissolved in THF (20 mL) and 
stirred at room temperature for 18 h. To the resulting white suspension was added THF (30 mL) 
and silica (5 g), and the resulting slurry sonicated for 5 min then stirred at rt for 8 h. Hexanes 
(50 mL) were added slowly with vigorous stirring, and the slurry then loaded onto a column of 
silica in CH2Ch, Elution with 2: 1 CH2ChIEtOAe (2% MeOH) followed by warm 
2% MeOHJTHF afforded the protected dipeptide conjugate as a white solid (326 mg, -80% pure, 
quantitative yield). 
Mp: 189-193 °C. 
1H NMR (500 MHz, d6-DMSO): (5 3.71 (d, J = 5.9 Hz, 2H, H-16), 3.96 (d, J = 5.9 Hz, IH, 
H-13), 4.25 (t, J:::: 7.1 Hz, IH, H-4'), 4.32 (d, J:: 7.3 Hz, 2H, H-3'), 7.33 (t, J"'" 7.8 Hz, 2H, H-7'), 
7.40-7.43 (m, 3H, H-8 and H~8'), 7.46 (dt, J:;:: 1.0,7.3 Hz, lH, H-7), 7.62 (dd, J = 2.0,8.8 Hz, 
Chapter 6: Experimental- Experiments Described in Chapter 4 217 
1H, H-3), 7.88 (t, J = 6.1 Hz, 1H, H-17), 7.72 (d, J = 7.3 Hz, 2H, H-6'), 7.78 (d, J = 7.8 Hz, 1H, 
H-9), 7.83 (d, J = 8.3 Hz, 1H, H-6), 7.86 (d, J 8.8 Hz, 1H, H-4), 7.89 (d, J = 7.3 Hz, 2H, H-9'), 
8.26 (s, Ill, H-1), 8.29 (t, J 5.6 Hz, IH H-14), 10.16 (s, 1H, H-ll). 
13e NMR (75 MHz, d6-DMSO): D 42.9 (C-13), 43.7 (C-16), 46.8 (C-4'), 66.0 (C-3'), 115.5 
(C-1), 120.1 (C-3), 120.3 (C-9'), 124.9 (e-8), 125.4 (C-6'), 126.7 (C-7), 127.3 (C-7'), 127.4 
(C-9), 127.7 (C-6), 127.8 (C-8'), 128.6 (e-4), 130.0 (C-10), 133.5 (C-5), 136.5 (C-2), 140.9 
(C-lO'), 144.0 (C-5'), 156.9 (e-1'), 168.1 (C-12), 169.9 (C-lS). 
IR (KBr): Umax 3040, 1693, 1659, 1595, 1570, 1533, 1400, 1369, 1285, 1267, 1107, 986, 851, 
816,756, 741. 
HRMS (ESI): Calcd for C29H26N304 (MEt) m/z 480.1923, found m/z 480.1930. 
Glycylglycyl-p-naphthylamide hydrochloride salt 4.8 
1 
Fmoc-glycylg1ycyl-~-naphthylamide (330 mg, 80% pure, 0.55 mmol) was dissolved in 
20% piperidine/THF (100 mL) and stirred at rt for 20 min. The solution was concentrated in 
vacuo to a volume of -1 mL, diluted with THF (10 mL), and hexanes (100 mL) added with 
vigorous stirring. The resulting white precipitate was collected by filtration, washed with 
hexanes, then left at reduced pressure (0.03 mm Hg) for 2 d. This material was dissolved in 
I: 1 THFIlM aq HCI (10 mL) then concentrated in vacuo to leave the title compound in high 
purity as a white solid (121 mg, 75% yield). 
Mp: 222-225 °C. 
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III NMR (SOO MHz, d6~DMSO): 15 3.66 (s, lH, H-16), 4.07 (d, J S.9 Hz, IH, H-13), 7.41 (td, J 
'= 1.S, 7.6 Hz, lH, H-8), 7.48 (td, J 1.0, 7.3 Hz, IH, H~7), 7.62 (dd, J:::: 2.0, 8.8 Hz, lH, H-3), 
7.80 (d, J:::: 8.3 Hz, lH, H-6), 7.84 (d, J = 7.8 Hz, IH, H-9), 7.87 (d, J:::: 8.8 Hz, lH, H-4), 8.10 
(s, 3H, H-l7), 8.25 (s, IH, H-l), 8.79 (, t, J = 5.6 Hz, IH, H~14), 10.34 (s, 1H, H-l1). 
13e NMR (75 MHz, d6-DMSO): 0 39.9 (C-16), 43.0 (C-13), 115.5 (C-l), 120.2 (C-3), 12S.0 
(C-8), 126.7 (C-7), 127.5 (C-6), 127.7 (C-9), 128.7 (C-4), 130.0 (C-I0), 133.6 (C-S), 136.6 
(C-2), 166.7 (C~IS), 167.7 (C-12). 
(KBr): t)max 2611, 1695, 1643, 1541, 1495, 1431, 1396, 1375, 1240, 1150,980,856,820, 
748. 
HRMS (ESI): Calcd for Cl~16N302 (MH+) m/z = 258.1242, found mlz = 258.1238. 
HPMA copolymer carrying glycylglycyl-p-naphthylamide60 
A solution ofpMAOS (100 mg, 546IJ.mol), naphthylamide 4.8 (14 mg, 55!J.M) and TEA (15!J.L, 
108 IJ.mol) in DMSO (400 !J.L) was stirred at under argon at 50°C for 2.5 h. lA2P (86 !J.L, 
1.09 mmol) was added and the solution stirred for a further 1.25 h at 50°C. The reaction 
mixture was subjected to LH20 chromatography, eluting with MeOH, and the high Mr material 
collected and concentrated in vacuo to give the copolymer as a clear, colourless glass (93 mg, 
74% yield). 
Following analysis by IH NMR spectroscopy, this polymeric material (90 mg, 391 Ilffiol) was 
dissolved in DMSO (400 IlL), lA2P (86 !J.L, 1.09 mmol) added, and the solution stirred under 
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argon at 50°C for 3 d, The reaction mixture was subjected to LH20 chromatography, eluting 
with MeOH, and the high Mr material collected and concentrated in vacuo to give the copolymer 
as a clear, colourless glass (55 mg, 97% yield). 
In NlVlR (500 MHz, drmethanol): (all signals are broad) 8 0.9-1.5 (H-l, H-l', H-l", H-9 and 
H-9'), 1.5-2.4 (H-3 and H-3', H-3"), 2.9-3.3 (H-6'), 3.4-4.2 (H-6, H-6", H-7 H-7' and H-9"), 
7.3-7.9 (H-5', H-5", H-8", H-ll and 6 x Ar), 8.1-8.3 (H-13). Integrals: H-l, H-l', H-l", H-9 and 
H-9' = 5.48; H-3, H-3' and H-3" = 2.00; H-6' = 1.05; H-6, H-6", H-7, H-7' and H-9":=; 1.21; H-5', 
H-5", H-8", H-11 and 6 x Ar = 0.82; H-13 = 0.08. 
IR (KBr); uma:.,(all signals are weak) 2925, 1731, 1522, 1202, 1090, 948, 862. 
nPMA copolymer carrying benzylamine 
o 
H~5° 8 9 
11 
o NH 
eX" 
a) These protocols are an exact replication of those reported by Monge and Haddleton.62 A 
solution of pMAOS (50 mg, 275 !lmol) and benzylamine (60 !JL, 549 !lffiol) in DMSO (300 !JL) 
was stirred under argon at 50°C for 5 h. The colourless solution was allowed to cool to rt then 
concentrated in vacuo (0.03 mm Hg for 7 d at rt). The white residues thus obtained were 
dissolved in DMSO (100 !JL) and diluted with MeOH (10 mL). The solution was left at -20°C 
for 3 d but no precipitation occurred. 
b) The above protocols were repeated exactly, with the only difference being that, rather than 
attempted precipitation, the polymer product was purified by LH20 chromatography, eluting 
with MeOH. 
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c) The above protocols were repeated exactly, with the only difference being that the polymer 
product was purified by LH20 chromatography, eluting with MeOH, immediately following the 
reaction, ie, without the 7 d under reduced pressure. 
IH NMR (500 MHz, d6-DMSO): (all signals are broad) 0 0,6-1.4 (H-I, H-I' and H-!"), 1.4-2.2 
(H-3, H-3' and H-3"), 2,3-2,5 (H-8" and H-9"), 4,0-4.4 (H-l2"), 4.2-4.4 (H-12), 4,6-4,8 (H-12'), 
7,1-7.3 (Ar), 7,7-8,1 (H-I1"), 8.3-8.5 (H-ll), 11.0-12,6 (H-6). 
Construction of a calibration curve for p-nitrophenol on the HPLC 
A small sample of p-nitrophenol was diluted 1: 10 with MeOH, and aliquots (1, 2, 5 and 10 ~) 
of the resulting solution were injected onto the HPLC and analysed using the standard gradient 
elution protocols, All measurements were in close agreement and gave an average 
Peak Are<l(315mn) = 6,5 x lOll AU.min,mor l " 
Reaction of poiy(p-nitrophenyl methacrylate) (pNPMA) with lA2P 
A solution of pNPMA (20 mg, 97 llmol) and 1A2P (15 ~, 193 llmol) in DMSO (500 ~) was 
stirred under argon at 45°C. Aliquots (5 llL) were periodically removed (at t == 0, 1.25, 3, 4,5, 
7,5,21 and 48 h), diluted into DMSO (1 mL), and an aliquot (10 ~) of the resulting solution 
injected onto the HPLC and analysed using the standard gradient elution prorocols. After 48 h at 
45°C, the solution was subjected to LH20 chromatography, eluting with MeOH, with the high 
Mr early-eluting fraction (which precipitated as it eluted from the column) being collected and 
concentrated in vacuo to give the copolymer as a white solid (10.3 mg, 84% yield). 
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III NMR (500 MHz, d6~DMSO): (all signals are broad) 8 0.8-1.1 (H-9 and H-9!), 1.0-1.5 (R-l, 
H-I! and H_ltt), 1.3-2.5 (H-3, H-3' and H-3"), 2.8-3.1 (H-6'), 3.4-3.9 (H-6, H-7 and H-T), 4.4-4.8 
(H-8 or H-8'), 4.5-4.8 (H-8 or H-8'), 7.3-7.6 (H-5' and PNPMA Ar), 7.6-7.8 (end group Ar), 
8.2-8.4 (end group Ar), 8.3-8.4 (PNPMA Ar). 
Poly(methacryloyl chloride) (pMAC) 
This was synthesised from methacrylorl chloride following the slightly modified procedure of 
Yamaguchi and Gibson.132 AlBN (9.0 mg, 56 Ilmol) was weighed into a round-bottomed flask, 
methacryloyl chloride (1.00 mL, 10.2 mmol) and toluene (1.80 mL) added, a reflux condenser 
fitted, and the solution degassed with 3 successive freeze-pump-thaw cycles. The solution was 
then stirred under argon at 85°C for 21 h. The solution was allowed to cool to rt, then hexanes 
(20 mL) added with vigorous stirring and the resulting white precipitate collected by filtration, 
washed with hexanes and dried in vacuo to give the polymeric product as a white powder 
(296 mg, 28% yield). 
1H NMR (500 MHz, CDCb): 8 (signals are broad and 'spikey') l.2-l.5 (CH3), 2.2-2.4 (CH2). 
Poly(rnethyl methacrylate) (pMMA)132 
A solution of pMAC (40 mg, 0.38 mmol), MeOH (700 jlL, 17.3 mmol), and pyridine (145 ilL, 
1.8 mmol) in THF (7.0 mL) was refluxed under argon for 3 d. The colourless solution was 
allowed to cool to rt then concentrated in vacuo. The residues thus obtained were dissolved in 
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1:1 THFfMeOH (3 mL), MeOH (20 mL) added, and the resulting white precipitate collected by 
filtration and dried in vacuo to give the polymeric product as a white powder (9 mg, 24% yield). 
IH NlVIR (500 MHz, CDCh): 0 (signals are broad and backbone signals are 'spikey') 0.8-2.1 
(SH, backbone CH3 and CHz), 3.5-3.7 (2H, OCH3). 
Reaction of pMAC with lA2P 
pMAC (20 mg, 0.19 mmol) was weighed into a Young's tube and placed under argon. lA2P 
(76~, 0.96 mmol), TEA (40 ~, 0.29 mmo!) and DMSO (0.5 mL) were added and the resulting 
solution left in the oven at 70°C for 16 h. The solution was allowed to cool to rt, diluted with 
MeOH (0.5 mL) and subjected to LH20 chromatography, eluting with MeOH, with the high Mr 
fraction being collected and concentrated in vacuo to give the polymeric product as a clear 
colourless glass (23 mg, 96 % yield). 
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ApPENDIX I: HPLC RETENTION TIMES 
Compound Retention time (min) Elution protocol * 
Variolin B 8.1 Standard gradient 
DVB 7.3 Standard gradient 
2.16 10.2 Standard gradient 
2.16 3.0 85% MeOHJH2O 
FmocGFLG 15.3 Standard gradient 
2.18 19.3 Standard gradient 
2.18 8.6 85% MeOHJH2O 
2.19 5.0 85% MeOHJH2O 
2.20 4.3 85% MeOHJH2O 
2.27 1l.4 Standard gradient 
FmocGly 13.6 Standard gradient 
2.28 15.1 Standard gradient 
2.29 9.9 Standard gradient 
2.32 10.7 Standard gradient 
2.33 11.6 Standard gradient 
2.34 15.8 Standard gradient 
3.26 10.2 Standard gradient 
3.26 9.6 60% MeOHJH2O 
4.8 8.8 Standard gradient 
p-nitrophenol 11.6 Standard gradient 
* See General experimental for the standard gradient elution protocol 
